camptothecin has been researched along with levoleucovorin in 1863 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (1.29) | 18.2507 |
| 2000's | 625 (33.55) | 29.6817 |
| 2010's | 1002 (53.78) | 24.3611 |
| 2020's | 212 (11.38) | 2.80 |
| Authors | Studies |
|---|---|
| Geoffroy, F; Grem, JL | 1 |
| Bleiberg, H | 1 |
| Aiba, K | 2 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C | 1 |
| Egashira, Y; Hirata, I; Katsu, K; Kawabe, S; Nakagawa, K; Nakagawa, Y; Takao, Y; Takiuchi, H | 1 |
| Sasaki, T | 1 |
| Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL | 1 |
| Bours, V; Fillet, G; Jerusalem, G | 1 |
| Erlichman, C; Goldberg, RM | 1 |
| Antoine, EC; Bastian, G; Benhammouda, A; Coeffic, D; Gil-Delgado, M; Grapin, JP; Khayat, D | 1 |
| Erlichman, C; Kaufmann, SH; Mullany, S; Svingen, PA | 1 |
| Goldberg, RM | 2 |
| Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E | 1 |
| André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M | 1 |
| Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H | 1 |
| Miller, M | 1 |
| Allegrini, G; Antonuzzo, A; Brunetti, I; Cianci, C; Conte, P; Falcone, A; Galli, C; Lencioni, M; Masi, G; Pfanner, E | 1 |
| Twelves, C | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Comis, S; De Vita, F; Faranda, A; Gravina, A; Orditura, M; Petrillo, A | 1 |
| Angerstein, C; Becker, H; Becker, W; Béhé, M; Behr, TM; Blumenthal, RD; Fayyazi, A; Goldenberg, DM; Hiddemann, W; Liersch, T; Ringe, B; Salib, AL; Sharkey, RM; Wörmann, B | 1 |
| Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M | 1 |
| André, T; Carola, E; Couteau, C; de Gramont, A; Gilles-Amar, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F | 1 |
| Kobayashi, T; Maeda, Y; Okamoto, R; Omuro, Y; Sasaki, T; Takeda, N | 1 |
| Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P | 1 |
| Schallhorn, A | 1 |
| Azoulay, D; Goldwasser, F; Gornet, JM; Lévi, F; Misset, JL; Yovine, A | 1 |
| Hisano, C; Ishikawa, T; Kaji, Y; Maruyama, T; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Ohkuma, K | 1 |
| Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB | 1 |
| Mayer, RJ | 1 |
| Graeven, U; Schmiegel, W | 1 |
| Borsellino, N; Cigolari, S; Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Paoletti, G; Pedicini, T | 1 |
| Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC | 1 |
| Hill, M; Price, T | 1 |
| Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G | 1 |
| Haller, D; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W | 1 |
| Avallone, A; Biglietto, M; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lena, M; De Lucia, L; De Vita, F; Farris, A; Ianniello, GP; Leo, SS; Lorusso, V; Mancarella, S | 1 |
| Saltz, LB | 2 |
| Maeda, Y; Sasaki, T | 1 |
| Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB | 1 |
| Messori, A; Trippoli, S; Vaiani, M | 1 |
| Erlichman, C; Goldberg, RM; O'Connell, MJ | 1 |
| Pestalozzi, BC | 1 |
| Ducreux, M; Pignon, JP | 1 |
| Enzinger, PC; Ilson, DH | 1 |
| Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH | 1 |
| Saltz, L | 1 |
| Douillard, JY | 2 |
| Berlin, J | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Rothenberg, ML | 2 |
| Dubreuil, A; Etienne, MC; Fischel, JL; Formento, P; Milano, G; Rostagno, P | 1 |
| Achterrath, W; Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U | 1 |
| Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D | 1 |
| Aschelter, AM; Comis, S; D'Attino, RM; Dogliotti, L; Garufi, C; Nisticó, C; Perrone, M; Pugliese, P; Tampellini, M; Terzoli, E | 1 |
| Astrow, AB; Macdonald, JS | 1 |
| O'Connell, MJ | 2 |
| Cunningham, D; James, RD | 1 |
| Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D | 1 |
| Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H | 1 |
| Krieger, G | 1 |
| Traynor, K | 1 |
| Niedzwiecki, D; O'Connell, MJ; Sargent, DJ; Schilsky, RL | 1 |
| Ledermann, JA; Leonard, P; Seymour, M | 1 |
| Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E | 1 |
| Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G | 1 |
| Meropol, NJ; Poplin, EA; Rothenberg, ML; Van Cutsem, E; Wadler, S | 1 |
| Saitoh, S; Sakata, Y | 1 |
| Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H | 1 |
| Amaya, K; Miwa, K; Nishijima, K; Nishimura, G; Sasaki, S; Shimizu, K; Tani, T; Terada, I | 1 |
| Bécouarn, Y; Bekradda, M; Coudert, B; Gamelin, E; Germa, C; Krisch, C; Mignard, D; Mousseau, M; Négrier, S; Pierga, JY; Provençal, J; Raoul, JL; Rixe, O | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Araneo, M; Barzdins, A; Bruckner, HW; DeGregorio, P; Frager, D; Grossbard, ML; Homel, P; Kozuch, P; Marino, J; Robin, A | 1 |
| Wen, Z; Xiong, X; Zhu, Z | 1 |
| Douillard, JY; Köhne, CH; Van Cutsem, E | 1 |
| Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML | 1 |
| Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Bleiberg, H; Di Leo, A | 1 |
| Brugger, S; Depisch, D; Fiebiger, W; Kornek, GV; Kovats, E; Lang, F; Raderer, M; Scheithauer, W; Ullrich-Pur, H; Valencak, J | 1 |
| Boige, V; Ducreux, M; Taïeb, J | 1 |
| Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M | 1 |
| Fietkau, R; Klautke, G | 1 |
| Giacchetti, S | 1 |
| Hara, H; Hiramatsu, M; Sako, S; Shinohara, H; Tanigawa, N; Toyoda, M | 1 |
| Benchalal, M; Fingerhut, A; Fouere, S; Yahchouchy-Chouillard, E | 1 |
| Dimitrakopoulos, A; Gennatas, K; Giannopoulos, A; Kosmas, Ch; Koufos, Ch; Macheras, A; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Tsavaris, NB; Tsipras, H; Vadiaka, M | 1 |
| Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Manzione, L; Reggiardo, G; Rosati, G; Rossi, A | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Crucitta, E; De Lucia, L; De Vita, F; Del Prete, S; Lorusso, V; Orditura, M; Palmeri, S | 1 |
| Cunningham, D; Falk, S; Jackson, D | 1 |
| Descos, L; Freyer, G; Kraft, D; Ligneau, B; Trillet-Lenoir, V | 1 |
| Buzzi, F; Comella, P; Crucitta, E; De Cataldis, G; De Lucia, L; De Vita, F; Del Gaizo, F; Farris, A; Lannelli, A; Maiorino, L; Mancarella, S; Palmeri, S; Tafuto, S | 1 |
| Berlin, JD | 1 |
| Hirose, T; Kobayashi, A; Yamada, T | 1 |
| Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E | 1 |
| Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA | 1 |
| Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F | 1 |
| Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT | 1 |
| Fisher, MD | 2 |
| Mitry, E; Rougier, P | 1 |
| D'Orazio, AI; Gambill, BD | 1 |
| Erlichman, C; Hobday, TJ | 1 |
| Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J | 1 |
| Chico, IM; Pazdur, R | 1 |
| Chu, E | 3 |
| Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM | 1 |
| Avallone, A; Casaretti, R; Comella, G; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Lapenta, L | 1 |
| Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Goldberg, RM; Hobday, TJ | 1 |
| Calvo, E | 1 |
| Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Kouro, T; Sakita, I; Souma, I; Yoshida, T | 1 |
| Kerr, D | 1 |
| Akbulut, H; Akbulut, KG; Altuntas, F; Cindoruk, M; Icli, F; Ozturk, G; Unal, E | 1 |
| Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C | 1 |
| Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J | 1 |
| Conroy, T; Gourgou, S; Hua, A; Kramar, A; Mery-Mignard, D; Seitz, JF; Ychou, M | 1 |
| Comte, S; Lebrun, T; Selke, B | 1 |
| Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC | 1 |
| Alimonti, A; Burattini, E; Pavese, I; Satta, F; Vecchione, A; Zoffoli, V | 1 |
| Glimelius, B | 1 |
| Lièvre, A; Mitry, E | 1 |
| Chiba, H; Hirayama, Y; Iyama, S; Niitsu, Y; Oku, T; Sagawa, T; Sakamaki, S; Sato, Y; Takahashi, M; Takayama, T; Takayanagi, N; Tsuji, Y | 1 |
| Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML | 1 |
| André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M | 1 |
| Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M | 1 |
| Gemici, C; Uygur-Bayramiçli, O | 1 |
| Jin, ML; Li, J; Li, Y; Shen, L; Yang, BQ; Zhang, XD | 1 |
| Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J | 1 |
| Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J | 1 |
| Cohen, Y; Geffen, DB; Gluzman, A; Lavrenkov, K; Man, S | 1 |
| Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M | 1 |
| Ferns, H | 1 |
| Chen, ZH; Feng, B | 1 |
| de Gramont, A; Louvet, C | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ | 1 |
| Buzzi, F; Comella, P; De Lucia, L; De Vita, F; Farris, A; Gambardella, A; Lorusso, V; Maiorino, L; Mancarella, S; Palmeri, S | 1 |
| Galle, PR; Haas, U; Heike, M; Hertkorn, C; Hoehler, T; Moehler, M; Schimanski, C; Siebler, J | 1 |
| Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L | 1 |
| Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N | 1 |
| Diasio, R | 1 |
| Sato, A; Shimada, K; Taguchi, S | 1 |
| de Gramont, A; Kuebler, JP | 1 |
| Bittorf, B; Brueckl, V; Brueckl, WM; Hahn, EG; Hegewald, J; Hohenberger, W; Jüngert, B; Männlein, G; Mühldorfer, S; Schirner, I; Stickel, F; Wein, A | 1 |
| Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L | 1 |
| Eisenberg, SG; Hwang, JJ; Marshall, JL | 1 |
| Maeda, Y; Sasaki, E; Sasaki, T | 1 |
| Kataoka, M; Kondo, K; Shimoyama, S | 1 |
| Motomura, S | 1 |
| Doi, T; Ohtsu, A | 1 |
| Shirao, K; Ura, T | 1 |
| Akazawa, S; Murakami, T; Nakazima, T; Sakurai, T; Yamashina, T | 1 |
| Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM | 1 |
| Furukawa, J; Ishigami, H; Katsumoto, Y; Kinuta, M; Maruyama, KT; Maruyama, N; Nagai, K; Nakaguchi, K; Tanaka, J; Yokouchi, H | 1 |
| Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Oshima, S; Tsujie, M; Yamamoto, H | 1 |
| Hasuike, Y; Kashiwazaki, M; Mishima, H; Nishisyo, I; Takeda, Y; Tsujinaka, T | 1 |
| Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Naoi, Y; Ohshima, S; Tsujie, M; Yamamoto, H | 1 |
| Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H | 1 |
| Achille, E; André, T; Buyse, M; Colin, P; Couteau, C; de Gramont, A; Flesh, M; Ganem, G; Landi, B; Lledo, G; Louvet, C; Mery-Mignard, D; Quinaux, E; Tournigand, C | 1 |
| Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Curley, SA; Ellis, LM; Gentner, B; Parikh, AA; Vauthey, JN; Wu, TT | 1 |
| Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS | 1 |
| Arciero, C; Peoples, GE; Shriver, CD | 1 |
| Comella, P | 1 |
| Altundag, K; Barista, I; Celik, I; Engin, H; Guler, N; Gullu, I; Kars, A; Oksuzoglu, B; Ozisik, Y; Tekuzman, G; Turker, A; Yalcin, S | 1 |
| Civitelli, S; Correale, P; De Martino, A; Fiaschi, AI; Francini, G; Giorgi, G; Lorenzi, M; Marsili, S; Marzocca, G; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Tani, F; Tanzini, G | 1 |
| Bafaloukos, D; Bamias, A; Economopulos, T; Fountzilas, G; Janinis, J; Kalofonos, HP; Kouvatseas, G; Papakostas, P; Skarlos, D; Stavropoulos, M; Timotheadou, E | 1 |
| Folprecht, G; Köhne, CH | 2 |
| Cohen, MH; Griebel, DJ; Hirschfeld, S; Ibrahim, A; Pazdur, R; Williams, GA | 1 |
| Fakih, M | 1 |
| Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS | 1 |
| Dietrich, M; Grossbard, ML; Kozuch, P; Malamud, S; Mathew, S; Rachamalla, R | 1 |
| Algars, A; Bendardaf, R; Collan, Y; Lamlum, H; Pyrhönen, S; Ristamäki, R | 1 |
| Bleiberg, H; Buyse, M; Di Leo, A | 1 |
| Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T | 1 |
| Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H | 1 |
| Goldberg, RM; Grothey, A; Sargent, D; Schmoll, HJ | 1 |
| Baba, E; Fujishima, H; Harada, M; Kikuchi, I; Mitsugi, K; Miyanaga, O; Nakano, S; Ueda, A | 1 |
| Ansari, RH; Eng, C; Kasza, K; Kindler, HL; Nattam, S; Vokes, EE; Wade-Oliver, K | 1 |
| Barone, C; Basso, M; Cassano, A; Giuliante, F; Nuzzo, G; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N; Vellone, M | 1 |
| Chen, VM; Flower, RL; Jackson, D; Morel-Kopp, MC; Thrift, KM; Ward, CM | 1 |
| Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S | 1 |
| Aozasa, S; Fujino, K; Hase, K; Ito, H; Okada, K; Shikina, A; Suganuma, T; Tanaka, M; Terauchi, R; Tsuda, T; Utsunomiya, K | 1 |
| Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R | 1 |
| Fox, R; Melisko, ME; Venook, A | 1 |
| Chiriatti, A; Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, J; Zito, A | 1 |
| Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M | 1 |
| Gürkan, A; Kaçar, S; Kahya, M; Karaca, C; Uslu, A; Varilsüha, C | 1 |
| Bathe, OF; Bigam, D; Butts, C; Dixon, E; Dowden, S; Ernst, S; Ruether, D; Sutherland, F; Walley, B | 1 |
| Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J | 1 |
| Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C | 1 |
| Goetz, MP; Grothey, A | 1 |
| Jahnke, K; Keilholz, U; Schmittel, A; Thiel, E | 1 |
| Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D | 1 |
| Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A | 1 |
| Harada, O; Kobayashi, M; Sasamoto, M; Shimaya, S | 1 |
| Liu, JH | 1 |
| Hayashi, T; Ishiwatari, H; Kato, J; Kogawa, T; Miyanishi, K; Niitsu, Y; Oku, T; Takada, K; Takahashi, M; Takanashi, K; Takayama, T | 1 |
| Allen, J; Beech, J; Carrington, B; Hogg, M; Saunders, MP; Sjursen, AM; Swindell, R; Valle, JW | 1 |
| Scheithauer, W | 1 |
| Cesta, A; Lalli, A; Lullo, LD; Nuzzo, A; Rea, S; Recchia, F; Saggio, G | 1 |
| Delaunoit, T; Findlay, BP; Fuchs, CS; Goldberg, RM; Green, E; Mailliard, JA; Morton, RF; Salim, M; Sargent, DJ; Schaefer, PL; Stella, PJ; Thomas, SP | 1 |
| Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN | 1 |
| Sharieff, W | 1 |
| Arsène, D; Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Etienne, PL; Giovannini, M; Guérin-Meyer, V; Kaminsky, MC; Lledo, G; Milan, C; Mitry, E; Paitel, JF; Raoul, JL; Rougier, P; Seitz, JF | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y | 1 |
| Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S | 1 |
| Hazama, S; Mori, N; Oka, M; Tamesa, T; Tangoku, A; Watanabe, Y; Yamamoto, S; Yoshimura, K | 1 |
| Reddy, GK | 1 |
| Geffen, DB; Gluzman, A; Idelevich, E; Lavrenkov, K; Man, S; Shani, A | 1 |
| Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Delvart, V; Levi, F; Pascal, G; Paule, B | 1 |
| Iishi, H; Narahara, H; Sugimoto, N; Tatsuta, M | 1 |
| Doggrell, SA | 1 |
| Babic, DR; Grbic, B; Jelic, SB; Matijasevic, MM; Popov, IP | 1 |
| Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX | 1 |
| Hadj Tahar, A | 1 |
| Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A | 1 |
| Hitre, E; Láng, I | 1 |
| André, T; Artru, P; de Gramont, A; Gayet, B; Goebel, FM; Hebbar, M; Louvet, C; Parc, R; Paye, F; Perez, N; Taïeb, J; Tournigand, C | 1 |
| Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M | 1 |
| Alberts, SR; Delaunoit, T; Findlay, BP; Fuchs, C; Goldberg, RM; Green, E; Krook, J; Morton, RF; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Hwang, JJ | 1 |
| Bugat, R; Conroy, T; Deplanque, G; François, E; Hua, A; Jacob, JH; Magherini, E; Metges, JP; Michel, P; Nasca, S; Paillot, B; Rixe, O; Stein, U | 1 |
| Haller, DG; Sun, W | 1 |
| Hamm, JT; Hecht, JR; Kabbinavar, FF; Mass, R; McCleod, M; Nelson, B; Novotny, WF; Patel, T; Perrou, B; Schulz, J | 1 |
| Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J | 1 |
| Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C | 1 |
| Asaka, M; Furukawa, S; Fuse, N; Kato, M; Kato, T; Komatsu, Y; Takeda, H; Takei, M; Yuki, S | 1 |
| Poston, GJ | 1 |
| Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Aravantinos, G; Bacoyiannis, C; Bamias, A; Basdanis, G; Chalkidou, S; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalfarentzos, F; Kalofonos, HP; Karina, M; Kosmidis, P; Koutras, A; Papakostas, P; Pectasides, D; Samantas, E; Samelis, GF; Skarlos, D | 1 |
| Kallinowski, B | 1 |
| Galle, PR; Moehler, M; Teufel, A | 1 |
| Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E | 1 |
| Im, YH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, ST; Kim, WS; Lee, J; Lee, SH; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Brener, J; Chaitchik, S; Czerniak, A; Hayat, H; Schachter, P; Shimonov, M | 1 |
| Punt, CJ | 2 |
| Silberman, H | 1 |
| Jäger, D; Knuth, A; Pestalozzi, BC | 1 |
| Boige, V; Elias, D; Estphan, G; Laplanche, A; Malka, D; Pocard, M; Raynard, B | 1 |
| Schmoll, HJ | 1 |
| Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I | 1 |
| Borsellino, N; Cartenì, G; Colucci, G; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Manzione, L; Paoletti, G; Pezzella, G; Romito, S | 1 |
| Di Costanzo, F; Doni, L | 1 |
| Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA | 1 |
| Wu, WQ; Yu, BM | 1 |
| David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Agostara, B; Borsellino, N; Brunetti, C; Carrozza, F; Cartenì, G; Caruso, M; Chiarenza, M; Colucci, G; Cordio, S; Cramarossa, A; Di Bisceglie, M; Di Seri, M; Durini, E; Filippelli, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Guida, T; Leonardi, V; Lopez, M; Lorusso, V; Maiello, E; Mancarella, S; Manzione, L; Misino, A; Montemurro, S; Nettis, G; Paoletti, G; Pezzella, G; Pisconti, S; Romito, S; Rosati, G; Valdesi, M; Valerio, MR | 1 |
| Anak, O; Bokemeyer, C; El-Serafi, M; Frickhofen, N; Fuchs, R; Genicot, B; Köhne, CH; Langenbuch, T; Lorenz, M; Lutz, MP; Mergenthaler, HG; Müller, L; Nordlinger, B; Reichardt, P; Rougier, P; Rückle-Lanz, H; van Cutsem, E; Vanhoefer, U; Voigtmann, R; Wils, J | 1 |
| Eimermacher, A; Flieger, D; Galle, PR; Geer, T; Gracien, E; Heike, M; Höhler, T; Junginger, T; Menges, M; Moehler, M; Siebler, J; Wein, A | 1 |
| Blumgart, L; D'Angelica, M; DeMatteo, R; Fong, Y; Gönen, M; Jarnagin, W; Kemeny, N; Leonard, G; Morse, M; Paty, P; Schwartz, L | 1 |
| Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY | 1 |
| Benson, AB; Chen, YJ; Choti, MA; Dilawari, RA; Engstrom, PF; Enke, CA; Fakih, MG; Fuchs, C; Kiel, K; Knol, JA; Leong, LA; Ludwig, KA; Martin, EW; Rao, S; Saif, MW; Saltz, L; Skibber, JM; Venook, AP; Yeatman, TJ | 1 |
| Leong, LA; Rosales, J | 1 |
| El-Salhy, M; Hilding, L; Royson, H; Tjomsland, V | 1 |
| Bendardaf, R; Elzagheid, A; Lamlum, H; Pyrhönen, S; Ristamäki, R | 1 |
| Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J | 1 |
| Tyagi, P | 1 |
| Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA | 1 |
| Chan, AT; Ho, WM; King, A; Koh, J; Lai, P; Leow, CK; Lim, R; Ma, B; Mok, T; Wong, YY; Yeo, W | 1 |
| Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z | 1 |
| Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H | 1 |
| Jones, DH; Lynch, H; Silberstein, PT; Ternet, C | 1 |
| Abbruzzese, JL; Eng, C | 1 |
| Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Abbruzzese, JL; Chang, DZ | 1 |
| Fuchs, CS; Goldberg, RM; Hillner, BE; Sargent, DJ; Schrag, D | 1 |
| Akasaka, Y; Hata, Y; Honda, S; Ito, T; Matsuoka, S; Nakajima, N; Ohmori, K; Sano, F; Yokoyama, R | 1 |
| Mitsugi, K; Nakano, S; Tanaka, R; Ueki, T; Umeno, M | 1 |
| Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S | 1 |
| Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G | 1 |
| Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K | 1 |
| Dercksen, W; Giaccone, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Smorenburg, CH; van Groeningen, CJ; van Riel, AM | 1 |
| Jensen, BV; Pfeiffer, P | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L | 1 |
| Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y | 1 |
| Ichimori, T; Ishikawa, M; Ishikura, H; Kimura, S; Okitsu, H; Sakata, A; Seike, J; Yuasa, Y | 1 |
| Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS | 1 |
| Hurwitz, H; Kabbinavar, F | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T | 1 |
| Hamada, H; Katsuki, Y; Takada, J; Tsuji, Y | 1 |
| Dimou, E; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Xynotroulas, JP | 1 |
| Alonso, M; Balcells, M; Barceló, R; Castañón, C; Centelles, M; GarcíaGirón, C; López Vivanco, G; Navalón, M; Ramos, M; Rivera, F | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N | 1 |
| Hladíková, J; Kubácková, K; Kubala, E; Linke, Z; Pipková, R; Prausová, J | 1 |
| Dong, QM; He, YJ; Li, YH | 1 |
| Ishiguro, A; Munakata, M; Saitoh, S; Sakata, Y; Shitara, K | 1 |
| Aparicio, J; Balcells, M; Busquier, I; Campos, JM; Fernandez-Martos, C; Llorca, C; Maestu, I; Perez-Enguix, D; Vincent, JM | 1 |
| Gupta, C; Gupta, V; Malani, AK; Rangineni, S | 1 |
| Blanke, CD; Goldberg, RM; Hollis, DR; Lenz, HJ; Niedzwiecki, D; Sutherland, S; Taylor, JR; Venook, AP | 1 |
| Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL | 1 |
| Abderrahim, AG; Astre, C; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Abdalla, EK; Vauthey, JN | 1 |
| Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M | 1 |
| Bhatnagar, P; Levine, E; Saunders, MP; Swindell, R; Valle, JW; Young, E | 1 |
| Marshall, J | 1 |
| Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E | 1 |
| Bracco-Nolin, CH; Chaigneau, L; Huchet, B; Legat-Fagnoni, C; Limat, S; Pivot, X; Stein, U; Woronoff-Lemsi, MC | 1 |
| Goyle, S; Maraveyas, A | 1 |
| de Gramont, A; Tournigand, C | 1 |
| Arveux, P; Bedenne, L; Bonnetain, F; Bouché, O; Conroy, T; Etienne, PL; Giovannini, M; Girault, C; Mitry, E; Raoul, JL; Rougier, P; Seitz, JF | 1 |
| Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N | 1 |
| André, T; Aparicio, T; de Gramont, A; Flesch, M; Hebbar, M; Lledo, G; Louvet, C; Mabro, M; Tournigand, C; Varette, C | 1 |
| Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD | 1 |
| András, C; Farczádi, E; Szántó, J | 1 |
| André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A | 1 |
| Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N | 1 |
| Baudin, E; Boige, V; de Baere, T; Dromain, C; Ducreux, MP; Duvillard, P; Elias, D; Kergoat, P; Lasser, P; Leboulleux, S; Malka, D; Sabourin, JC; Schlumberger, M | 1 |
| Akazai, Y; Kimura, H; Nitta, Y | 1 |
| Beaven, AW; Goldberg, RM | 1 |
| Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S | 1 |
| Chen, JZ; Liao, WJ; Luo, RC; Zheng, H | 1 |
| Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S | 1 |
| Akita, H; Ishida, H; Kabuto, T; Nakaguchi, K; Watanabe, Y | 1 |
| Morimoto, N; Shibaki, T | 1 |
| Konietzny, P; Schmassmann, A; Schmassmann-Suhijar, D; Yoon, S; Zuber, M | 1 |
| Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G | 1 |
| Goto, A | 1 |
| Iwamoto, S; Yoshioka, K | 1 |
| Uemura, N; Yamada, Y | 1 |
| Boku, N; Yamazaki, K; Yoshino, T | 2 |
| Meropol, NJ | 2 |
| Alberts, S; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ | 1 |
| Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ | 1 |
| Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U | 1 |
| Biedrzycki, BA | 1 |
| Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C | 1 |
| Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C | 1 |
| Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K | 1 |
| Han, MJ; Kang, WK; Kim, HJ; Kwon, JM; Lee, HR; Lee, J; Lim, HY; Oh, SY; Park, BB; Park, JO; Park, YS | 1 |
| Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH | 1 |
| Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX | 1 |
| Adlakha, A; Allen, JA; Bergethon, PR | 1 |
| Cattral, MS; Chan, EK; Dixon, E; Gallinger, S; Grant, DR; Greig, PD; Sahajpal, A; Taylor, BR; Vollmer, CM; Wei, A | 1 |
| Abdalla, EK; Charnsangavej, C; Donadon, M; Loyer, EM; Vauthey, JN | 1 |
| Cai, X; Guo, YW; Lin, F; Sun, YJ; Tang, LN; Tang, XC; Yao, Y; Zhang, W; Zhao, H | 1 |
| Fukada, T; Hasegawa, A; Hashimoto, R; Hayashi, T; Kametaka, H; Kawano, H; Koyama, T; Seike, K; Tanaka, H; Yasuno, K | 1 |
| Sekine, N; Terada, K | 1 |
| Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M | 1 |
| Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N | 1 |
| Bruckner, HW; Coopeman, AM; Hrehorovich, VR; Meeus, SI; Sawhney, HS | 1 |
| Wang, JW; Zhou, ZT | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Desrame, J; Fallik, D; Landi, B; Lecomte, T; Lledo, G; Mansourbakht, T; Spano, JP; Taïeb, J | 1 |
| Berardi, R; Cascinu, S; Ceccarelli, C; Di Fabio, F; Funaioli, C; Giannetta, L; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL; Siena, S | 1 |
| Borojevic, N; Kecmanovic, D; Kezic, I; Micev, MT; Milicevic, M; Popov, IP; Radosevic-Jelic, Lj; Tomasevic, Z | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Wilson, G | 1 |
| Gyôrffy, B; Tegze, B; Tulassay, Z | 1 |
| Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX | 1 |
| Fujino, K; Ishikubo, T; Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N | 1 |
| Falk, S; Glynne-Jones, R; Maughan, TS; Meadows, HM; Sebag-Montefiore, D | 1 |
| Cicin, I; Karagol, H; Uygun, K; Uzunoglu, S | 1 |
| Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T | 1 |
| Guan, ZZ | 1 |
| Kitajima, M; Kubota, T; Wada, N | 1 |
| Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF | 1 |
| Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
| Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M | 1 |
| Kuboki, Y; Mizunuma, N | 1 |
| Kabeya, K; Kamoshita, N; Kobayashi, M; Makita, F; Matsuzaki, Y | 1 |
| Billard, V; Blot, F; Elias, D; Goere, D; Kohneh-Shahri, N; Pocard, M; Raynard, B | 1 |
| Cheng, J; Li, J; Wu, CP; Wu, Q; Xu, LG; Xu, N; Zhang, W; Zhao, ZY | 1 |
| Hyodo, I | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N | 1 |
| Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W | 1 |
| Shoji, Y; Toyooka, M | 1 |
| Wils, J | 1 |
| André, T; de Gramont, A; Larsen, AK; Louvet, C; Tournigand, C | 1 |
| Abbrederis, K; Kremer, M; Schuhmacher, C | 1 |
| Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y | 1 |
| Ardito, F; Barone, C; Cassano, A; Giovannini, I; Giuliante, F; Nuzzo, G; Pozzo, C; Vellone, M | 1 |
| Hatate, K; Ihara, A; Kokuba, Y; Nakamura, T; Onosato, W; Ozawa, H; Sato, T; Watanabe, M | 1 |
| Chiba, H; Honda, K; Kondo, H; Makino, K; Mizushima, T; Ohura, K; Sumiyoshi, T; Tamura, F; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N | 1 |
| Kasuga, T; Midorikawa, Y; Nakachi, T | 1 |
| Takahashi, K | 1 |
| Hirata, K; Imai, S; Imazeki, M; Iwata, S; Kaneko, J; Komatsu, Y; Mochiduki, H; Suzuki, C; Taguchi, Y; Ueno, M; Watanabe, K; Watanabe, Y | 1 |
| Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S | 1 |
| Caron, P; Liu, D; Patel, S; Seiter, K | 1 |
| Marshall, JL | 1 |
| Benson, AB; Mulcahy, MF; Wisinski, KB | 1 |
| Adoniou, E; Bacoyiannis, C; Felekouras, E; Gryniatsos, J; Kosmas, C; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Sigala, F; Skopelitis, H; Tsavaris, N; Zacharakis, M; Zografos, G | 1 |
| Gotoh, M; Hoshino, Y; Terashima, M | 1 |
| Komatsu, Y | 2 |
| Amado, RG; Berlin, J; Chan, D; Hecht, JR; Hu, E; Malik, I; Posey, J; Tchekmedyian, S; Yang, L | 1 |
| Fakih, MG; Gupta, B; LeVea, C; Litwin, A | 1 |
| Grothey, A; Marshall, JL | 1 |
| Alessandroni, P; Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Ficarelli, R; Fontana, A; Giustini, L; Graziano, F; Lippe, P; Loupakis, F; Magnani, M; Maltese, P; Mari, D; Menichetti, ET; Pizzagalli, F; Ruzzo, A; Santini, D; Schiavon, G; Testa, E; Tonini, G | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Krook, JE; McWilliams, RR; Morlan, BW; Rowland, KM; Salim, M | 1 |
| Alberts, SR; Ashley, AC; Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Grothey, A; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK | 1 |
| Doi, K; Kudo, K; Matsuo, A; Ogata, K; Ohchi, T; Ootao, R | 1 |
| Bearz, A; Berretta, M; Berretta, S; De Ruvo, N; Di Benedetto, F; Drigo, A; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U; Zanet, E | 1 |
| Kawamura, Y; Konishi, F | 1 |
| Benson, A; Wisinski, K | 1 |
| Ferry, DR; Griffiths, GO; Gwyther, SJ; James, R; Ledermann, JA; Maraveyas, A; Maughan, TS; Meade, AM; Parmar, MK; Seymour, MT; Shepherd, S; Smith, DB; Stephens, RJ; Thompson, L; Topham, C | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP | 1 |
| Berglund, A; Brünner, N; Byström, P; Christensen, IJ; Glimelius, B; Nielsen, HJ; Sørensen, NM | 1 |
| Artru, P; Bennouna, J; Bugat, R; Delord, JP; Desseigne, F; Douillard, JY; Faroux, R; François, E; Husseini, F; Naman, H; Perrier, H; Piedbois, P; Smith, D | 1 |
| Edelstein, E; Gutman, M; Klein, B; Paran, H | 1 |
| Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ | 1 |
| Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C | 1 |
| Aso, M; Higashi, H; Imamura, S; Kakeji, Y; Katoh, H; Maehara, S; Maehara, Y; Makino, I; Saeki, H; Tanaka, J | 1 |
| Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT | 1 |
| Klek, S; Kulig, J; Popiela, T; Richter, P | 1 |
| Alberts, SR; Delaunoit, T; Dy, GK; Findlay, BP; Fuchs, CS; Goldberg, RM; Green, EM; Krook, JE; Morton, RF; Pitot, HC; Pockaj, BA; Ramanathan, RK; Sargent, DJ; Sticca, RP; Williamson, SK | 1 |
| He, YJ; Jiang, WQ; Li, YH; Luo, HY; Shi, YX; Wang, F; Xu, RH; Zhang, L | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T | 1 |
| Eguchi, T; Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Tanaka, K; Toiyama, Y; Yoshiyama, S | 1 |
| Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG | 1 |
| Oestreicher, P | 1 |
| Chen, Y; Chu, Q; Iqbal, K; Mei, Q | 1 |
| Eigenbrod, T; Klebl, F; Kullmann, F | 1 |
| Abe, S; Araki, H; Chiba, H; Iyama, S; Kato, J; Murase, K; Niitsu, Y; Nikaido, T; Sagawa, T; Sato, T; Sato, Y; Takayama, T; Wada, Y | 1 |
| Bachelot, T; Biron, P; Blay, JY; Brantus, JF; Confavreux, C; Ghesquière, H; Guastalla, JP; Ray-Coquard, I; Rustam, F; Saba, C; Sebban, C | 1 |
| Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C | 1 |
| Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N | 1 |
| Ballem, N; Berber, E; Parikh, RT; Siperstein, AE | 1 |
| Astone, A; Barone, C; Basso, M; Cassano, A; D'Argento, E; Giuliante, F; Nuzzo, G; Pozzo, C; Schinzari, G; Trigila, N | 1 |
| Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M | 1 |
| Carroll, C; Jones, R; Paisley, S; Tappenden, P | 1 |
| Berglund, A; Dahl, O; Glimelius, B; Ogreid, D; Sørbye, H; Tveit, KM; Wanderås, EH; Wentzel-Larsen, T | 1 |
| Kim, HJ; Kim, JH; Kim, SG; Kim, SH; Kwon, HC; Lee, S; Oh, SY | 1 |
| Chang, HM; Kang, YK; Kim, MK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Baba, K; Matsuda, M; Tashima, R; Yamashita, Y; Yokoyama, S | 1 |
| Chu, E; Grothey, E | 1 |
| Barrueco, J; Fuchs, CS; Ganju, V; Jeffery, M; Marshall, J; Mitchell, E; Richards, D; Schulz, J; Soufi-Mahjoubi, R; Wang, B; Wierzbicki, R | 1 |
| Akiyama, S; Gotoh, H; Gotoh, Y; Nakayama, H; Takami, H | 1 |
| Meric, JB | 1 |
| Arnold, D; Lordick, F | 1 |
| Fujisawa, M; Ishibiki, Y; Ishiyama, S; Kitabatake, T; Kojima, K; Machida, M; Nakayama, Y; Nitta, S; Ono, S; Shinjou, K; Urao, M | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A | 1 |
| Inaba, Y; Muro, K; Najima, M; Nishiofuku, H; Sato, Y; Shimamoto, H; Ura, T; Yamaura, H | 1 |
| Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N | 1 |
| Ahn, JB; Cha, SH; Choi, JS; Kim, H; Kim, KS; Kim, NK; Min, BS; Roh, JK | 1 |
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
| Ando, M; Hirayama, Y; Kohda, K; Konuma, Y; Nakamura, Y; Obata, M; Seki, R; Wada, Y; Yoshida, M | 1 |
| Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY | 1 |
| Amadio, P; Caputo, G; Condorelli, S; Cordio, S; Germano, D; Manzione, L; Mattina, M; Reggiardo, G; Rosati, G | 1 |
| Clavero, JM; Garrido, M; González, S; O'Brien, A; Orellana, E | 1 |
| Hori, S; Hyodo, I; Iguchi, H; Imamine, S; Kajiwara, T; Kataoka, J; Moriwaki, T; Nasu, J; Nishina, T | 1 |
| Hasegawa, H; Kanekiyo, S; Kubo, H; Tada, K; Watanabe, Y | 1 |
| Cho, EK; Chung, M; Lee, JH; Lee, SI; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB | 1 |
| Castellucci, P; Di Fabio, F; Fanti, S; Funaioli, C; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Pinto, C; Rojas Llimpe, FL; Sperandi, F | 1 |
| Mohile, SG; Petrylak, DP; Schleicher, L | 1 |
| Hentrich, M; Hoffmann, U; Lutz, L; Reitmeier, M; Scheidt, B; Schiel, X | 1 |
| Bachellier, P; Casnedi, S; Chenard-Neu, MP; Dufour, P; Jaeck, D; Nakano, H; Oussoultzoglou, E; Rosso, E | 1 |
| Bramhall, SR; Buckels, JA; Coldham, CA; Hubscher, SG; Mayer, AD; Mehta, NN; Mirza, DF; Ravikumar, R; Wigmore, SJ | 1 |
| Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C | 1 |
| Goldberg, RM; Grothey, A; Hedrick, EE; Hurwitz, HI; Mass, RD; Ramanathan, RK; Sargent, DJ; Sarkar, S; Suzuki, S | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Siriwittayakorn, P; Somwangprasert, A; Sukthomya, V; Tharavichitkul, E | 1 |
| Balteskard, L; Braendengen, M; Sørbye, H | 1 |
| Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K | 1 |
| Bascoul-Mollevi, C; Bec, N; Conseiller, E; Copois, V; Del Rio, M; Denis, V; Fraslon, C; Gongora, C; Larroque, C; Martineau, P; Molina, F; Robert, B; Vié, N | 1 |
| Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G | 1 |
| Ariad, S; Gluzman, A; Lavrenkov, K; Man, S; Mermershtain, W; Rubinov, K | 1 |
| Barrueco, J; Fuchs, CS; Marshall, J | 1 |
| Wijesinghe, N | 1 |
| Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E | 1 |
| Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C | 1 |
| Fukuda, H; Hirokawa, S; Nagata, T; Sawada, S; Tazawa, K; Tsukada, K; Uotani, H; Yamagishi, F | 1 |
| Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Floriani, I; Fontana, A; Giustini, L; Graziano, F; Humar, B; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Rulli, E; Ruzzo, A; Santini, D; Schiavon, G; Tonini, G; Torresi, U | 1 |
| Douillard, JY; Folprecht, G; Hecker, H; Köhne, CH; Maughan, TS; Mitry, E; Rougier, P; Saltz, L; Schubert, U; Seymour, MT; Stephens, RJ; Van Cutsem, E | 1 |
| Chu, E; Lee, JJ | 2 |
| Barutca, S; Bolaman, Z; Kadikoylu, G; Meydan, N; Yavasoglu, I | 1 |
| Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E | 1 |
| Chang, HM; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
| Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM | 1 |
| Durán Merás, I; López de Alba, PL; López Martinez, L; Ornelas Soto, NE; Rodríguez Cáceres, MI | 1 |
| D'Angelica, MI; Fong, Y; Jarnagin, WR; Kemeny, NE; Munoz, JA; Raggio, G; Schwartz, LH; White, RR | 1 |
| Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Kubota, T; Ochiai, H; Okabayashi, K | 1 |
| Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S | 1 |
| Di Fiore, F | 1 |
| Bouillet, T; Des Guetz, G; Morere, JF; Wind, P | 1 |
| Akiyoshi, T; Asami, A; Baba, H; Hayashi, N; Ichisaka, S; Ikeda, M; Matsui, J; Oikawa, F; Okamoto, N; Takeshima, K; Yamafuji, K | 1 |
| Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP | 1 |
| Chang, HM; Kang, BW; Kang, YK; Kim, JC; Kim, JH; Kim, TW; Lee, JL; Lee, JS; Ryu, MH; Yu, CS | 1 |
| Heinemann, V; Moosmann, N | 1 |
| Duffy, A; Fong, Y; Huitzil-Melendez, FD; O'Reilly, EM; Shia, J | 1 |
| Boige, V; Ducreux, M; Marti, P; Merrouche, Y; Raoul, JL; Rebischung, C; Tigaud, JM | 1 |
| Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL | 1 |
| Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J | 1 |
| Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E | 1 |
| Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D | 1 |
| Duhoux, F; Mano, MS | 1 |
| Fukazawa, A; Hayashi, T; Konno, H; Kurachi, K; Nakajima, A; Nakamura, K; Nakamura, T; Suzuki, S | 2 |
| Kanekiyo, S; Katayama, S; Kitahara, M; Kubo, H; Tada, K | 1 |
| Bafaloukos, D; Bamias, A; Basdanis, G; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Karanikiotis, C; Kardamakis, D; Karina, M; Koutras, A; Misailidou, D; Papadimitriou, C; Papakostas, P; Pectasides, D; Pentheroudakis, G; Pisanidis, N; Samantas, E; Skarlos, DV; Stavropoulos, M; Vourli, G | 1 |
| Chen, P; Lin, F; Sun, Y; Tang, L; Yao, Y; Zhao, H | 1 |
| Healey-Bird, BR; Kemeny, NE; Power, DG | 1 |
| Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M | 1 |
| Benson, AB; Berinstein, NL; Caterini, J; Conry, RM; Cripps, C; Dalfen, R; Debenedette, M; Elias, I; Garett, C; Heim, WJ; Kaufman, HL; Kim-Schulze, S; Lenz, HJ; Marshall, J; Moore, M; Salha, D; Singh, D; Urba, WJ; Vogel, T; von Mehren, M; Yu, M | 1 |
| Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Waddell, T; Wilson, G | 1 |
| Stebbing, J | 1 |
| Hama, T; Hatake, K; Hirata, Y; Imada, H; Kamisugi, K; Kawakami, K; Matsusaka, S; Mizunuma, N; Nakamoto, E; Nawano, K; Ogawa, M; Shinozaki, E; Shoji, D; Suenaga, M; Yokokawa, T | 1 |
| Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM | 1 |
| Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M | 1 |
| Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD | 1 |
| McBride, D | 1 |
| Bang, YJ; Im, SA; Kim, DY; Kim, JH; Kim, TY; Lee, JS; Lee, KW; Lim, JH; Oh, DY; Seo, MD; Yi, HG | 1 |
| Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ | 1 |
| Grothey, A; Sargent, DJ | 1 |
| Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO | 1 |
| Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F | 1 |
| Hurwitz, H; Irl, C; Kabbinavar, F; Zurlo, A | 1 |
| Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J | 1 |
| Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K | 1 |
| Dintinjana, M; Dintinjana, RD; Guina, T; Krznarić, Z; Radić, M | 1 |
| Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE | 1 |
| Lam, MG; Nijsen, JF; van den Bosch, MA; van der Tweel, I; van Het Schip, AD; Vente, MA; Wondergem, M; Zonnenberg, BA | 1 |
| Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sanoff, HK; Sargent, DJ; Williamson, SK | 1 |
| Aono, T; Fujii, M; Hasegawa, J; Hirota, M; Iwase, K; Kimura, T; Matsuda, C; Nakai, S; Nasu, S; Nishikawa, K; Shimada, K; Tanaka, Y; Wada, D | 1 |
| Aoki, K; Hoshikawa, K; Nitta, H; Noda, H; Oyama, K; Wakabayashi, G | 1 |
| Chin, K; Hatake, K; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Shouji, D; Suenaga, M; Yamaguchi, T | 1 |
| Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S | 1 |
| Arnold, D; Hacker, U; Kubicka, S; Schmoll, HJ; Siewczynski, R | 1 |
| Ardito, R; Ariu, L; Boselli, S; de Braud, F; Di Meglio, G; Fazio, N; Lorizzo, K; Magni, E; Minchella, I; Nolè, F; Radice, D; Rocca, A; Squadroni, M; Zampino, MG | 1 |
| Hurwitz, HI; Kabbinavar, FF; Rosen, O; Sarkar, S; Yi, J | 1 |
| Aderka, D; Ben-Haim, M; Figer, A; Klausner, JM; Lubezky, N; Nakache, R; Shmueli, E; Small, RM | 1 |
| Baki, M | 1 |
| Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S | 1 |
| Khan, AZ; Makuuchi, M; Morris-Stiff, G | 1 |
| Arnold, D | 1 |
| Barone, C; Pozzo, C | 1 |
| Akagi, K; Fujita, J; Hata, T; Hayashi, S; Ikeda, K; Kagawa, Y; Kato, H; Kawanishi, K; Kitada, M; Maeda, S; Nomura, M; Oshima, N; Sasaki, T; Shimano, T; Shimizu, J; Takamoto, K; Tsukahara, Y | 1 |
| Augé, JM; Carcereny, E; Codony-Servat, J; Gallego, R; García-Albéniz, X; Gascón, P; Longarón, R; Maurel, J; Oliveras, A; Tosca, M | 1 |
| Chin, K; Hatake, K; Konishi, F; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Hurwitz, HI; Ince, W; Novotny, WF; Rosen, O; Yi, J | 1 |
| Hendlisz, A; Van den Eynde, M | 1 |
| André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C | 1 |
| Ahn, JB; Byun, JH; Hong, YS; Im, SA; Jung, KH; Kang, WK; Kim, TW; Lee, J; Lee, N; Lim, HY; Oh, DY; Park, JO; Park, SH; Park, YS; Shin, DB; Shin, SJ | 1 |
| Cao, W; Geng, M; Jiang, J; Jin, Y; Li, H; Lou, G; Ma, T; Xi, W; Yang, W | 1 |
| Becouarn, Y; Bedenne, L; Bouché, O; Bugat, R; Conroy, T; Douillard, JY; Ducreux, M; Gamelin, E; Gourgou-Bourgade, S; Kramar, A; Mineur, L; Raoul, JL; Seitz, JF; Viret, F; Ychou, M | 1 |
| Cannone, M; Casaretti, R; Comella, P; Franco, L; Greco, E; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Palmeri, S; Putzu, C; Roselli, M; Sandomenico, C; Vessia, G | 1 |
| Flowers, C; Kauh, J; Moore, SG; Shenoy, PJ; Tumeh, JW | 1 |
| Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M | 1 |
| Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D | 1 |
| Hokkoku, K; Kiba, T; Mori, M; Nakagawa, T; Nakai, M; Oikawa, M; Sakuma, H; Shintaku, K; Ueda, H; Watanabe, Y; Yoshimitsu, Y | 1 |
| Andreuccetti, M; Baldi, G; Brunetti, IM; Cupini, S; Falcone, A; Ferraldeschi, R; Filipponi, F; Fornaro, L; Goletti, O; Loupakis, F; Masi, G; Naso, G; Pietrabissa, A; Pollina, L; Ricci, S; Vasile, E | 1 |
| Kawabata, Y; Nakagawa, A; Tamiya, Y; Uchikoshi, H | 1 |
| Bertagnolli, MM; Compton, CC; Damas, B; Goldberg, RM; Hahn, HP; Hall, M; Jewell, SD; Mayer, RJ; Niedzwiecki, D; Redston, M; Saltz, LB; Warren, RS | 1 |
| Adachi, M; Iida, A; Mori, K; Sakakibara, T; Sugawara, S; Sugiura, M; Takimoto, N; Yamamura, K | 1 |
| Arai, H; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Nishi, Y; Sasajima, K; Sugiura, A; Suzuki, S; Tajiri, T; Wakabayashi, H; Yanagi, K; Yokoyama, T | 1 |
| Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A | 1 |
| Bodoky, G; Chang Chien, CR; D'Haens, G; Folprecht, G; Hitre, E; Köhne, CH; Lim, R; Makhson, A; Nippgen, J; Pintér, T; Roh, JK; Rougier, P; Ruff, P; Schlichting, M; Stroh, C; Tejpar, S; Van Cutsem, E; Zaluski, J | 1 |
| Carloni, F; Nicoletti, S; Ravaioli, A; Tamburini, E; Tassinari, D | 1 |
| Chang, MH; Ji, SH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lim, DH; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY | 1 |
| Aussilhou, B; Belghiti, J; Dokmak, S; Faivre, S; Paradis, V; Vilgrain, V | 1 |
| Biason, P; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Innocenti, F; Toffoli, G | 1 |
| Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL | 1 |
| Alberts, SR; Fitch, TR; Goldberg, RM; Kim, GP; Mahoney, MR; Mathews, AP; Mitchell, E; Philip, PA; Pitot, HC; Rowland, KM; Sargent, DJ | 1 |
| Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Berry, S; Bridgewater, J; Canon, JL; Cunningham, D; DiBartolomeo, M; Georgoulias, V; Kretzschmar, A; Mazier, MA; Michael, M; Peeters, M; Rivera, F; Van Cutsem, E | 1 |
| Berg, DJ; Bernaards, C; Blanchard, R; Denlinger, CS; Dorr, A; Hambleton, J; Holden, S; Kearns, A; Kenkare-Mitra, S; Litwin, S; Lum, B; McLaughlin, S; Meropol, NJ; O'Dwyer, PJ; Redlinger, M; Spittle, C; Xu, L | 1 |
| Korbakis, D; Scorilas, A | 1 |
| André, T; Aranda, E; Barone, C; Bodoky, G; Bokemeyer, C; Cisar, L; Collette, L; Cunningham, D; Di Costanzo, F; Greil, R; Khayat, D; Labianca, R; Mini, E; Nordlinger, B; Roth, AD; Sobrero, AF; Tabernero, J; Topham, C; Van Cutsem, E; Zhang, X | 1 |
| Bathe, OF; Bigam, D; Butts, C; Dixon, E; Dowden, S; Ernst, S; Holland, D; Koppel, J; Porter, GA; Sutherland, FR | 1 |
| García-López, JL; Jaén, P; Medina, J; Moreno, C; Pérez-García, B; Vano-Galvan, S | 1 |
| Kannerup, AS; Knudsen, AR; Mortensen, FV; Nielsen, DT | 1 |
| Han, H; Kim, HJ; Kim, SG; Kim, SH; Kwon, HC; Lee, S; Oh, SY; Seo, BG | 1 |
| Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y | 1 |
| Chang, YT; Chen, CW; Chu, KS; Lin, SR; Lu, CY; Tsai, HL; Wang, HM; Wang, JY; Yeh, YS; Yen, LC | 1 |
| Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nakajima, T; Shimada, Y; Yamada, Y | 1 |
| Gill, S; Goldberg, RM | 1 |
| Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M | 1 |
| Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J | 1 |
| Li, J; Saif, MW | 1 |
| Chang, HJ; Hong, YS; Jeong, SY; Jung, KH; Park, JG; Shin, YK; Yoo, BC | 1 |
| Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H | 1 |
| Fukuoka, T; Hatano, N; Imamura, Y; Morita, Y; Usui, H; Yokoyama, S | 1 |
| Gon, H; Hamabe, Y; Inui, K; Ishida, T; Kanemitsu, K; Nakajima, T; Tanaka, K; Toyokawa, A; Tsukamoto, T; Yamashita, H | 1 |
| Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S | 1 |
| Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N | 1 |
| Goldberg, RM; Green, EM; McLeod, HL; Sanoff, HK; Sargent, DJ | 1 |
| Ishizuka, M; Kubota, K; Nagata, H; Takagi, K | 1 |
| Fukumitsu, H; Hirakawa, H; Hoshikawa, T; Makuuchi, H; Mukai, M; Ogoshi, K; Okada, K; Tajima, T; Yazawa, N | 1 |
| Cunningham, D; Okines, A | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wang, XN; Wen, Q | 1 |
| Del Monte, G; Formica, V; Guadagni, F; Ludovici, G; Palmirotta, R; Roselli, M; Savonarola, A | 1 |
| Schmidt, C | 1 |
| Bodnar, L; Stec, R; Szczylik, C | 1 |
| Chin, K; Fujiwara, Y; Hatake, K; Ichimura, T; Kobayashi, K; Konishi, F; Kuboki, Y; Matsueda, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M | 1 |
| Saif, MW | 3 |
| Fournier, P; Hebbar, M; Romano, O | 1 |
| Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK | 1 |
| Chen, J; Chen, Z; Ge, J; Li, J; Li, X; Wu, S; Yin, J | 1 |
| Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, L | 1 |
| An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karampeazis, A; Kouroussis, Ch; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Del Vecchio Blanco, G; Fiaschetti, V; Formica, V; Grenga, I; Massara, MC; Pallone, F; Portarena, I; Roselli, M; Sileri, P; Skoulidis, F; Tosetto, L | 1 |
| Kemeny, NE; Power, DG | 2 |
| de Gramont, A; Hebbar, M; Pruvot, FR; Romano, O; Triboulet, JP | 1 |
| Boostrom, SY; Donohue, JH; Harmsen, S; Kendrick, M; Nagorney, DM; Que, F; Reid-Lombardo, KM; Thomsen, K | 1 |
| Jang, JS; Kim, BG; Kim, DK; Kim, HJ; Kim, MC; Kim, SG; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY | 1 |
| Habbema, JD; Kuipers, EJ; Lansdorp-Vogelaar, I; van Ballegooijen, M; Zauber, AG | 1 |
| Assenat, E; Bachet, JB; Boyer-Gestin, C; Lepère, C; Lièvre, A; Mitry, E; Portales, F; Rougier, P; Samalin, E; Vaillant, JN; Ychou, M | 1 |
| Cunningham, D; Yim, KL | 1 |
| Landherr, L; Nagykálnai, T | 1 |
| Bodrogi, I; Küronya, Z; Lövey, J; Manninger, S; Pápai, Z; Plótár, V | 1 |
| Han, DJ; Hwang, JY; Kim, JE; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, JS; Lee, SK; Lee, SS; Park, DH; Seo, DW; Yoo, C | 1 |
| Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; Weide, R | 1 |
| Kato, S; Kawami, H; Nishigami, K; Yamaguchi, K; Yamaguchi, T | 1 |
| Adlard, JW; Allan, JM; Braun, MS; Daly, CL; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Seymour, MT; Thompson, L | 1 |
| Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE | 1 |
| Baselga, J; Cervantes, A; Ciardiello, F; Kisker, O; Liebscher, S; Macarulla, T; Martinelli, E; Ramos, FJ; Rivera, F; Rodriguez-Braun, E; Roselló, S; Tabernero, J; Vega-Villegas, ME | 1 |
| Bechstein, WO; Folprecht, G; Frilling, A; Goekkurt, E; Gruenberger, T; Hartmann, JT; Herrmann, T; Köhne, CH; Konopke, R; Lang, H; Liersch, T; Lordick, F; Ockert, D; Parisi, F; Raab, HR; Stoehlmacher, J; Stroszczynski, C; Weitz, J | 1 |
| Adam, R; Tejpar, S; Van Cutsem, E | 1 |
| Dohn, LH; Jensen, BV; Larsen, FO | 1 |
| Abbruzzese, JL; Adinin, R; Ellis, LM; Eng, C; Glover, KY; Heymach, JV; Hoff, PM; Kopetz, S; Lieu, C; Morris, JS; Overman, MJ; Tran, HT; Valero, V; Wen, S; Wolff, RA; Yan, S | 1 |
| Baba, N; Ishigami, S; Kitaguchi, K; Nakauchi, M; Nakayama, Y; Ohe, H; Sakikubo, M; Taira, K; Tamura, J; Ura, K; Yoshikawa, A | 1 |
| Lin, SR; Lu, CY; Uen, YH; Wang, JY; Wu, DC; Wu, IC; Yen, LC; Yu, FJ | 1 |
| Prewett, M; Steiner, P; Surguladze, D; Tonra, JR | 1 |
| Avital, I; Berger, A; Duffy, A; Giaccone, G; Goldspiel, BR; Kammula, US; Kemp, CD; Kerkar, SP; Kwong, KF; Quezado, M; Rosenberg, SA; Schrump, DS; Steinberg, SM; Toomey, MA; Venkatesan, A; Walker, M | 1 |
| Chika, N; Hatano, S; Hokama, N; Ishibashi, K; Ishida, H; Ishiguro, T; Ishii, M; Kubota, S; Kuwabara, K; Miyazaki, T; Okada, N; Tajima, Y | 1 |
| Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Takaoka, M; Yanagida, N; Yoneya, R | 1 |
| Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Ohashi, M; Suzuki, Y; Takahashi, K; Yamaguchi, T | 1 |
| Iida, A; Kaneko, T; Mishima, T; Miyazaki, M; Muto, T; Shimizu, K; Yoshidome, H | 1 |
| Inoue, S; Nasu, K; Noda, K; Umekita, N | 1 |
| Hazama, S; Nakatsu, H; Oka, M; Sakamoto, K; Tomochika, S; Yoshino, S | 1 |
| Fujitani, K; Hirao, M; Ikenaga, M; Miki, Y; Mishima, H; Miyamoto, A; Miyazaki, M; Nakamori, S; Tsujie, M; Tsujinaka, T; Yasui, M | 1 |
| Hokama, N; Inokuma, S; Ishibashi, K; Ishida, H; Ishiguro, T; Miyazaki, T; Ohsawa, T; Okada, N; Yokoyama, M | 1 |
| Kawasaki, N; Maeda, Y; Nakamura, M; Nishimura, T; Okada, T; Sakata, K; Setoguchi, M | 1 |
| Azzarello, G; Basso, U; Buonadonna, A; Cecchin, E; D'Andrea, M; De Mattia, E; De Paoli, P; Gasparini, G; Innocenti, F; Lo Re, G; Mini, E; Nobili, S; Pessa, S; Toffoli, G | 1 |
| Cho, SH; Go, SI; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Lee, GW | 1 |
| Choi, SH; Chun, HK; Lee, WS; Lee, WY | 1 |
| Adam, R; Azoulay, D; Castaing, D; de Haas, RJ; Ducreux, M; Flores, E; Lemoine, A; Lévi, F; Paule, B; Wicherts, DA | 1 |
| Chiriatti, A; Fiorentini, G; Francini, G; Montagnani, F; Turrisi, G | 1 |
| Kopper, L; Tímár, J | 1 |
| Hoshino, S; Matsuo, K; Naito, M; Nakano, M; Noda, N; Shinohara, T; Tanaka, S; Yamashita, Y; Yamauchi, Y | 1 |
| Abe, T; Fujii, K; Goto, A; Hasegawa, Y; Nishimura, S; Shinomura, Y; Sukawa, Y; Suzuki, K; Yonezawa, K | 1 |
| Baba, K; Ishigami, S; Kitazono, M; Matsushita, D; Natsugoe, S; Ogawa, H; Shinchi, H; Ueno, S | 1 |
| Kubo, N; Matuoka, T; Nobuhara, Y; Yo, T | 1 |
| Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK | 1 |
| Biffi, R; Catania, C; De Braud, F; De Pas, T; Fazio, N; Maggioni, A; Noberasco, C; Pelosi, G; Spitaleri, G; Toffalorio, F; Trifirò, G; Vigna, PD; Zampino, MG | 1 |
| Akase, T; Arakawa, I; Harada, T; Inoue, T; Miyazaki, Y | 1 |
| Arcara, C; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E | 1 |
| Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS | 1 |
| Blair, EA; Haraf, DJ; Pederson, AW; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Coche, E; Gala, JL; Humblet, Y; Marot, L; Sempoux, C; Seront, E | 1 |
| Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G | 1 |
| Aka, H; Hanashiro, N; Kiyuna, M; Matsuura, F; Miyahira, T; Murayama, S; Nishihara, M; Okushima, N; Teruya, J; Teruya, N; Toda, Y | 1 |
| Bao, HY; Chen, J; Deng, J; Fang, WJ; Huang, S; Mou, HB; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC | 1 |
| Afchain, P; Aparicio, T; Bonnetain, F; Costes, L; Gauthier, M; Gornet, JM; Lecomte, T; Locher, C; Malka, D; Mitry, E; Moulin, V; Sobhani, I; Taïeb, J; Tougeron, D; Zaanan, A | 1 |
| Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S | 1 |
| Heye, S; Maleux, G; Oyen, R; van Cutsem, E; Vaninbroukx, J | 1 |
| Allegrini, G; Andreuccetti, M; Cascinu, S; Cortesi, E; Falcone, A; Fontana, E; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Mentuccia, L; Merlano, M; Salvatore, L; Vasile, E | 1 |
| Doi, T; Fuse, N; Joh, T; Minashi, K; Ohtsu, A; Shimura, T; Tahara, M; Yoshino, T | 1 |
| Ciardiello, F; Normanno, N; Tejpar, S | 1 |
| Hasegawa, G; Hoffman, RM; Iijima, H; Ishihara, Y; Kobayashi, T; Matsunaga, K; Sato, A; Suzuki, T; Yang, M | 1 |
| Arita, M; Kuga, Y; Miwata, T; Moriya, T; Murakami, E; Nishida, T; Numata, Y; Ohya, T; Okanobu, H; Tanaka, T; Yoshimi, S | 1 |
| Asaka, M; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Miyazaki, T; Nakatsumi, H; Sasaki, T; Sogabe, S; Takagi, T; Takano, H; Uehata, Y; Yuki, S | 1 |
| Falcone, A; Loupakis, F | 1 |
| Kawabata, Y; Nakagawa, A | 1 |
| Boehm, KA; Cartwright, T; McCollum, D | 1 |
| Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F | 1 |
| Barrois, M; Beaune, P; Boige, V; Bouché, O; Castaing, M; Ducreux, M; Laurent-Puig, P; Le Corre, D; Loriot, MA; Malka, D; Mendiboure, J; Miran, I; Mulot, C; Pignon, JP; Trégouët, DA | 1 |
| Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R | 1 |
| Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L | 1 |
| Awatsu, A; Hayakari, M; Itoh, J; Koyama, M; Saijo, Y; Sato, J; Terui, K | 1 |
| Hirata, K; Nakamura, Y; Takashima, T; Tayama, Y | 1 |
| Hashimoto, T; Inoue, K; Kokudo, N; Makuuchi, M; Maruyama, Y; Ogata, S; Sano, K; Takamoto, T; Takemura, T | 1 |
| Chen, W; Liu, G; Promkan, M; Singh, N; Wang, X | 1 |
| Doi, T; Fuse, N; Ikematsu, H; Kaneko, K; Koike, K; Kojima, T; Minashi, K; Mochizuki, S; Ohtsu, A; Tahara, M; Yano, T; Yoshino, T | 1 |
| Amemiya, T; Aoki, M; Hosoda, K; Kamoshida, T; Kido, H; Kojima, M; Natsu, K; Tamura, H | 1 |
| Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M | 1 |
| Chua, TC; Esquivel, J; Koong, HN; Liauw, W | 1 |
| Audrain, O; Boucher, E; Kerjouan, M; Le Roux, C; Pracht, M; Raoul, JL | 1 |
| Kandefer-Szerszeń, M; Paduch, R; Piersiak, T | 1 |
| Berrevoet, F; Bocchetti, T; de Hemptinne, B; Ricciardi, S; Rogiers, X; Sainz-Barriga, M; Troisi, RI; Van Huysse, J; Vandenbossche, B; Vinci, A | 1 |
| Muro, K | 1 |
| Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Moritani, K; Ochiai, H; Okabayashi, K; Watanabe, M | 1 |
| Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E | 1 |
| Awatsu, A; Gasa, F; Hakamada, K; Kimura, N; Kimura, Y; Koyama, M; Morohashi, H; Murata, A; Sakamoto, Y; Sato, J; Terui, K | 1 |
| Goto, M; Hata, M; Ishiyama, S; Kojima, Y; Komiyama, H; Nagayasu, K; Niwa, K; Okuzawa, A; Ono, S; Sakamoto, K; Sengoku, H; Sugimoto, K; Takahashi, M; Tanaka, M; Tashiro, Y; Tomiki, Y; Yaginuma, Y | 1 |
| Engelman, JA; Ferrone, CR; Lisovsky, M; Ryan, DP; Sahani, DV | 1 |
| Chau, GY; Chen, WS; Hsieh, YY; Hsu, YN; King, KL; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH | 1 |
| Ajima, H; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Nakayama, H; Ogata, H; Sasaki, Y; Sunakawa, Y; Takahashi, H; Yamashita, K | 1 |
| Beslija, S; Brodowicz, T; Ciuleanu, TE; Esser, R; Faluhelyi, Z; Koza, I; Kurteva, G; Messinger, D; Mrsic-Krmpotic, Z; Ocvirk, J; Pápai, Z; Papamichael, D; Scheithauer, W; Shacham-Shmueli, E; Vrbanec, D; Wenczl, M; Wrba, F; Yalcin, S; Yilmaz, U; Zielinski, CC | 1 |
| Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N | 1 |
| Goldberg, RM; McLeod, H; Sargent, DJ | 1 |
| Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K | 1 |
| Díaz-Rubio, E; García-Foncillas, J | 1 |
| Armakolas, A; Batzios, S; Batziou, C; Koutantos, J; Legakis, J; Stathopoulos, GP; Stathopoulos, J; Trafalis, D | 1 |
| Baxevanis, CN; Gritzapis, AD; Kosmas, C; Tsavaris, N; Voutsas, IF | 1 |
| Berglund, A; Fernebro, E; Flygare, P; Glimelius, B; Gubanski, M; Johnsson, A; Kadar, L; Karlberg, I; Lind, PA | 1 |
| Goto, Y; Hirata, T; Ikeda, O; Kubota, T; Kume, S; Takahashi, M; Torigoe, Y | 1 |
| Fukuyama, T; Hachiya, Y; Hirano, Y; Hirata, K; Ishikawa, N; Koui, S; Minagawa, N; Nakashima, H; Sako, T; Tamura, T | 1 |
| Bruns, H; Büchler, MW; Hoffmann, K; Longerich, T; Mikalauskas, S; Mikalauskiene, L; Nickkholgh, A; Schemmer, P; Strupas, K | 1 |
| Biondo, S; Dominguez, J; Escalante, E; Frago, R; Kreisler, E; Salazar, R | 1 |
| Han, B; Kang, WK; Kim, JA; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Kim, HJ; Kim, HS; Kim, SG; Kim, TG; Oh, ST; Park, HM; Park, JS; Sohn, HJ | 1 |
| Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F | 1 |
| Grothey, A | 1 |
| André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Collins, S; Ducreux, M; Gansert, J; Hotko, Y; Lordick, F; Oliner, KS; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Rong, A; Sobrero, AF; Strickland, AH; Tzekova, V; Van Cutsem, E; Wilson, G | 1 |
| Fan, J; Ling, W; Ma, Y; Wang, H | 1 |
| Candamio, S; de la Cámara, J; Grande, C; Jorge, M; López, R; Méndez, JC; Quintero, G; Reboredo, M; Romero, C; Salgado, M | 1 |
| Egawa, H; Kadokawa, Y; Kawabe, A; Nakajima, S; Sonoda, K; Yamamoto, T | 1 |
| Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Lefkowitz, RA; Rathkopf, D; Schwartz, GK; Shah, MA; Tse, A; Wu, N | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Campanella, C; Cognetti, F; Ettorre, GM; Garufi, C; Mottolese, M; Sperduti, I; Torsello, A; Tumolo, S; Vennarecci, G; Zeuli, M | 1 |
| Akiyama, Y; Ando, M; Ando, Y; Endo, H; Fujita, K; Kawara, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W; Yamashita, K | 1 |
| Bosse, D; Fischer von Weikersthal, L; Giessen, C; Goebeler, M; Grundeis, M; Heinemann, V; Lambertz, H; Maubach, PA; Mittermüller, J; Oruzio, D; Quietzsch, D; Schalhorn, A; Schlag, R; Schulze, M; Stauch, M; Szukics, B; Truckenbrodt, J; Vehling-Kaiser, U; Weigang-Köhler, K; Zwingers, T | 1 |
| Adam, R; Azoulay, D; Castaing, D; Ciacio, O; de Haas, RJ; Giacchetti, S; Guettier, C; Lévi, F; Paule, B; Sebagh, M; Wicherts, DA | 1 |
| Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N | 1 |
| Berglund, A; Byström, P; Einarsson, R; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Kim, R | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S; Vincent, J | 1 |
| Kaley, K; Saif, MW | 1 |
| Jakab, F | 1 |
| Aglietta, M; Barni, S; Beretta, GD; Corsi, D; Cortesi, E; Dapretto, E; Floriani, I; Fornarini, G; Isa, L; Labianca, R; Lonardi, S; Nicolella, D; Sobrero, A; Turci, D; Zaniboni, A | 1 |
| Chin, K; Fujimoto, Y; Hatake, K; Ichimura, T; Matsusaka, S; Mitsuhashi, K; Mizunuma, N; Ogura, M; Ozaka, M; Saiura, A; Shinozaki, E; Suenaga, M; Yamamoto, N | 1 |
| Heinemann, V; Hoff, PM | 1 |
| Jatoi, A; Ramiscal, JA | 1 |
| Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Galle, PR; Geißler, M; Kanzler, S; Kubicka, S; Lordick, F; Moehler, M; Mueller, A; Schwarz, S; Seufferlein, T; Trarbach, T | 1 |
| Allegrini, G; Andreuccetti, M; Baldi, G; Brunetti, I; Chiara, S; Cremolini, C; Crinò, L; Cupini, S; Fabbri, MA; Falcone, A; Fioretto, L; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Puglisi, M; Salvatore, L; Stasi, I; Trenta, P; Vasile, E | 1 |
| Allegra, C; George, T; Yothers, G | 1 |
| Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K | 1 |
| Barber, B; Gregory, C; Long, SR; Song, X; Wang, PF; Zhao, Z | 1 |
| Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Ait-Arsa, I; Askari, N; Bibeau, F; Boissière, F; Causse, A; Cortijo, C; Del Rio, M; Denis, V; Denouel, A; Gongora, C; Martineau, P; Marzi, L; Mollevi, C; Paillas, S; Pourquier, P; Vezzio-Vié, N | 1 |
| Daimaru, H; Fukuda, Y; Imamura, Y; Kouyama, M; Kuwada, A; Nakamitsu, A; Taogoshi, H; Touge, K; Uekami, S | 1 |
| Ge, FJ; Li, SS; Li, ZQ; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X | 1 |
| Chua, TC; Doerfer, J; Esquivel, J; Germer, CT; Kerscher, AG; Maeder, U; Morris, DL; Pelz, JO; Stojadinovic, A | 1 |
| Arends, J; Büchert, M; Fasol, U; Fischer, R; Hense, J; Jaehde, U; Kanefendt, F; Moritz, B; Mross, K; Scheulen, ME; Strumberg, D | 1 |
| Faybik, P; Fleischmann, E; Gruenberger, T; Herberger, B; Krieger, PM; Maresch, J; Tamandl, D | 1 |
| Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K | 1 |
| Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, N; Kurokawa, T; Nagahama, T; Okada, Y; Tei, S | 1 |
| Enomoto, Y; Inagaki, M; Inatsugi, N; Kawaguchi, C; Kuge, H; Masuda, T; Matsuoka, M; Nakajima, Y; Nonomura, A; Otsuji, T; Saraya, T; Shimobayashi, T; Sho, M; Tatsumi, K; Uchida, H; Yamaguchi, T; Yamanishi, K; Yamaoka, K; Yamochi, Y; Yokotani, T; Yoshikawa, S | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Higuchi, T; Isogai, J; Kaneko, J; Katsuta, E; Maejima, S; Ono, H; Saguchi, M; Someno, Y; Sugihara, K; Takahata, T; Yoshida, M | 1 |
| Goto, H; Hosokawa, T; Kakimoto, M; Koshiishi, H; Masuda, D; Matsuyama, T; Nishida, K; Okamura, T; Tokita, H; Yoshimura, T | 1 |
| Aritake, N; Endoh, A; Katsumoto, Y | 1 |
| Fujimoto, T; Itagaki, H; Matsumoto, A; Ogawa, K; Osawa, G; Otani, T; Umehara, A; Yano, Y; Yokomizo, H; Yoshimatsu, K | 1 |
| Arii, S; Ishikawa, T; Kikuchi, A; Sugihara, K; Tanaka, S; Uetake, H | 1 |
| Doki, Y; Hirose, H; Ikeda, M; Ishii, H; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Uemura, M; Yamamoto, H; Yamashita, S | 1 |
| Doki, Y; Hirose, H; Ikeda, M; Kim, HM; Miyoshi, N; Mizushima, T; Mori, M; Okano, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S | 1 |
| Aoyagi, H; Hamada, S; Hasegawa, K; Isogai, J; Kaneko, J; Katsuta, E; Maejima, S; Saguchi, M; Someno, Y; Takahata, T | 1 |
| Arai, K; Funahashi, K; Kaneko, H; Koike, J; Kubota, Y; Kurihara, A; Maeda, T; Otsuka, Y; Shimada, H; Shiokawa, H; Suzuki, T; Tamura, A; Tsuchiya, M; Watanabe, M | 1 |
| Gotoh, K; Ishikawa, O; Kano, S; Kishi, K; Miyashiro, I; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Takahashi, H; Yamada, T; Yano, M | 1 |
| Doki, Y; Hirose, H; Ikeda, M; Kagawa, Y; Kim, HM; Mizushima, T; Mori, M; Sekimoto, M; Takemasa, I; Yamamoto, H; Yamashita, S | 1 |
| Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wen, Q; Zhang, Y; Zhou, MQ | 1 |
| Arai, T; Kobayashi, S; Koike, J; Koizumi, S; Makizumi, R; Miura, K; Miyajima, N; Nakano, H; Otsubo, T; Sakurai, J; Shimamura, T; Yamada, K | 1 |
| Chatelut, E; Delord, JP; Duret, A; Etienne, MC; Falandry, C; Freyer, G; Lledo, G; Merrouche, Y; Milano, G; Rebischung, C | 1 |
| Endo, I; Kumamoto, T; Nojiri, K; Takeda, K; Tanaka, K | 1 |
| Aravantinos, G; Bafaloukos, D; Bamias, A; Basdanis, G; Dimopoulos, MA; Economopoulos, T; Efstratiou, I; Fountzilas, G; Kafiri, G; Kalofonos, HP; Karanikiotis, C; Karina, M; Klouvas, G; Korantzis, I; Makatsoris, T; Malettou, L; Matsiakou, F; Miliaras, D; Papadimitriou, CA; Papakostas, P; Papaspirou, I; Pectasides, D; Pentheroudakis, G; Pisanidis, N; Samantas, E; Xiros, N | 1 |
| Chang, HJ; Choi, HS; Kim, DY; Kim, SY; Kim, TH; Oh, JH; Park, JW; Sohn, DK; Yeo, SG | 1 |
| Fujikawa, K; Hazama, S; Kato, T; Kimura, H; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Okuyama, Y; Sakamoto, J; Takahashi, K | 1 |
| Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S | 1 |
| Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K | 1 |
| Akiyama, Y; Ando, Y; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Arai, Y; Asami, S; Endo, H; Idani, H; Iguchi, T; Inaba, Y; Kanazawa, S | 1 |
| Falcoz, PE; Massard, G; Renaud, S; Santelmo, N | 1 |
| Hanatate, F; Kobayashi, K; Komaki, C | 1 |
| Hasegawa, Y; Kameyama, N; Kuboi, K; Matsumoto, N; Mitsuhashi, H; Sekimoto, Y; Tomita, M | 1 |
| Kang, SP; Saif, MW | 1 |
| Bocci, G; Canu, B; Cremolini, C; Danesi, R; Di Desidero, T; Di Paolo, A; Falcone, A; Fioravanti, A; Frumento, P; Loupakis, F; Masi, G; Orlandi, P; Salvatore, L; Schirripa, M | 1 |
| Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y | 1 |
| Aparicio, T; Bonnetain, F; Gauthier, M; Gornet, JM; Locher, C; Malka, D; Taïeb, J; Thirot-Bidault, A; Tougeron, D; Zaanan, A | 1 |
| Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G | 1 |
| Blasco, H; Bourgoin, H; Le Guellec, C; Le Louarn, A; Lecomte, T; Pichereau, S | 1 |
| Cascinu, S; Celik, I; Ciardiello, F; Cunningham, D; Folprecht, G; Köhne, CH; Láng, I; Maurel, J; Nowacki, MP; Rougier, P; Schlichting, M; Shchepotin, I; Tejpar, S; Van Cutsem, E; Zubel, A | 1 |
| Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K | 1 |
| Begnami, MD; Cezana, L; Costa, LA; Dettino, AL; Fanelli, MF; Mello, CA; Oliveira, TB; Pinto, CA | 1 |
| Van Loon, K; Venook, AP | 2 |
| Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M | 1 |
| Des Groseilliers, S; Ferland, É; Garant, A; Martin, L; Vuong, T | 1 |
| Chang, HJ; Kim, BC; Kim, DY; Kim, MJ; Kim, SY; Kim, TH; Oh, JH; Park, JW; Sohn, DK; Yeo, SG | 1 |
| Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C | 1 |
| Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G | 1 |
| Boc, M; Ocvirk, J; Rebersek, M | 1 |
| Branda, ME; Goldberg, RM; Grothey, A; Heun, JM; Sargent, DJ | 1 |
| Asseburg, C; Frank, M; Griebsch, I; Hartmann, JT; Köhne, CH; Mittendorf, T; Mohr, A; Osowski, U; Schulten, J | 1 |
| Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A | 1 |
| Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J | 1 |
| Bencardino, K; Canestrari, E; Catalano, V; Cremolini, C; Danova, M; Falcone, A; Frumento, P; Galluccio, N; Graziano, F; Loupakis, F; Magnani, M; Manzoni, M; Masi, G; Ricci, V; Ruzzo, A; Salvatore, L; Santini, D; Schirripa, M; Tonini, G; Vincenzi, B | 1 |
| Kabbinavar, F; Kozloff, M | 1 |
| Boisen, MK; Jensen, BV; Johansen, JS; Larsen, O | 1 |
| Chabot, J; Saif, MW | 1 |
| Ankerst, DP; Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Moosmann, N; Schalhorn, A; Schulz, C; Stintzing, S; von Weikersthal, LF | 1 |
| Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Matsuda, K; Nozawa, K; Watanabe, T; Yamamoto, Y | 1 |
| Holt, K | 1 |
| Geh, JI; Ma, YT | 1 |
| Abad, MH; de Melo, JV; Vieira de Melo, MS | 1 |
| Afonso, S; Afonso, V; Stefano, E; Viani, G | 1 |
| Rocha, JA | 1 |
| Aprile, G; Avallone, A; Bordonaro, R; Butera, A; Cordio, S; De Pauli, F; Di Lucca, G; Parra, HS; Reggiardo, G; Rosati, G | 1 |
| Bethke, A; Kühne, K; Platzek, I; Stroszczynski, C | 1 |
| Matsueda, S; Sasaki, H; Tokunaga, Y | 1 |
| Hatake, K; Matsusaka, S; Mizunuma, N; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T; Yamamoto, N | 1 |
| Anne, PR; Erickson, BA; Haddock, M; Kachnic, L; Lee, RJ; Meropol, NJ; Mitchell, E; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Winter, K; Wong, SJ | 1 |
| Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M | 1 |
| Akiyoshi, K; Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Miyake, M; Nakajima, T; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Tateishi, U; Yamada, Y | 1 |
| Giaccone, G; Giovannetti, E; Hanauske, AR; Leon, LG; Peters, GJ; Smid, K; van Houte, BP | 1 |
| Bosset, JF; Créhange, G; Maingon, P | 1 |
| Bennouna, J; Borg, C; Bouché, O; Delord, JP; Douillard, JY; Faroux, R; François, E; Goldwasser, F; Husseini, F; Kraemer, S; Senellart, H; Trillet-Lenoir, V; Ychou, M | 1 |
| Abe, S; Horinouchi, Y; Kawazoe, K; Kujime, T; Minakuchi, K; Nakamura, T; Nishisako, H; Sakurada, T; Tajima, S; Teraoka, K | 1 |
| Korovina, IaV; Nasyrov, AR; Pirtskhalava, TL | 2 |
| Lowery, MA; O'Reilly, EM | 1 |
| Adenis, A; Boige, V; Boucher, E; Chauffert, B; Conroy, T; Cvitkovic, F; Ducreux, M; Farace, F; François, E; Galais, MP; Guichard, P; Jacques, N; Malka, D; Pierga, JY; Vimond, N | 1 |
| Asaka, M; Fukushima, H; Iwanaga, I; Kawamoto, Y; Kobayashi, Y; Komatsu, Y; Nakatsumi, H; Sasaki, T; Sogabe, S; Takano, H; Uehata, Y; Yuki, S | 1 |
| Hanna, N; Hsiao, FY; Mullins, CD; Onukwugha, E; Pandya, N | 1 |
| Bedenne, L; Bonnetain, F; Brixi-Benmansour, H; Cadiot, G; Hentic, O; Jouve, JL; Landi, B; Mitry, E | 1 |
| Berglund, Å; Blomqvist, L; Byström, P; Glimelius, B; Jacobsson, H; Nygren, P; Sundin, A; Suzuki, C | 1 |
| Inoue, N; Ishibashi, K; Ishida, H; Kishino, T; Kumamoto, K; Okada, N; Sano, M | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Ebata, T; Hiramatsu, K; Ishiguro, S; Muro, K; Nagino, M; Nishio, H; Takahari, D; Takahashi, Y; Takeuchi, E; Uehara, K; Yoshimura, K; Yoshioka, Y | 1 |
| Cohn, AL; Khandelwal, P; Mehta, N; Neubauer, MA; Richards, D; Shumaker, GC; Smith, DA; Watkins, DL; Yassine, MR; Zhang, K | 1 |
| Critchfield, GC; Hamilton, SA; Kaldate, RR; Roa, BB; Saam, J; Wenstrup, RJ | 1 |
| Brenckman, W; Cheng, YC; Chu, E; Copur, MS; Jiang, Z; Kummar, S; Liu, SH; O'Rourke, M; Rose, M; Stephenson, J; Su, T; Tilton, R; Wadler, S | 1 |
| André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C | 1 |
| Milella, M; Sperduti, I; Vaccaro, V | 1 |
| Chen, QQ; Gao, XP; Li, W; Pan, SY; Sun, J | 1 |
| Efrusy, MB; Göke, B; Goldberg, RM; Kirchner, T; Santas, CC; Vijayaraghavan, A | 1 |
| Peeters, M; Price, T | 1 |
| Ko, AH | 1 |
| Seymour, M | 1 |
| Abbas, M; Auby, D; Azzedine, A; Bedenne, L; Bouché, O; Castaing, M; Denis, B; Ducreux, M; Etienne, PL; Gargot, D; Gasmi, M; Geoffroy, P; Lombard-Bohas, C; Malka, D; Mendiboure, J; Michel, P; Pignon, JP; Rougier, P; Texereau, P | 1 |
| Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E | 1 |
| Auby, D; Becouarn, Y; Bellera, C; Brunet, R; Cany, L; Dauba, J; Fonck, M; Legoux, JL; Mathoulin-Pélissier, S; Mertens, C; Rainfray, M; Smith, D; Soubeyran, P; Terrebonne, E; Traissac, L | 1 |
| Fujiwara, K; Iwashita, T; Nagayoshi, Y; Nakahara, C; Yamasaki, T | 1 |
| Hata, Y; Honda, K; Ihara, E; Ihara, Y; Misawa, T; Miyata, S; Sumida, Y; Tomita, Y | 1 |
| Hattori, M; Hayashi, T; Kawase, Y; Kozaki, K; Mizuno, A; Okochi, O; Sasada, Y; Sato, Y; Takami, Y; Takamura, S; Takeda, S; Tsuboi, K; Uno, Y | 1 |
| Crea, F; Cremolini, C; Danesi, R; Falcone, A; Farrar, WL; Fornaro, L; Frumento, P; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Salvatore, L; Schirripa, M | 1 |
| Beachler, C; El-Deiry, WS; Finnberg, NK; Gingrich, R; Kline, CL; Liao, J; Scicchitano, A; Sheikh, HS; Sivik, J | 1 |
| Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY | 1 |
| Decosta, L; Fernebro, E; Gamelin, E; Greil, R; Hofheinz, R; Karthaus, M; Köhne, CH; Letocha, H; Mineur, L; Thaler, J | 1 |
| Chen, MJ; Chuang, SC; Hou, MF; Huang, MY; Kuo, CH; Lin, SR; Ma, CJ; Tsai, HL; Wang, JY | 1 |
| Allegra, CJ; Bonnetain, F; Buyse, M; Chibaudel, B; de Gramont, A; Goldberg, RM; Sargent, DJ; Shi, Q; Tournigand, C | 1 |
| Dumke, K; Krüger, M; Reymond, M; Weissinger, F | 1 |
| Chang, CY; Cho, YB; Choi, DH; Chun, HK; Kim, HC; Lee, WY; Park, HC; Park, JO; Park, YS; Yun, SH | 1 |
| Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M | 1 |
| Akiyoshi, K; Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nagashima, K; Nakajima, T; Shimada, Y; Yamada, Y | 1 |
| Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M | 1 |
| Hanna, N; Hsiao, FY; Mullins, CD; Onukwugha, E; Pandya, NB | 1 |
| Bechstein, WO; Folprecht, G | 1 |
| Ishikawa, K; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M | 1 |
| Adleff, V; Budai, B; Hitre, E; Komlósi, V; Kralovánszky, J; Láng, I; Nagy, T; Pap, É; Réti, A | 1 |
| Abu-Ghanem, S; Abu-Ghanem, Y; Man, S; Novik, EF; Shelef, I | 1 |
| Baba, H; Beppu, T; Hayashi, N; Sawayama, H; Takamori, H; Watanabe, M | 1 |
| Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Hollis, D; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Ng, K; Ogino, S; Saltz, LB; Schaefer, P; Shima, K; Spiegelman, D; Whittom, R | 1 |
| Alberts, SR; Franko, J; Goldberg, RM; Goldman, CD; Grothey, A; Nelson, GD; Pitot, HC; Pockaj, BA; Sargent, DJ; Shi, Q | 1 |
| Hyodo, I; Maehara, Y; Mishima, H; Muro, K; Oba, K; Sakamoto, J; Yoshino, T | 1 |
| Barber, B; Bhosle, M; Gao, S; Klingman, D; Pelletier, E; Wang, S; Zhao, Z | 1 |
| Benhaim, L; Labonte, MJ; Lenz, HJ | 1 |
| Goh, PG; Jeong, HY; Kim, ES; Kim, SH; Kim, YJ; Lee, BS; Lee, ES; Lee, SY; Moon, HS; Sung, JK | 1 |
| Akiyama, Y; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Maekawa, H; Matsumoto, F; Nomura, R; Saito, A; Tagami, K; Takahashi, H; Tanda, S; Tokumura, H | 1 |
| Chang-Yun, L; Elnemr, A; Hirano, M; Ichinose, M; Ishibashi, H; Kitai, T; Li, Y; Matsuda, N; Mizumoto, A; Ozamto, Y; Sako, S; Takao, N; Togawa, T; Xiao-Jun, Y; Yonemura, Y | 1 |
| Nishimura, Y; Sakamoto, H; Tanaka, Y; Yamaguchi, K; Yatsuoka, T | 1 |
| Baba, H; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Sanada, T; Wakabayashi, M | 1 |
| Chan, KM; Chen, JS; Chiang, JM; Lee, CF; Lee, WC; Wang, JY; Yu, MC | 1 |
| Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S | 1 |
| Kawakami, H; Nakagawa, K; Satoh, T | 1 |
| Ikenaga, M; Mishima, H; Yasui, M | 1 |
| Decker, T; Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Heintges, T; Jäger, E; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Scheithauer, W; Stintzing, S; Stoll, C; Vehling-Kaiser, U | 1 |
| Bourgeois, V; Ferte, C; Hebbar, M; Ladrat, L; Lindet, C; Mariette, C; Peugniez, C; Romano, O; Triboulet, JP | 1 |
| Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, Ch; Makrantonakis, P; Polyzos, A; Souglakos, J; Vamvakas, L; Xynogalos, S; Ziras, N | 1 |
| Capussotti, L; Ferrero, A; Langella, S; Lo Tesoriere, R; Russolillo, N; Vigano', L | 1 |
| Gaya, A; Tse, V | 1 |
| Abe, T; Ando, M; Kato, T; Nakashima, H; Shindo, J; Shiraki, A; Yamamoto, K; Yukita, Y | 1 |
| Bando, Y; Katakawa, M; Ogata, S; Tagami, Y | 1 |
| Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K | 1 |
| Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M | 1 |
| Crea, F; Cremolini, C; Danesi, R; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Salvatore, L; Schirripa, M | 1 |
| Baek, JH; Choi, YJ; Kang, MJ; Kim, YS; Kwon, HC; Lee, HS; Oh, SY; Park, LC; Park, MI; Park, SJ; Shin, SH | 1 |
| Chen, L; Duan, G; Huang, C; Jiang, Y; Li, Z; Wang, X | 1 |
| Colucci, G; Di Maio, M; Giuliani, F; Perrone, F | 1 |
| Choi, BI; Eo, JS; Goo, JM; Han, JK; Han, SW; Im, SA; Kim, DH; Kim, SH; Lee, ES; Paeng, JC; Willmann, JK | 1 |
| Akiyama, Y; Araki, K; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Nagashima, F; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Bo, X; Dexiang, Z; Haifu, W; Haohao, L; Jia, F; Jianmin, X; Lechi, Y; Li, L; Li, R; Qinghai, Y; Shenyong, Z; Tianshu, L; Xiangou, P; Xinyu, Q; Ye, W; Yunshi, Z | 1 |
| Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D | 1 |
| Denda, T; Hashigaki, S; Kato, T; Komatsu, Y; Lechuga, MJ; Miyata, Y; Mizutani, N; Muro, K; Nagase, M; Nishina, T; Satoh, T; Tsuji, A; Tsuji, Y; Yoshida, M | 1 |
| Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P | 1 |
| Aitini, E; Barni, S; Cascinu, S; Catalano, V; Codignola, C; Ferrara, D; Ferrari, D; Labianca, R; Valmadre, G; Veltri, E; Zaniboni, A | 1 |
| Asao, T; Fujii, T; Fukasawa, T; Kigure, W; Kuwano, H; Tabe, Y; Tsutsumi, S | 1 |
| Shimada, Y | 1 |
| Ceelen, W; De Bruyne, S; Ferdinande, L; Geboes, K; Laurent, S; Libbrecht, L; Mertens, J; Peeters, M; Smeets, P; Troisi, R; Van Damme, N; Van de Wiele, C | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isıkdogan, A; Kaplan, MA; Ozkan, M; Ozturk, SC | 1 |
| Benoist, S; Goyer, P; Hajjam, ME; Julié, C; Nordlinger, B; Penna, C | 1 |
| Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Ernani, V; Hosein, PJ; Kawamura, C; Levi, JU; Loaiza-Bonilla, A; Macintyre, J; Maldonado, JC; Merchan, JR; Narayanan, G; Portelance, L; Ribeiro, A; Rocha-Lima, CM | 1 |
| Cakar, B; Karabulut, B; Karaca, B; Sezgin, C; Uslu, R; Varol, U | 1 |
| Barot, TC; Gulec, SA; Hall, M; Pennington, K; Schwartzentruber, D; Suthar, RR; Wheeler, J | 1 |
| Bae, EJ; Kang, MJ; Kwon, JM; Lee, EK; Lee, MA; Lee, NS; Lister, J; Ngoh, CA; Park, MH; Park, SJ; Park, YS; Revil, C; Shin, SJ; Zang, DY | 1 |
| Boku, N; Doyama, H; Fukutomi, A; Machida, N; Onozawa, Y; Taniguchi, H; Todaka, A; Tsuji, K; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Akay, OM; Bal, C; Gulbas, Z; Keskin, M; Kuş, E; Ustuner, Z | 1 |
| Endo, T; Hasegawa, H; Hoshino, G; Hoshino, H; Hoshino, Y; Ishii, Y; Kitagawa, Y; Matsunaga, A; Ochiai, H; Seo, Y; Shigeta, K | 1 |
| Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R | 1 |
| Kawahara, H; Kitamura, H; Onda, S; Saito, R; Toyama, Y; Ushigome, T; Watanabe, K; Yanaga, K; Yanagisawa, S; Yoshida, S | 1 |
| Bafaloukos, D; Economopoulos, T; Eleftheraki, AG; Fountzilas, G; Kalogeras, KT; Klouvas, G; Koutras, A; Makatsoris, T; Nikitas, N; Papakostas, P; Papandreou, CN; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Samantas, E; Sgouros, J; Syrigos, KN; Timotheadou, E; Varthalitis, I; Xanthakis, I | 1 |
| Akiyama, S; Andoh, H; Gamoh, M; Ishioka, C; Kato, S; Maeda, S; Mori, T; Murakawa, Y; Ohori, H; Sasaki, Y; Shimodaira, H; Suzuki, T; Takahashi, S; Yamaguchi, T; Yoshioka, T | 1 |
| Chargari, C; Deutsch, E; Huguet, F; Levy, A; Védrine, L | 1 |
| Chang, SC; Chen, WS; Jiang, JK; Lan, YT; Lee, LK; Lin, CC; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH; Wang, HS; Yang, SH; Yen, CC | 1 |
| de Braud, F; Garassino, MC; Pietrantonio, F; Torri, V | 1 |
| Ando, Y; Eguchi, T; Fujii, T; Fujiwara, M; Ishigure, K; Ishiyama, A; Kodera, Y; Koike, M; Nakayama, G; Ohashi, N; Sugimoto, H; Tsuboi, K; Uehara, K; Yokoyama, H | 1 |
| Asao, T; Hosouchi, Y; Ishibashi, K; Ishida, H; Kigure, W; Kuwano, H; Ojima, H; Tsutsumi, S; Uchida, N; Yamauchi, S; Yashuda, N | 1 |
| Arnold, D; Edelmann, T; Glockzin, G; Hildebrandt, B; Hollerbach, S; Illerhaus, G; Königsrainer, A; Richter, M; Schlitt, HJ; Schmoll, HJ; Stein, A; Wienke, A | 1 |
| Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M | 1 |
| Hokkoku, K; Kitade, H; Mori, M; Nakai, M; Okuda, M; Sakuma, H; Shimasaki, T; Shintaku, K; Ueda, H; Yoshimitsu, Y | 1 |
| Assadourian, S; Billemont, B; Cartot-Cotton, S; Khayat, D; Meric, JB; Rixe, O; Soussan-Lazard, K; Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Araki, T; Hashimoto, K; Inoue, Y; Kawamura, M; Kusunoki, M; Matsushita, K; Mizoguchi, A; Mohri, Y; Morimoto, Y; Okigami, M; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Uchida, K | 1 |
| Carlsson, G; Holmberg, C; Pettersson, K; Sporrong, SK | 1 |
| Couvelard, A; Gillet, A; Goujon, G; Hammel, P; Hentic, O; Lévy, P; Maire, F; Palazzo, M; Rebours, V; Ruszniewski, P; Zappa, M | 1 |
| Brodowicz, T; Heinemann, V; Jung, A; Kirchner, T; Knittelfelder, R; Kurteva, G; Laubender, RP; Modest, DP; Neumann, J; Ocvirk, J; Papai, Z; Stintzing, S; Zielinski, CC | 1 |
| Allegra, C; Castan, R; Ferry, D; Lakomy, R; Macarulla, T; McKendrick, J; Moiseyenko, V; Polikoff, J; Prausová, J; Prenen, H; Ruff, P; Tabernero, J; Tellier, A; Van Cutsem, E; van Hazel, GA | 1 |
| Budai, B; Hitre, E; Láng, I; Nagy, T | 1 |
| Gao, F; Linehan, D; Lockhart, AC; Lubner, S; McWilliams, R; Menias, C; Peddi, PF; Picus, J; Sorscher, SM; Suresh, R; Tan, BR; Wang, J; Wang-Gillam, A | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Berglund, Å; Byström, P; Glimelius, B; Johansson, B; Larsson, A; Nygren, P; Wernroth, L | 1 |
| Köhne, CH | 1 |
| Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V | 1 |
| Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z | 1 |
| Akiyoshi, K; Hamaguchi, T; Hosokawa, A; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Ogawa, K; Shimada, Y; Sugiyama, T; Ueno, T; Yamada, Y | 1 |
| Lieberman, R | 1 |
| Bekaii-Saab, TS; Bendell, JC; Cohn, AL; Dalal, D; Fish, S; Flick, ED; Grothey, A; Hurwitz, HI; Kozloff, M; Mun, Y; Roach, N; Tezcan, H | 1 |
| Bretagne, JF; Desgrippes, R; Leconte, B; Manfredi, S; Tchoundeu, B; Uguen, T | 1 |
| Baños, A; Fernebro, E; Gamelin, E; Greil, R; Hofheinz, R; Karthaus, M; Köhne, CH; Letocha, H; Mineur, L; Thaler, J | 1 |
| Basu, B; Jodrell, D | 1 |
| Adua, D; Barucca, V; Colonna, M; Di Seri, M; Giannarelli, D; Longo, F; Mottolese, M; Romiti, A; Rossi, L; Ruco, L; Tomao, S; Veltri, E; Zoratto, F; Zullo, A | 1 |
| Alkis, N; Arpacı, E; Benekli, M; Berk, V; Bilici, A; Budakoglu, B; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Gumus, M; Inal, A; Isıkdogan, A; Kaya, AO; Ozkan, M; Yumuk, F | 1 |
| Aloia, TA; Tzeng, CW | 1 |
| Lyseng-Williamson, KA | 1 |
| Hijikawa, K; Kitade, H; Kwon, AH; Matsuura, T; Takada, H; Yanagida, H; Yoshida, R | 1 |
| Bendell, JC; Berlin, J; Bray, GL; Firdaus, I; Gore, I; Graham, RA; Hart, LL; Hermann, RC; Low, JA; Mackey, HM; Mulcahy, MF; Yauch, RL; Zalupski, MM | 1 |
| Schwartzman, AD; Sethi, R; Smith, R | 1 |
| Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N | 1 |
| Bosman, F; Cisar, L; Cunningham, D; d'Ario, G; Delorenzi, M; Fiocca, R; Klingbiel, D; Labianca, R; Nordlinger, B; Roth, AD; Tejpar, S; Van Cutsem, E; Yan, P | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isikdogan, A; Kaplan, MA; Ozkan, M; Tufan, G | 1 |
| Curran, D; Folprecht, G; Griebsch, I; Hitre, E; Köhne, CH; Láng, I; Rougier, P; Sartorius, U; Van Cutsem, E | 1 |
| Berger, A; Brieau, B; Dubreuil, O; Landi, B; Lepère, C; Markoutsaki, T; Rougier, P; Roussel, H; Taieb, J; Trouilloud, I; Vaillant, JN; Zaanan, A | 1 |
| Kamata, H; Koisumi, J; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A | 1 |
| Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J | 1 |
| Baba, H; Baba, Y; Beppu, T; Chikamoto, A; Iwatsuki, M; Miyamoto, Y; Okabe, H; Sakamoto, Y; Watanabe, M | 1 |
| Androulakis, N; Georgoulias, V; Hatzidaki, D; Kabouraki, E; Kalbakis, K; Mavroudis, D; Saridaki, Z; Souglakos, J; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Asayama, M; Boku, N; Doi, T; Fujino, T; Machida, N; Ohtsu, A; Onozawa, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
| Bertarelli, G; Biondani, P; Cortinovis, D; de Braud, F; Di Bartolomeo, M; Fanetti, G; Mariani, L; Melotti, F; Milione, M; Perrone, F; Pietrantonio, F | 1 |
| Douillard, JY; Peeters, M; Siena, S; Van Cutsem, E; Wiezorek, J; Williams, R; Zhang, K | 1 |
| Cho, EK; Chung, M; Hong, J; Kim, HS; Lee, JH; Lee, WK; Park, J; Park, SH; Park, YH; Shin, DB; Sym, SJ | 1 |
| Prenen, H; Van Cutsem, E | 1 |
| Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ | 1 |
| Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M | 1 |
| Dvorák, J; Krajina, A; Malírová, E; Melichar, B; Nová, M; Ryska, A; Voboril, Z; Weiner, P | 1 |
| Hezel, AF; Katz, AW; Mondo, EL; Noel, MS; Schoeniger, LO | 1 |
| Benhaim, L; Boige, V; Bonnet, S; De Baere, T; Deschamps, F; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Faron, M; Goéré, D; Lefèvre, JH; Malka, D | 1 |
| Cinar, V; Erdik, B; Oyan, B; Ozturk, MA; Ozveren, O | 1 |
| Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Endo, W; Fujie, Y; Fukunaga, H; Hojo, S; Maeura, Y; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S | 1 |
| Amano, K; Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Kumamoto, K; Kuwabara, K; Ohsawa, T; Okada, N; Sobajima, J; Tajima, Y; Tsuji, Y | 1 |
| Fukushima, M; Hoshino, M; Murakami, M; Naruse, H; Suzuki, N; Suzuki, S; Tominaga, K | 1 |
| Cong, X; Gunturu, KS; Hochster, HS; Lacy, J; Stein, SM; Thumar, JR; Yao, X | 1 |
| Ben-Haim, M; Geva, R; Klausner, J; Lahat, G; Lubezky, N; Nakache, R; Papoulas, M; Shacham-Shmueli, E; Winograd, E | 1 |
| Assadourian, S; Bloch, J; Cartot-Coton, S; Khayat, D; Soussan-Lazard, K; Spano, JP; Tejpar, S; Van Cutsem, E; Vandecaveye, V; Verslype, C | 1 |
| Fragoulis, EG; Korbakis, D; Scorilas, A | 1 |
| Conroy, T; Ducreux, M; Gavoille, C; Samalin, E; Ychou, M | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Huang, X; Jain, R; Lichinitser, M; Manikhas, G; Peeters, M; Rogowski, W; Shapiro, J; Strickland, AH; Suresh, AV; Tebbutt, NC; Warner, D; Wu, B | 1 |
| Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G | 1 |
| Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M | 1 |
| Akagi, Y; Baba, H; Emi, Y; Kakeji, Y; Maehara, Y; Natsugoe, S; Nishimaki, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Shirouzu, K; Tanaka, T; Tokunaga, S | 1 |
| Barni, S; Beretta, GD; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F; Squadroni, M; Stinco, S | 1 |
| Hamada, T; Ohashi, S; Ohta, K; Taniguchi, E; Yamagami, Y; Yoshikawa, M | 1 |
| Baranyai, ZS; Besznyák, I; Bursics, A; Dede, K; Jakab, F; Landherr, L; Mersich, T; Salamon, F; Zaránd, A | 1 |
| Berlin, J; Chan, E; Ciombor, KK | 1 |
| Bauernhofer, T; Hubmann, E; Jilek, K; Keil, F; Leitner, G; Pichler, A; Pichler, M; Rabl, H; Tinchon, C; Uggowitzer, M | 1 |
| Amptoulach, S; Gritzapis, AD; Karadima, ML; Kosmas, C; Skopelitis, E; Tsavaris, N; Voutsas, IF; Xynos, ID | 1 |
| Machado, MA; Makdissi, FF; Surjan, RC | 1 |
| Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Grillo, E; Jaén, P; Longo, F; Vañó-Galván, S | 1 |
| Auby, D; Bouché, O; Ducreux, M; Etienne, PL; Michiels, S; Pénichoux, J; Pignon, JP; Rougier, P; Texereau, P | 1 |
| Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D | 1 |
| Burge, M; Clarke, S; Cordwell, C; Gibbs, P; Reece, W; Tebbutt, N | 1 |
| Horioka, K; Jimi, S; Kaku, K; Kamei, T; Oohata, Y | 1 |
| Ji, W; Jung, SW; Kim, DS; Suh, SO; Yu, YD | 1 |
| Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J | 1 |
| Albino, V; Aloj, L; Caracò, C; Daniele, G; de Lutio di Castelguidone, E; Delrio, P; Giordano, P; Iaffaioli, RV; Izzo, F; Lastoria, S; Nasti, G; Ottaiano, A; Palaia, R; Piccirillo, MC; Romano, C; Romano, G | 1 |
| Cattan, S; Desauw, C; Hebbar, M; Piessen, G; Pruvot, FR; Sergent-Baudson, G; Truant, S | 1 |
| Alcindor, T; Moreau, LC; Rajan, R; Thirlwell, MP | 1 |
| Liu, TS; Qin, XY; Ren, L; Wei, Y; Xu, B; Xu, J; Ye, LC; Ye, QH; Yu, Y; Zai, SY; Zhu, DX | 1 |
| Engstrom, PF; Kiel, K | 1 |
| Diasio, RB | 1 |
| Cervantes, A; de Gramont, A; Schmoll, HJ; Tournigand, C | 1 |
| Ceelen, W; De Bruyne, S; Geboes, K; Goethals, I; Laurent, S; Mertens, J; Peeters, M; Smeets, P; Troisi, R; Van Damme, N; Van de Wiele, C | 1 |
| Jiao, SC; Li, JY; Wen, XY; Wu, LL; Zhang, GQ; Zhao, H | 1 |
| Bruno, R; Claret, L; Gupta, M; Han, K; He, J; Joshi, A; Powell, B; Sarapa, N | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Dias, LE; Faris, JE; Fernandez-del Castillo, C; Ferrone, CR; Guimaraes, AR; Hong, TS; Huynh, MA; Kwak, EL; Lillemoe, KD; McDermott, S; Murphy, JE; Ryan, DP; Sahani, DV; Szymonifka, J; Thayer, SP; Wargo, JA; Wo, JY; Zhu, AX | 1 |
| Aprile, G; Bergamo, F; Bracarda, S; Cremolini, C; Falcone, A; Fontanini, G; Fornaro, L; Lonardi, S; Loupakis, F; Lupi, C; Masi, G; Morvillo, M; Salvatore, L; Schirripa, M; Sensi, E; Vivaldi, C; Zagonel, V; Zaniboni, A | 1 |
| Gajdos, C; Jones, EL; Jones, TS; McManus, M; Shah, R | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX | 1 |
| André, T; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Pruvot, FR; Smith, D | 1 |
| Antoniotti, C; Caparello, C; Cremolini, C; Falcone, A; Funel, N; Loupakis, F; Marmorino, F; Masi, G; Morvillo, M; Pollina, L; Salvatore, L; Schirripa, M; Vasile, E | 1 |
| Bekaii-Saab, T; Goldberg, RM | 1 |
| Aksu, G; Bilici, A; Cabuk, D; Gumus, M; Kaya, S; Oven Ustaalioglu, BB; Seker, M; Temiz, S; Uygun, K; Yildiz, R | 1 |
| Fu, Z; Wang, X; Yin, H; Zhang, X | 1 |
| Barni, S; Beretta, GD; Borgonovo, K; Cabiddu, M; Ghilardi, M; Lonati, V; Maspero, F; Petrelli, F; Sauta, MG | 1 |
| Biasco, G; Brandi, G; de Rosa, F; Derenzini, E; Di Girolamo, S; Ercolani, G; Falcone, A; Grazi, GL; Loupakis, F; Masi, G; Pantaleo, MA; Pietrabissa, A; Pinna, AD | 1 |
| Ashkenazi, A; Beachler, C; El-Deiry, WS; Gusani, N; Lim, B; Portera, C; Sarwani, N; Scicchitano, A; Staveley-O'Carroll, K; Yang, Z | 1 |
| El-Deiry, WS; Lamparella, NE; Saroya, BS; Sarwani, NE; Yang, Z | 1 |
| Cooper, AB; Katz, MH; Tzeng, CW | 1 |
| Thomas, AL; Walter, H | 1 |
| Alberts, SR; Blanke, CD; Cassidy, J; Cheung, WY; Kerr, DJ; Meyers, J; O'Connell, M; Sargent, DJ; Shi, Q; Van Cutsem, E; Yothers, G | 1 |
| Ahn, JS; Jeon, JR; Paik, SW; Park, CK; Park, TK; Sinn, DH; Yoo, HS | 1 |
| Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM | 1 |
| Antoniotti, C; Aprile, G; Benhaim, L; Bohanes, P; Cremolini, C; De Vita, F; Falcone, A; Graziano, F; Lenz, HJ; Lonardi, S; Loupakis, F; Lucchesi, S; Ronzoni, M; Ruzzo, A; Salvatore, L; Schirripa, M; Tonini, G; Wakatsuki, T; Yang, D; Zhang, W | 1 |
| Abe, H; Abe, M; Hirata, T; Mafune, K; Minamimura, K; Umemura, A | 1 |
| Hashimoto, Y; Kawachi, Y; Kawahara, M; Kitami, C; Makino, S; Nikkuni, K; Nishimura, A; Okamura, T | 1 |
| Chen, H; Deng, X; Jin, J; Li, H; Peng, C; Shen, B; Zhan, Q; Zhang, X | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Carlomagno, C; Cella, CA; De Placido, S; De Stefano, A; Matano, E; Moretto, R; Raimondo, L | 1 |
| Goi, T; Katayama, K; Koneri, K; Sawai, K; Yamaguchi, A | 1 |
| Brunetti, AE; Nardulli, P; Russano, M; Silvestris, N | 1 |
| Bray, C; Celik, I; Chang, SC; Denne, J; Green, G; Harbison, C; Horak, C; Khambata-Ford, S; Van Cutsem, E; Zhao, L | 1 |
| Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Dreussi, E; Polesel, J; Toffoli, G; Zagonel, V | 1 |
| Ando, H; Fujita, Y; Hamamoto, Y; Hazama, S; Hinoda, Y; Inoue, Y; Kanekiyo, S; Kato, T; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Oka, M; Okayama, N; Okuyama, Y; Sakamoto, J; Takahashi, K; Takemoto, H; Tsunedomi, R | 1 |
| Allegra, C; Hoyle, M; Iqbal, SU; Joulain, F; Proskorovsky, I; Tabernero, J; Van Cutsem, E | 1 |
| André, T; Chibaudel, B | 1 |
| Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F | 1 |
| Dasanu, CA; Joseph, R | 1 |
| Baba, H; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Mochiki, E; Okada, N; Tajima, Y; Yokoyama, M | 1 |
| Antoniotti, C; Bergamo, F; Brunetti, I; Cremolini, C; Falcone, A; Fontanini, G; Lonardi, S; Loupakis, F; Lupi, C; Masi, G; Michelucci, A; Pfanner, E; Salvatore, L; Schirripa, M; Sensi, E; Simi, P; Zagonel, V | 1 |
| Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA | 1 |
| Brutcher, E; Chen, Z; El-Rayes, BF; Hawk, N; Kauh, J; Kim, S; Kooby, DA; Landry, J; Mahaseth, H; Maithel, SK | 1 |
| Arimoto, A; Iwamoto, S; Kanazawa, A; Kataoka, K; Kato, T; Nakajima, A | 1 |
| Ba, Y; Bai, YX; Deng, T; Han, Y; Li, YH; Liu, XJ; Wang, Y; Xu, JM; Zhang, L | 1 |
| Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Giessen, C; Heinemann, V; Laubender, RP; Modest, DP; Quietzsch, D; Schalhorn, A; Schulz, C; Stintzing, S; Vehling-Kaiser, U; von Einem, JC; von Weikersthal, LF | 1 |
| Ahn, JB; Baik, SH; Choi, GH; Choi, JS; Jung, M; Kim, H; Kim, NK; Min, BS; Shin, SJ; Yi, JH | 1 |
| Lenz, HJ; Stintzing, S | 1 |
| Benson, AB; Bertagnolli, MM; Fuchs, CS; Goldberg, RM; Hantel, A; Imamura, Y; Liao, X; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Mowat, RB; Ng, K; Niedzwiecki, D; Ogino, S; Saltz, LB; Spiegelman, D; Whittom, R; Yamauchi, M | 1 |
| Aoyama, K; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Tsurushima, M; Uchiyama, K | 1 |
| Bezan, A; Greil, R; Hauser-Kronberger, C; Hohla, F; Hopfinger, G; Rinnerthaler, G; Romeder, F; Stättner, S; Ulmer, H | 1 |
| Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Hiraki, M; Isohashi, F; Mizushima, T; Mori, M; Nishimura, J; Ogawa, K; Ohtsuka, M; Shiomi, H; Takemasa, I; Uemura, M; Yamamoto, H; Yoshioka, Y | 1 |
| Bruera, G; Cannita, K; Ficorella, C; Giordano, AV; Ricevuto, E; Vicentini, R | 1 |
| Chen, Y; Cui, YH; Guo, X; Liu, TS; Yu, YY; Zhou, YH; Zhuang, RY | 1 |
| Choi, ZS; Kim, DY; Kim, YB; Lee, JH; Lee, MY; Oh, SY; Paek, TY; Suh, KW | 1 |
| Amodio, A; Barba, M; Belli, F; Boggia, S; Di Lauro, L; Fattoruso, S; Giannarelli, D; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Vici, P | 1 |
| Elias, D; Eveno, C; Gayat, E; Glehen, O; Goéré, D; Passot, G; Pocard, M; Soyer, P | 1 |
| Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S | 1 |
| Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D | 1 |
| Jeong, HY; Kang, DY; Kang, GH; Kim, SH; Lee, BS; Lee, ES; Lee, HY; Moon, HS; Sung, JK | 1 |
| Chang, SC; Chen, WS; Chiou, SH; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Lin, TC; Wang, HS; Yang, SH | 1 |
| Berger, AK; Jäger, D; Springfeld, C; Weber, TF | 1 |
| André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Ducreux, M; Hotko, Y; Lordick, F; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Sidhu, R; Sobrero, AF; Strickland, AH; Tian, Y; Van Cutsem, E; Wilson, G | 1 |
| Borg, C; Cléau, D; Curtit, E; Demarchi, M; Dobi, E; Fratte, S; Guiu, B; Heyd, B; Jary, M; Kim, S; Lakkis, Z; Lamfichekh, N; Monnien, F; Nerich, V; Nguyen, T | 1 |
| Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y | 1 |
| Hirano, S; Ikura, Y; Ishimura, M; Iwai, Y; Kadota, C; Kadota, T; Kitami, M; Nakajima, E; Nakata, S; Ogawa, H; Osuga, T; Shigaki, Y; Tamura, T; Ueno, N; Yoshikawa, T | 1 |
| Andoh, H; Hazama, S; Hirata, K; Kato, T; Mishima, H; Nagata, N; Oba, K; Okuyama, Y; Sakamoto, J; Takahashi, K | 1 |
| Dasanu, CA; Nandy, N | 1 |
| Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J | 1 |
| Aparicio, T; Breysacher, G; Chapet, S; Dousset, B; Faroux, R; Jouve, JL; Maillard, E; Martel-Lafay, I; Michel, P; Mornex, F; Nguyen, S; Pere-Verge, D; Pezet, D; Seitz, JF; Sobhani, I | 1 |
| Gervaz, P; Mentha, G; Morel, P; Naiken, SP; Roth, A; Rubbia-Brandt, L; Thomopoulos, T; Toso, C | 1 |
| Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM | 1 |
| Beachler, C; El-Deiry, WS; Harvey, HA; Kline, CL; Mackley, HB; McKenna, K; Messaris, E; Poritz, L; Schiccitano, A; Sheikh, H; Sivik, J; Staveley-O'Carroll, K; Stewart, D; Zhu, J | 1 |
| Guo, Y; Shen, X; Shi, M; Yang, C; Yang, L; Zhang, J | 1 |
| Chang, SF; Hu, HM; Huang, CM; Huang, CW; Huang, ML; Huang, MY; Lu, CY; Tsai, HL; Wang, JY; Yu, FJ | 1 |
| Kim, JH; Kim, SE; Ku, KH; Moon, W; Park, MI; Park, SJ; Song, SE | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Aster, RH; Curtis, BR; George, JN; Mirtsching, BC | 1 |
| Akashi, K; Ariyama, H; Baba, E; Ijichi, K; Komoda, M; Kubo, N; Kusaba, H; Tamura, S; Tsuchihashi, K; Uchino, K | 1 |
| Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V | 1 |
| Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA | 1 |
| Akiyoshi, K; Hamaguchi, T; Hashimoto, H; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Shimada, Y; Terazawa, T; Yamada, Y | 1 |
| Alberts, SR; Berenberg, JL; Chan, E; Farr, GH; Gill, S; Goldberg, RM; Grothey, A; Huang, J; Kahlenberg, MS; Mahoney, MR; Mooney, M; Nair, SG; Nelson, GD; Pockaj, BA; Quesenberry, JT; Sargent, DJ; Shields, AF; Sinicrope, FA; Smyrk, TC; Thibodeau, SN; Webb, TA | 1 |
| Bitzer, M; König, C; Malek, NP; Plentz, RR; Schempf, U; Sipos, B | 1 |
| Ando, M; Fujii, H; Ooki, A; Sakamoto, J; Sato, A; Yamaguchi, K | 1 |
| Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A | 1 |
| Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L | 1 |
| Ando, Y; Fujii, T; Fujiwara, M; Hayashi, N; Kanda, M; Kobayashi, D; Kodera, Y; Koike, M; Mashita, N; Nakayama, G; Nomoto, S; Sugimoto, H; Tanaka, C; Uehara, K; Yamada, S | 1 |
| Bechstein, W; Folprecht, G; Gruenberger, T; Hartmann, JT; Jaeger, D; Köhne, CH; Lang, H; Liersch, T; Lordick, F; Ockert, D; Raab, HR; Rentsch, A; Steger, U; Stoehlmacher-Williams, J; Suedhoff, T; Trarbach, T; Weitz, J | 1 |
| Aksun, S; Alacacioglu, A; Bayoglu, IV; Coban, E; Demir, L; Dirican, A; Kucukzeybek, Y; Sutcu, R; Tarhan, MO; Varol, U | 1 |
| Büchler, MW; Jäger, D; Koch, M; Rahbari, NN; Reissfelder, C; Schulze-Bergkamen, H; Weitz, J | 1 |
| Mukherji, D; Shamseddine, A; Temraz, S | 1 |
| Jia, Y; Marks, E; Saif, MW | 1 |
| Oikonomopoulos, GM; Saif, MW; Skoura, E; Syrigos, KN | 1 |
| Caravatta, L; Cilla, S; Deodato, F; Macchia, G; Massaccesi, M; Mignogna, S; Morganti, AG; Picardi, V; Plantamura, NM; Valentini, V | 1 |
| Baba, H; Baba, Y; Etoh, K; Ishimoto, T; Iwagami, S; Iwatsuki, M; Miyamoto, Y; Murata, A; Sakamoto, Y; Shigaki, H; Sugihara, H; Watanabe, M; Yoshida, N | 1 |
| Glimelius, B; Gubanski, M; Lind, PA | 1 |
| Allard, MA; Malka, D | 1 |
| Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS | 1 |
| Ahn, JB; Baek, SJ; Baik, SH; Cho, MS; Chung, M; Hur, H; Kim, CW; Kim, MS; Kim, NK; Min, BS; Shin, SJ | 1 |
| Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M | 1 |
| Bando, H; Fukunaga, M; Hazama, S; Iwamoto, S; Kato, T; Matsuda, C; Mishima, H; Miyake, Y; Oba, K; Sakamoto, J | 1 |
| Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y | 1 |
| Blaszkowsky, LS; Cashavelly, BJ; Kim, CY; Penson, RT; Riley, JP; Ryan, DP; Schapira, L; Wold, MC | 1 |
| Aitini, E; Amadori, D; Bajetta, E; Bidoli, P; Boni, C; Cantore, M; Carlomagno, C; Casaretti, R; Comella, G; Daniele, B; Di Bartolomeo, M; Di Costanzo, F; Di Fabio, F; Falcone, A; Floriani, I; Labianca, R; Landi, L; Marchet, A; Mini, E; Mosconi, S; Nitti, D; Pinotti, G; Pinto, C; Poli, D; Ravaioli, A; Rosati, G; Santoro, A | 1 |
| Choi, PR; Kim, JH; Kim, SE; Lee, GW; Moon, W; Park, MI; Park, SJ | 1 |
| Bolonesi, RM; Rogers, JE; Shureiqi, I | 1 |
| Aitouferoukh, S; Béchade, D; Bécouarn, Y; Beyssac, R; Brunet, R; Cany, L; Fonck, M; Lalet, C; Le Morvan, V; Mathoulin-Pélissier, S; Pulido, M; Robert, J; Texereau, P | 1 |
| Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ | 1 |
| Hu, AP; Li, SL; Liang, HL; Liu, JY | 1 |
| Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D | 1 |
| Arao, T; Hamaguchi, T; Hayashi, H; Hirashima, Y; Honma, Y; Horita, Y; Iwasa, S; Kato, K; Kimura, H; Matsumoto, K; Nakagawa, K; Nishio, K; Okita, NT; Shimada, Y; Takashima, A; Togashi, Y; Yamada, Y | 1 |
| Kræmer, PC; Ladekarl, M; Schmidt, HH | 1 |
| de Weger, VA; Griffioen-Keijzer, A; van Bunderen, CC | 1 |
| Bertagnolli, MM; Dzieciatkowski, S; Emond, MJ; Foster, NR; Goldberg, RM; Grady, WM; Lao, VV; Luo, Y; Maizels, N; Monnat, RJ; Nam, E; Niedzwiecki, D; Renfro, LA; Saltz, LB; Shiovitz, S; Venook, A; Warren, RS | 1 |
| Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W | 1 |
| Ema, A; Naito, M; Nakamura, T; Sato, T; Watanabe, M; Yamashita, K | 1 |
| Barone, C; Bordonaro, R; Botti, G; Cartenì, G; Ciardiello, F; Cinieri, S; Colucci, G; De Vita, F; Febbraro, A; Fenizia, F; Giuliani, F; Lambiase, M; Maiello, E; Martinelli, E; Montesarchio, V; Normanno, N; Orditura, M; Pisconti, S; Rachiglio, AM; Rinaldi, A; Rizzi, D; Tatangelo, F; Tonini, G; Troiani, T | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Bekaii-Saab, T; Benson, AB; Chan, E; Chen, YJ; Cooper, HS; Engstrom, PF; Enzinger, PC; Fenton, MJ; Freedman-Cass, DA; Fuchs, CS; Gregory, KM; Grem, JL; Hunt, S; Kamel, A; Leong, LA; Lin, E; Messersmith, W; Mulcahy, MF; Murphy, JD; Nurkin, S; Rohren, E; Ryan, DP; Saltz, L; Sharma, S; Shibata, D; Skibber, JM; Sofocleous, CT; Stoffel, EM; Stotsky-Himelfarb, E; Venook, AP; Willett, CG | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Can, A; Coban, E; Demir, L; Dirican, A; Erten, C; Koyuncu, B; Kucukzeybek, Y; Somali, I; Tarhan, MO; Varol, U; Yildiz, Y | 1 |
| Hong, SM; Ihn, MH; Kang, SB; Kim, DW; Lee, SY; Oh, HK | 1 |
| Aoki, T; Fukayama, M; Hamada, T; Hasegawa, K; Isayama, H; Koike, K; Kokudo, N; Morikawa, T; Nakai, Y; Sakamoto, Y; Sasaki, T; Tanaka, M | 1 |
| Chaix, M; Ghiringhelli, F; Lorgis, V; Vincent, J | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T | 1 |
| Avital, I; Beane, JD; Beresnev, T; Langan, RC; Mullinax, JE; Pandalai, P; Rudloff, U; Schrump, D; Steinberg, SM; Stojadinovic, A; Toomey, MA; Walker, M; Webb, CC | 1 |
| Aprile, G; Barsevick, A; Bonaventura, A; Elting, LS; Grunberg, SM; Keefe, DM; Koczwara, B; Nguyen, HT; Selva-Nayagam, S; Sonis, ST | 1 |
| Carter, GC; Johnson, BH; Landsman-Blumberg, PB; Li, L; Nicol, SJ; Sedgley, R; Shankaran, V | 1 |
| Cremolini, C; El-Khoueiry, RE; Falcone, A; Kardosh, A; Lenz, HJ; Li, JE; Loupakis, F; Ning, Y; Scherer, SJ; Stintzing, S; Volz, NB; Wakatsuki, T; Yang, D; Zhang, W | 1 |
| Battisti, S; Guida, FM; Pagliara, E; Santini, D; Tonini, G; Zobel, BB | 1 |
| Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Hielscher, J; Höffkes, HG; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Lindig, RU; Link, H; Modest, DP; Moehler, M; Müller, S; Niederle, N; Rossius, L; Rost, A; Scheithauer, W; Scholz, M; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Cunningham, D; Sclafani, F | 1 |
| Aksoy, S; Benekli, M; Ekinci, AS; Günaydın, Y; Oksuzoglu, B; Özatlı, T; Ozdemir, N; Sendur, MA; Yazıcı, O; Yazılıtaş, D; Zengin, N | 1 |
| Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H | 1 |
| Hirakawa, K; Ikeya, T; Maeda, K; Nagahara, H; Ohtani, H; Shibutani, M; Sugano, K | 1 |
| Baba, H; Chika, N; Haga, N; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Okada, N; Sano, M; Tajima, Y | 1 |
| Melichar, B; Mohelnikova-Duchonova, B; Soucek, P | 1 |
| Abad, A; Echave, M; Frías, C; Giménez, E; Joulain, F; Lamas, MJ; Naoshy, S; Oyagüez, I; Pericay, C; Rubio, M | 1 |
| Bridgewater, J; Chau, I; Iqbal, SU; Joulain, F | 1 |
| Bišof, V; Dedić Plavetić, N; Krpan, AM; Ozretić, D; Rakušić, Z; Simetić, L | 1 |
| Chen, L; Ju, HX; Liu, BX; Liu, LY; Luo, C; Xu, Q; Yang, YS; Ying, JE; Zhao, YZ; Zhong, HJ; Zhu, LM | 1 |
| Brunetti, AE; Lorusso, V; Maiello, E; Mangia, A; Paradiso, A; Partipilo, G; Scarpi, E; Silvestris, N; Simone, G | 1 |
| Papadatos-Pastos, D; Rabbie, R; Ross, P; Sarker, D; Thillai, K | 1 |
| Ahn, JB; Bello, M; Charoentum, C; Chen, LT; Cheng, AL; Ciardiello, F; de Lima Lopes, G; Ho, GF; Kim, TW; Köhne, CH; Kong, HL; Lam, KO; Li, J; Liu, TS; Ma, BB; Park, YS; Shaw, M; Sriuranpong, V; Sudoyo, AW; Teh, C; Vaid, AK; Wang, JY; Zhang, J; Zhang, SZ | 1 |
| Baniyash, M; Biton, M; Goldshtein, A; Hubert, A; Ish-Shalom, E; Kanterman, J; Lasry, A; Sade-Feldman, M | 1 |
| André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M | 1 |
| Boucher, E; Boudjema, K; Hénno, S; Le Prisé, E; Levi Sandri, GB; Meunier, B; Sulpice, L; Turner, K | 1 |
| Arnold, D; Boxberger, F; Herrenberger, J; Hinke, A; Hoeffkes, HG; Kutscheidt, A; Leutgeb, B; Petersen, V; Schroeder, J; Schulze, M; Seraphin, J; Stein, A; Valdix, AR | 1 |
| Bertagnolli, MM; Caracol, A; Emond, M; Foster, NR; Goldberg, RM; Grady, WB; Lao, VV; Maizels, N; Monnat, RJ; Niedzwiecki, D; Pavelitz, T; Rabinovitch, PS; Renfro, L; Saltz, LB; Welsch, P | 1 |
| Kirstein, MM; Kubicka, S; Lange, A; Manns, MP; Prenzler, A; Vogel, A | 1 |
| Chen, HM; Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Teng, HW; Yang, SH | 1 |
| Allegrini, G; Amoroso, D; Boni, C; Boni, L; Buonadonna, A; Carlomagno, C; Chiara, S; Cortesi, E; Cremolini, C; Falcone, A; Lonardi, S; Loupakis, F; Masi, G; Ronzoni, M; Salvatore, L; Spadi, R; Tomasello, G; Tonini, G; Zagonel, V; Zaniboni, A | 1 |
| Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR | 1 |
| Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E | 1 |
| Bosman, FT; Delorenzi, M; Klingbiel, D; Roth, AD; Saridaki, Z; Tejpar, S | 1 |
| Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Goldberg, RM; Nordlinger, B; Poston, GJ | 1 |
| André, T; Auby, D; Bonnetain, F; Brucker, P; Brusquant, D; Carola, E; Chibaudel, B; Dalban, C; de Gramont, A; Dutel, JL; Faroux, R; Flesch, M; Gayet, B; Hadengue, A; Hebbar, M; Khalil, A; Landi, B; Legoux, JL; Louvet, C; Mabro, M; Martin, P; Mineur, L; Paye, F; Pruvot, FR; Smith, D; Taieb, J; Truant, S; Vaillant, E; Ychou, M | 1 |
| Bae, KS; Hong, YS; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG | 1 |
| Benson, AB; Chan, AT; Chan, JA; Fuchs, CS; Giovannucci, EL; Goldberg, RM; Hantel, A; Mayer, RJ; Meyerhardt, JA; Ng, K; Niedzwiecki, D; Ogino, S; Saltz, LB; Sato, K; Schaefer, PL; Venook, AP; Whittom, R | 1 |
| Chau, I; Cunningham, D; Khan, K; Moorcraft, SY; Peckitt, C; Rao, S; Watkins, D | 1 |
| Anne, PR; Erickson, BA; Haddock, M; Kachnic, LA; Lee, RJ; Meropol, NJ; Mitchell, EP; Moughan, J; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Wong, SJ | 1 |
| Adam, R; Allard, MA; Baillie, G; Boige, V; Dartigues, P; Elias, D; Faitot, F; Faron, M; Goéré, D; Lemoine, A; Sa Cunha, A; Sebagh, M; Vibert, E; Vitadello, F | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Bonnetain, F; Dubreuil, O; Dupont-Gossard, AC; Fein, F; Gauthier, M; Landi, B; Lecomte, T; Lobry, C; Malka, D; Manet-Lacombe, S; Taïeb, J; Thirot-Bidault, A; Trouilloud, I; Zaanan, A | 1 |
| Alvarez-Cuesta, E; Angel-Pereira, D; Berges-Gimeno, MP; Madrigal-Burgaleta, R; Ureña-Tavera, A; Zamora-Verduga, M | 1 |
| Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ | 1 |
| Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL | 1 |
| Cao, R; Hu, L; Ma, D; Zhang, S | 1 |
| Cen, P; Rowe, J | 1 |
| Rahman, A | 1 |
| Benoist, S; Bensignor, T; Brouquet, A; Dariane, C; Julié, C; Lazure, T; Nordlinger, B; Penna, C; Thirot-Bidault, A | 1 |
| Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD | 1 |
| Adam, R; Bridgewater, J; Chau, I; García Alfonso, P; Gruenberger, T; Hermann, F; Lasserre, S; Mudan, S; Rivoire, M; Waterkamp, D | 1 |
| Aksoy, A; Arpaci, E; Bahceci, A; Bayoglu, IV; Besiroglu, M; Dane, F; Duran, AO; Hacibekiroglu, I; Inanc, M; Karaca, H; Menekse, S; Ozkan, M; Sevinc, A; Tanriverdi, O; Uysal, M; Yapici, HS; Yazilitas, D | 1 |
| Desurmont, T; Duchene, B; Duhamel, A; Gosset, P; Hebbar, M; Huet, G; Jonckheere, N; Leteurtre, E; Millet, G; Pruvot, FR; Ramdane, N; Skrypek, N; Truant, S; Van Seuningen, I | 1 |
| Beaty, K; Choe, JH; Eng, C; Fournier, KF; Mansfield, PF; Ohinata, A; Overman, MJ; Phillips, JK; Rafeeq, S; Royal, RE; Wolff, RA | 1 |
| Atreya, CE; Corcoran, RB; Kopetz, S | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Deshpande, V; Faris, JE; Fernández-del Castillo, C; Ferrone, CR; Goyal, L; Hong, TS; Kwak, EL; Lillemoe, KD; Marchegiani, G; McDonnell, EI; Murphy, JE; Ryan, DP; Sabbatino, F; Santos, DD; Ting, DT; Warshaw, AL; Wo, JY; Zhu, AX | 1 |
| Erickson, BA; Evans, DB; Ritch, PS | 1 |
| Anchisi, S; Baertschi, D; Betticher, DC; Borner, M; Brauchli, P; Dietrich, D; Frueh, M; Herrmann, R; Hess, V; Koeberle, D; Kollar, A; Kueng, M; Matter, K; Moosmann, P; Popescu, RA; Roth, A; Saletti, P; Schacher, S; von Moos, R; Winterhalder, R | 1 |
| Beier, F; Ciardiello, F; Heinemann, V; Köhne, CH; Lenz, HJ; Melezínek, I; Rougier, P; Stroh, C; Tejpar, S; Van Cutsem, E; van Krieken, JH | 1 |
| Nygren, P | 1 |
| Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N | 1 |
| Chan, E; de La Bourdonnaye, G; Heiskala, M; Hwang, J; Kwak, EL; Mita, M | 1 |
| Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY | 1 |
| Aydin, N; Gushchin, V; Ledakis, P; Milovanov, V; Nieroda, C; Nunez, M; Sardi, A; Sittig, M | 1 |
| Magdy, T; Nies, AT; Schwab, M; Zanger, UM | 1 |
| Nipp, RD; Ryan, DP | 1 |
| Dropkin, E; Strickler, JH; Strosberg, JR; Zhu, J | 1 |
| Büchler, MW; Strobel, O | 1 |
| Aparicio, T; Bedenne, L; Ben Abdelghani, M; Boige, V; Bouché, O; Dahan, L; Faroux, R; François, E; Ghiringhelli, F; Le Malicot, K; Legoux, JL; Linot, B; Phelip, JM; Taieb, J | 1 |
| Ashcroft, L; Backen, A; Beech, J; Chau, I; Dive, C; Gollins, S; Hasan, J; Krebs, MG; Morris, K; Renehan, AG; Saunders, MP; Valle, JW | 1 |
| Herman, JM; Katz, MH; Marsh, Rde W; Talamonti, MS | 1 |
| El-Deiry, WS; Marks, E; Rizvi, SM; Sarwani, N; Yang, Z | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Piacentini, P | 1 |
| Berry, DP; Byrne, B; Cameron, IC; Davidson, B; Helmy, S; Khan, AZ; Malik, H; Pope, I; Pulfer, A; Sherlock, D; Thompson, M | 1 |
| Antoniotti, C; Barone, C; Bonetti, A; Boni, L; Cortesi, E; Cremolini, C; D'Amico, M; Di Donato, S; Falcone, A; Granetto, C; Lonardi, S; Longarini, R; Loupakis, F; Masi, G; Salvatore, L; Spadi, R; Tomasello, G; Tonini, G; Vitello, S; Zaniboni, A | 1 |
| Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J | 1 |
| Arai, I; Hayashi, N; Inoue, S; Ohashi, I; Tamura, C; Wakasa, T | 1 |
| Akita, H; Amagasa, H; Ami, K; Ando, M; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Gokita, K; Imai, K; Matsunaga, Y; Nagahama, T; Ohshima, N; Okada, Y; Tei, S | 1 |
| Amadori, D; Cavanna, L; Fontana, A; Frassineti, GL; Lorusso, V; Mucciarini, C; Nanni, O; Passardi, A; Ragazzini, A; Ruscelli, S; Tassinari, D; Turci, D | 1 |
| André, T; Buyse, M; Delbaldo, C; Douillard, JY; Dupuis, O; Faroux, R; Guerin-Meyer, V; Jouhaud, A; Piedbois, P; Quinaux, E; Rougier, P; Ychou, M; Zawadi, A | 1 |
| Addeo, P; Bachellier, P; Belletier, C; De Blasi, V; Dufour, P; Fuchshuber, P; Oussoultzoglou, E; Rosso, E; Simone, G | 1 |
| Burris, HA; Chen, L; Goldstein, D; Hsu, CP; Hurwitz, H; Kotasek, D; Schwartzberg, LS; Stephenson, J; Tebbutt, N; Warner, DJ | 1 |
| Bossi, I; Cheli, S; Clementi, E; de Braud, F; Di Bartolomeo, M; Falvella, FS; Gariboldi, M; Iacovelli, R; Maggi, C; Martinetti, A; Mazzali, C; Mennitto, R; Pierotti, MA; Pietrantonio, F; Sottotetti, E | 1 |
| Hassan, AS; Naicker, M; Wan Ishak, WZ; Yusof, KH | 1 |
| Masuishi, T; Muro, K | 1 |
| Hashiguchi, K; Kuramoto, T; Matsuyama, S; Tanaka, R | 1 |
| Botti, G; Ciardiello, F; Colucci, G; Esposito, C; Fenizia, F; Lambiase, M; Maiello, E; Martinelli, E; Normanno, N; Rachiglio, AM; Rizzi, D; Roma, C; Tatangelo, F; Troiani, T | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Elmali, F; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M; Ucar, M | 1 |
| Shimizu, S | 1 |
| Barni, S; Bozzarelli, S; Carnaghi, C; Destro, A; Floriani, I; Galli, F; Gerardi, C; Labianca, R; Personeni, N; Raschioni, C; Rimassa, L; Rubino, L; Santoro, A; Tronconi, MC; Verusio, C; Villa, E | 1 |
| Aitini, E; Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Lonati, V; Petrelli, F | 1 |
| Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY | 1 |
| Bodoky, G; Chang, SC; Ciuleanu, TE; Clingan, PR; Cohn, AL; Garcia-Alfonso, P; Garcia-Carbonero, R; Grothey, A; Kim, TW; Lonardi, S; Nasroulah, F; Obermannova, R; Portnoy, DC; Prausová, J; Simms, L; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yoshino, T | 1 |
| Denda, T; Esaki, T; Ikeda, J; Mizunuma, N; Muro, K; Nishina, T; Nishisaki, H; Suenaga, M; Sugiyama, Y; Takano, Y; Ura, T; Yasui, H | 1 |
| Bencsikova, B; Bortlicek, Z; Dusek, L; Halamkova, J; Kiss, I; Melichar, B; Ostrizkova, L; Pavlik, T; Valik, D; Vyzula, R; Zdrazilova-Dubska, L | 1 |
| André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN | 1 |
| Bonetti, A; Giuliani, J; Piacentini, P | 1 |
| Addeo, A; Bini, R; Comelli, S; Leli, R; Savio, D; Vana, F; Vaudano, GP; Viora, T | 1 |
| Baba, H; Denda, T; Hata, T; Ina, K; Inukai, M; Iwamoto, S; Kato, T; Kunieda, K; Kurachi, K; Mishima, H; Morita, Y; Munemoto, Y; Nagata, N; Nakamura, M; Oba, K; Ooshiro, M; Sakamoto, J; Shimoyama, T; Takahashi, T; Tamagawa, H | 1 |
| Fusco, R; Granata, V; Izzo, F; Lastoria, S; Palaia, R; Petrillo, A; Piccirillo, M | 1 |
| Adachi, Y; Doi, K; Furumoto, K; Furuyama, H; Hasegawa, S; Hatano, E; Hirose, T; Horimatsu, T; Inoue, N; Ishii, T; Kaihara, S; Kanazawa, A; Manaka, D; Matsumoto, S; Nakamura, K; Okuno, M; Sakai, Y; Seo, S; Taura, K; Terajima, H; Tokka, A; Uemoto, S; Yasuchika, K; Yazawa, T; Zaima, M | 1 |
| Cui, Y; Dong, N; Meng, F; Wang, M; Wu, Y; Zhang, S | 1 |
| de Jong, KP; de Wilt, JH; Dejong, KH; Engelbrecht, MR; Huiskens, J; Kazemier, G; Keijser, A; Meijer, GA; Mol, L; Molenaar, IQ; Punt, CJ; Ruers, TM; Schriek, J; van Grieken, NC; van Gulik, TM; van Lienden, KP; van Tinteren, H; Verhoef, C | 1 |
| Azvolinsky, A | 1 |
| Hsu, WH; Huang, CW; Kuo, CH; Lin, CH; Tsai, HL; Tseng, FY; Wang, JY; Wu, JY; Yang, IP; Yeh, YS | 1 |
| Ayez, N; Eggermont, AM; Grünhagen, DJ; Rothbarth, J; van der Stok, EP; van Meerten, E; Verhoef, C | 1 |
| Cline-Burkhardt, M; Cohn, A; Dakhil, S; Go, WY; Hecht, JR; Piperdi, B; Saleh, M; Tian, Y | 1 |
| Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J | 1 |
| Gao, SR; Li, LM; Wang, AR; Wang, GM; Xia, HP; Xu, HY | 1 |
| Cervantes, A; Ciardiello, F; Jego, V; Laffranchi, B; Macarulla, T; Martinelli, E; Prenen, H; Roselló, S; Tabernero, J; Tejpar, S; Troiani, T; Van Cutsem, E; von Richter, O | 1 |
| Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A | 1 |
| Danciu, M; Negru, SM; Scripcariu, V; Volovat, C; Volovat, SR | 1 |
| Bortlicek, Z; Büchler, T; Dusek, L; Finek, J; Kocak, I; Kocakova, I; Kohoutek, M; Melichar, B; Mohelnikova-Duchonova, B; Petruzelka, L; Prausová, J; Vyzula, R | 1 |
| Antoch, G; Graf, D; Häussinger, D; Knoefel, WT; Kröpil, P; Riemer, J; Schneitler, S | 1 |
| Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T | 1 |
| Jung, SH; Kim, JH; Kim, SH | 1 |
| El-Rayes, B; Landry, J; Maithel, SK; Nanda, RH | 1 |
| Díaz de Corcuera, I; García de la Torre, M; Pérez Hoyos, MT; Salgado Fernández, M; Vidal Arbués, A | 1 |
| Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI | 1 |
| Butzke, B; Giessen-Jung, C; Heinemann, V; Oduncu, FS; Pfeufer, A; Rogowski, WH; Severin, F; Stollenwerk, B | 1 |
| Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T | 1 |
| Fausti, V; Gallo, P; Imperatori, M; Picardi, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vespasiani Gentilucci, U; Vincenzi, B | 1 |
| Barriuso, J; Borbath, I; Chougnet, CN; Crespo, G; Heetfeld, M; O'Toole, D; Olsen, IH; Pavel, M; Rinke, A; Walter, T | 1 |
| Gao, L; Gotoh, M; Nasroulah, F; Ohtsu, A; Yamazaki, K; Yoshino, T; Yoshizuka, N | 1 |
| Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M; Yamaguchi, T | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E | 1 |
| Crocenzi, TS; Garcia-Monaco, RD; Kelly, LR; Laing, CJ; Martin, RC; Rilling, WS; Schreeder, M; Scoggins, CR; Sharma, VR; Strasberg, SM; Tatum, CM | 1 |
| Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ | 1 |
| Asao, T; Fujii, T; Kato, T; Kuwano, H; Morita, H; Suto, T; Tsutsumi, S; Yajima, R; Yamaguchi, S | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Choi, YJ; Kim, JH; Kim, SE; Kwon, HJ; Lee, HW; Moon, W; Park, MI; Park, SJ | 1 |
| Cremolini, C; Falcone, A; Folwaczny, M; Heinemann, V; Jung, A; Kemmerling, R; Kirchner, T; Lenz, HJ; Loupakis, F; Matsusaka, S; Neureiter, D; Ning, Y; Sebio, A; Stintzing, S; Stremitzer, S; Sunakawa, Y; Yamauchi, S; Yang, D; Zhang, W | 1 |
| Dartigues, P | 1 |
| Kim, JH; Park, MI | 1 |
| Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H | 1 |
| Barretta, ML; Cassata, A; De Divitiis, C; Iaffaioli, RV; Nappi, A; Nasti, G; Ottaiano, A | 1 |
| Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG | 1 |
| Skoropad, VY | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK | 1 |
| Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Held, S; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Modest, DP; Möhler, M; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| El-Rayes, BF; Goldstein, DA | 1 |
| Bachet, JB; Blanc, JF; Coriat, R; Cunha, AS; Hentic, O; Innominato, P; Laurent, C; Marthey, L; Pietrasz, D; Raoul, JL; Regenet, N; Taieb, J; Terrebonne, E; Trouilloud, I; Turrini, O; Wagner, M | 1 |
| Chan, DL; Karapetis, CS; Pavlakis, N; Price, TJ; Segelov, E; Shapiro, J; Tebbutt, NC | 1 |
| Almhanna, K; Fulp, W; Kim, R; Mahipal, A; Shibata, D; Siegel, E; Springett, G; Williams-Elson, I | 1 |
| Chen, ZJ; Huang, P; Ren, LL; Tao, G; Xin, WX; Yin, WJ; Zhang, YW; Zheng, XW | 1 |
| Cheng, PC; Kuo, MY; Lai, JK; Liang, KH; Liao, MY; Lin, CW; Lu, RM; Wu, HC | 1 |
| Jabbar, AA; Zahir, MN | 1 |
| Atanackovic, D; Bluemner, E; Bokemeyer, C; Brugger, W; Hapke, G; Hildebrandt, B; Illerhaus, G; Steffens, CC; Stein, A; Stöhlmacher, J; Stübs, P | 1 |
| Allegrini, G; Antoniotti, C; Boni, L; Carlomagno, C; Cazzaniga, M; Chiara, S; Cremolini, C; D'Amico, M; Falcone, A; Fontanini, G; Granetto, C; Lonardi, S; Loupakis, F; Lupi, C; Mezi, S; Ronzoni, M; Sensi, E; Tomasello, G; Tonini, G; Zaniboni, A | 1 |
| André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Ducreux, M; He, P; Hotko, Y; Jung, AS; Koukakis, R; Lordick, F; Oliner, KS; Patterson, SD; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Sidhu, R; Sobrero, AF; Strickland, AH; Terwey, JH; Van Cutsem, E; Wilson, G; Yu, H | 1 |
| Braren, R; Erkan, M; Esposito, I; Friess, H; Holzapfel, K; Kleeff, J; Kong, B; Michalski, CW; Nitsche, U; Schlitter, AM; Siveke, JT; Stöß, C; Wenzel, P | 1 |
| Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S | 1 |
| Basu, B; Calder, J; Corrie, P; Ghorani, E; Hewitt, C; Wong, HH | 1 |
| Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H | 1 |
| Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ | 1 |
| Chun, HJ; Park, SC | 1 |
| Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I | 1 |
| Beltjens, F; Bengrine, L; Ghiringhelli, F; Ladoire, S; Vincent, J | 1 |
| Aparicio, T; Bedenne, L; Bouché, O; Breysacher, G; Dahan, L; Etienne, PL; Khemissa, F; Lafargue, JP; Le Malicot, K; Lécaille, C; Lecomte, T; Legoux, JL; Loriot, MA; Maillard, E; Manfredi, S; Michel, P; Mitry, E; Rougier, P | 1 |
| Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A | 1 |
| Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS | 1 |
| Grapsa, D; Saif, MW; Syrigos, K | 1 |
| Chen, L; Ji, M; Jiang, J; Li, X; Li, Z; Lu, Q; Pei, H; Qiang, W; Shi, L; Wang, H; Wang, J; Wu, C; Wu, J; Xu, B; Zhao, J | 1 |
| Azadeh, P; Hosseini Kamal, F; Mortazavi, N; Novin, K; Tahmasebi, A | 1 |
| Bartnik, CM; Flowers, CR; Goldstein, DA; Neustadter, E; Zeichner, SB | 1 |
| Amato, DM; Avallone, A; Catalano, O; Filice, S; Fusco, R; Granata, V; Izzo, F; Nasti, G; Petrillo, A | 1 |
| Ahn, JB; Baik, SH; Hong, SP; Hur, H; Jung, I; Jung, M; Keum, KC; Kim, H; Kim, NK; Kim, TI; Koom, WS; Lim, JS; Min, BS; Park, YS; Roh, JK; Shin, SJ | 1 |
| Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J | 1 |
| Arita, S; Fujii, T; Isaka, N; Koike, N; Ohshima, Y; Shinozaki, E; Takeuchi, T | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Azzopardi, N; Boisdron-Celle, M; Gamelin, E; Gouilleux-Gruart, V; Gruel, Y; Lecomte, T; Morel, A; Paintaud, G; Payancé, A; Rollin, J; Watier, H | 1 |
| Annaratone, L; Bonin, S; Bussolati, G; Capella, C; Chiaravalli, AM; Donada, M; Hoefler, G; Nardon, E; Pichler, M; Stanta, G | 1 |
| Andria, M; Arnold, D; Cunningham, D; Dochy, E; Grávalos, C; Hoff, PM; Humblet, Y; Joulain, F; Kröning, H; Lakomý, R; Le-Guennec, S; Macarulla, T; McKendrick, J; Mitchell, E; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Tabernero, J; Ten Tije, AJ; Van Cutsem, E; van Hazel, G; Vishwanath, RL | 1 |
| Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T | 1 |
| Amitesh, R; Beeke, C; Karapetis, C; Lo, L; Maddern, G; Moore, J; Padbury, R; Price, TJ; Roder, D; Townsend, AR | 1 |
| Buc, E; Chatelut, E; De la Fouchardière, C; Mendoza, C; Mineur, L; Pezet, D; Phelip, JM; Quesada, JL; Rivoire, M; Roblin, X | 1 |
| Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V | 1 |
| Andoh, M; Kadowaki, S; Kimura, K; Kinoshita, T; Komori, A; Komori, K; Muro, K; Narita, Y; Taniguchi, H; Ura, T; Yatabe, Y | 1 |
| Doi, T; Hatake, K; Ishihara, Y; Shirao, K; Takahashi, Y; Uetake, H | 1 |
| Aroldi, F; Zaniboni, A | 1 |
| Hirakawa, K; Ikeya, T; Iseki, Y; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Ohira, G; Sakurai, K; Shibutani, M; Tamura, T; Tanaka, H; Toyokawa, T; Yamazoe, S | 1 |
| Amikura, K; Asayama, M; Fukuda, T; Ishikawa, H; Kawashima, Y; Kazama, S; Kurozumi, M; Mori, Y; Nishimura, Y; Nishizawa, Y; Sakamoto, H; Takano, M; Takenoya, T; Tanaka, Y | 1 |
| André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG | 1 |
| Kakuta, S; Kou, T; Satou, M; Sugaya, M; Takayama, W | 1 |
| Huang, CW; Lin, YW; Lu, CY; Sung, YC; Tang, HC; Tsai, HL; Wang, JH; Wang, JY; Wu, CC; Yeh, YS | 1 |
| Autorino, R; Balducci, M; Buwenge, M; Caravatta, L; Cellini, F; Cilla, S; Deodato, F; Di Lullo, L; Gambacorta, MA; Macchia, G; Mattiucci, GC; Mignogna, S; Morganti, AG; Padula, GD; Picardi, V; Valentini, V | 1 |
| Allen, PJ; Boucher, TM; Capanu, M; Cercek, A; Chou, JF; D'Angelica, MI; DeMatteo, RP; Fong, YC; Jarnagin, WR; Kemeny, NE | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Berger, MD; Cao, S; Hanna, DL; Lenz, HJ; Loupakis, F; Matsusaka, S; Miyamato, Y; Ning, Y; Okazaki, S; Parekh, A; Stintzing, S; Sunakawa, Y; Yang, D; Zhang, W | 1 |
| Lenz, HJ; Schirripa, M; Sunakawa, Y | 1 |
| Byrne, JD; DeSimone, JM; Jajja, MR; Keeler, AW; Luft, JC; Schorzman, AN; Yeh, JJ; Zamboni, WC | 1 |
| Allegrini, G; Barbara, C; Bergamo, F; Boni, L; Buonadonna, A; Bustreo, S; Chiara, S; Cremolini, C; Falcone, A; Granetto, C; Lonardi, S; Loupakis, F; Mancini, ML; Masi, G; Moretto, R; Ronzoni, M; Rossini, D; Tomasello, G; Tonini, G; Vitello, S | 1 |
| Chang, W; Chen, J; Ding, J; Feng, Q; Lin, Q; Qin, X; Ren, L; Wei, Y; Xu, J; Yang, L; Ye, Q; Yu, Y; Zheng, P; Zhong, Y; Zhu, D | 1 |
| Albayrak, D; Cicin, I; Erdogan, B; Hacibekiroglu, I; Kodaz, H; Tozkir, H; Turkmen, E; Uzunoglu, S | 1 |
| Bendell, JC; Boccia, R; Earwood, C; Gian, V; Lane, CM; Lipman, A; LoCicero, R; Meluch, A; Moskowitz, M; Peyton, JD; Waterhouse, D; Zakari, A | 1 |
| Ahn, DH; Bekaii-Saab, T; Bupathi, M; Ciombor, KK; Goldstein, DA; Reardon, J; Stephens, JA; Wu, C | 1 |
| Franken, MD; Koopman, M; van Oijen, MG | 1 |
| Bekaii-Saab, T; Stintzing, S; Sunakawa, Y | 1 |
| Boustani, AM; Cha, CH; Chang, B; Cong, X; Deng, Y; Hochster, HS; Indukala, D; James, ES; Kortmansky, JS; Lacy, J; Li, J; Patel, V; Salem, RR; Staugaard, C; Stein, SM | 1 |
| Bai, X; Gao, S; Li, G; Liang, T; Lou, J; Ma, T; Que, R; Shen, S; Su, R; Wei, Q; Yu, R; Yuan, Y | 1 |
| Caparello, C; Catanese, S; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Vasile, E; Vivaldi, C | 1 |
| Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A | 1 |
| Lim, K; Ur Rehman, SS; Wang-Gillam, A | 1 |
| Belt, BA; Cusworth, BM; DeNardo, DG; Fields, RC; Fowler, KJ; Goedegebuure, SP; Hawkins, WG; Lim, KH; Linehan, DC; Lockhart, AC; Nieman, RK; Nywening, TM; Panni, RZ; Sanford, DE; Strasberg, SM; Suresh, R; Tan, BR; Toriola, AT; Wang-Gillam, A; Worley, LA; Yano, M | 1 |
| Chen, H; Li, Q; Tang, R; Wen, F; Wu, Y; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Endo, T; Hasegawa, H; Ishii, Y; Kitagawa, Y; Kondo, T; Ochiai, H; Okabayashi, K; Shigeta, K; Tsuruta, M | 1 |
| Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G | 1 |
| Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G | 1 |
| Becouarn, Y; Fourrier-Réglat, A; Grelaud, A; Guimbaud, R; Jové, J; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N | 1 |
| Chai, CY; Chien, TM; Huang, CN; Lin, CH; Lu, YM | 1 |
| Cavaglione, G; Evesque, L; Follana, P; François, E; Gal, J; Reure, J; Saint, A | 1 |
| Artaç, M; Avcı, N; Çabuk, D; Coşkun, HŞ; Dane, F; Doruk, H; Faruk Aykan, N; Karaağaç, M; Karabulut, B; Karabulut, S; Korkmaz, L; Turhal, NS | 1 |
| Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG | 1 |
| Chang, JY; Chen, LT; Chiang, NJ; Shan, YS | 1 |
| Berry, SR; Chan, KK; Giotis, A; Ko, YJ; Lien, K; Mittmann, N; Riesco-Martínez, MC; Wong, WW | 1 |
| Barile, R; Barone, C; Basso, M; Cassano, A; D'Argento, E; Martini, M; Rossi, S; Schinzari, G; Strippoli, A | 1 |
| Bennouna, J; Cabart, M; Campion, L; Douillard, JY; Dupuis, O; Frénel, JS; Hiret, S; Ramée, JF; Senellart, H | 1 |
| Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A | 1 |
| Ando, M; Baba, E; Boku, N; Denda, T; Eguchi Nakajima, T; Esaki, T; Fujikawa, K; Funai, S; Hara, H; Hirashima, T; Hosokawa, A; Hyodo, I; Kawakami, K; Kurimoto, T; Morita, S; Moriwaki, T; Murata, K; Muro, K; Nagase, M; Nakashima, K; Nishina, T; Okabe, M; Okuno, T; Otsuji, T; Sato, M; Seki, N; Shibata, Y; Shimura, T; Shinozaki, E; Shinozaki, K; Sugimoto, N; Suyama, K; Suzuki, K; Taira, K; Takayama, T; Taku, K; Tamagawa, H; Tamura, F; Tamura, T; Tsuda, M; Tsuji, A; Tsuji, Y; Tsushima, T; Ueda, S; Umeki, M; Yamashita, H; Yamazaki, K; Yoshida, M | 1 |
| Ardito, F; Barone, C; Basso, M; Cassano, A; Cerchiaro, E; Dadduzio, V; Giuliante, F; Lombardi, P; Orlandi, A; Rossi, S; Strippoli, A; Vellone, M | 1 |
| Berger, MD; Cao, S; Cremolini, C; DePaolo, RW; Falcone, A; Heinemann, V; Lenz, HJ; Loupakis, F; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Parekh, A; Schirripa, M; Stintzing, S; Stremitzer, S; Suenaga, M; Sunakawa, Y; West, JD; Yang, D; Zhang, W | 1 |
| Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T | 1 |
| Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN | 1 |
| Al-Batran, SE; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Hielscher, J; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerch, MM; Lerchenmueller, C; Michl, M; Modest, DP; Mueller, S; Scheithauer, W; Scholz, M; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U | 1 |
| Aliustaoglu, M; Aydin, D; Aydin, O; Ercelep, O; Gumus, M; Isik, D; Isik, S; Kefeli, U; Odabas, H; Oyman, A; Ozcelik, M; Sendur, MA; Sener, N; Surmeli, H; Ustaalioglu, BB; Yildirim, E | 1 |
| Folprecht, G | 1 |
| Chiorean, EG; Coveler, AL; Herman, JM; Simeone, DM | 1 |
| Barreto, R; Bonetto, A; Gao, H; Liu, Y; Waning, DL; Zimmers, TA | 1 |
| Ahmad, SA; Bekaii-Saab, T; Cardin, D; Collisson, E; Conway, W; Frankel, W; Herman, JM; Hoffman, JP; Katz, MH; Kindler, H; LoConte, N; Lowy, AM; Marsh, Rde W; Martin, R; Philip, P; Schwartz, L; Shen, P; Shi, Q; Talamonti, M; Truty, M; Venook, AP | 1 |
| André, T; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Garcia-Larnicol, ML; Hamidou, Z; Hebbar, M; Hug de Larauze, M; Louvet, C | 1 |
| Havre, RF; Kalaitzakis, E; Meisner, S; Willemoe, GL | 1 |
| Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A | 1 |
| Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nishikawa, T; Nozawa, H; Otani, K; Tanaka, T; Watanabe, T; Yasuda, K | 1 |
| Besselink, MG; Mohammad, NH; Molenaar, IQ; Rombouts, SJ; van Rijssen, LB; van Santvoort, HC; Vogel, JA; Walma, MS; Wilmink, JW | 1 |
| Cohen, SJ; Dotan, E; Hall, MJ; Li, T; Vijayvergia, N; Wong, YN | 1 |
| Benson, AB; Burtness, BA; Cohen, SJ; Douglas, K; Enzinger, PC; Goldberg, RM; Ilson, DH; Mayer, RJ; Niedzwiecki, D; Venook, A; Villaflor, VM; Ye, X | 1 |
| Ball, A; Bowers, M; Bridgewater, JA; Corkhill, A; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Maishman, T; Maughan, TS; O'Reilly, DA; Primrose, JN; Pugh, SA; Radford, M; Rees, C; Rees, M; Siriwardena, AK; Stanton, L; Valle, JW | 1 |
| Ellenrieder, V; König, A; Seufferlein, T | 1 |
| Hirano, A; Hiroshima, Y; Ishida, Y; Kasahara, K; Kawaguchi, D; Kikuchi, Y; Koda, K; Kosugi, C; Matsuo, K; Mori, M; Murakami, T; Shuto, K; Tanaka, K; Yamada, M; Yamazaki, K | 1 |
| Corvera, CU; Harris, HW; Hirose, R; Kim, GE; Kim, SS; Kirkwood, KS; Ko, AH; Nakakura, EK; Tempero, MA; Wang, ZJ | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Brutcher, E; Cassidy, RJ; Chen, Z; El-Rayes, BF; Hawk, N; Kooby, D; Landry, J; Maithel, SK; Sarmiento, JM; Shaib, WL; Zhang, C | 1 |
| Bartlett, DL; Dhir, M; Magge, D; Novak, S; Zureikat, AH | 1 |
| Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D | 1 |
| Bodoky, G; Ciuleanu, T; Clingan, P; Cohn, A; Garcia Alfonso, P; Garcia-Carbonero, R; Kim, TW; Lonardi, S; Nasroulah, F; Obermannová, R; Portnoy, D; Prausová, J; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yang, L; Yoshino, T | 1 |
| Al-Batran, SE; Decker, T; Giessen-Jung, C; Heinemann, V; Heintges, T; Held, S; Jagenburg, A; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerch, MM; Lerchenmüller, C; Modest, DP; Moehler, M; Rossius, L; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Beier, F; Ciardiello, F; Folprecht, G; Köhne, CH; Poston, G; Ronga, P; Van Cutsem, E | 1 |
| Crea, F; Danesi, R; De Gregorio, V; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Vivaldi, C | 1 |
| Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H | 1 |
| Chen, Y; Cui, Y; Liang, L; Liu, T; Wang, Y; Wang, Z; Yu, Y; Zhou, Y; Zhuang, R | 1 |
| Arbez-Gindre, F; Borg, C; Cayre, A; Fein, F; Jacquin, M; Jary, M; Kim, S; Lakkis, Z; Nguyen, T | 1 |
| Caparello, C; Falcone, A; Funel, N; Garajova, I; Giovannetti, E; Kazemier, G; Le Large, TY; Meijer, LL; Peters, GJ; Vasile, E | 1 |
| Angele, MK; Boeck, S; Bruns, CJ; Burger, PJ; Haas, M; Hartwig, W; Heinemann, V; Kirchner, T; Kleespies, A; Kruger, S; Modest, DP; Ormanns, S; Werner, J; Westphalen, CB | 1 |
| Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS | 1 |
| Ahn, SJ; Han, JK; Kim, JH; Park, SJ | 1 |
| Blanc, JF; Carrato, A; Ciardiello, F; de Jong, FA; Ektare, V; Gill, S; Hubner, RA; Patel, DA; Vogel, A; Yang, Y | 1 |
| Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C | 1 |
| Boku, N; Denda, T; Hyodo, I; Moriwaki, T; Muro, K; Nishina, T; Nishio, K; Okuda, H; Sakai, K; Shitara, K; Takano, T; Tokunaga, S; Tsuda, M; Yamanaka, T; Yamazaki, K; Yonesaka, K | 1 |
| Artaç, M; Börüban, MC; Bozcuk, H; Er, Z; Güler, T; Karaağaç, M; Korkmaz, L; Uysal, M | 1 |
| Bohle, W; Egger, J; Hann, A; Zoller, WG | 1 |
| Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K | 1 |
| Pellerin, O; Pernot, S; Pointet, AL; Sueur, B; Taieb, J; Voron, T | 1 |
| Boedigheimer, M; Demonty, G; Fernebro, E; Greil, R; Hofheinz, RD; Karthaus, M; Köhne, CH; Letocha, H; Mineur, L; Oliner, KS; Thaler, J; Twomey, B; Zhang, Y | 1 |
| Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M | 1 |
| Beier, F; Chatterjee, S; Cheng, AL; Chung, IJ; Cornelio, G; Dai, GH; Doval, DC; Gibbs, P; Gorospe, C; Guan, Z; Hill, A; Lim, R; Lin, JK; Ma, B; Masood, N; Oh, ST; Price, T; Sharma, A; Shen, L; Shim, BY; Sirachainan, E; Srimuninnimit, V; Suh, KW; Wang, HM; Wang, X; Yang, TS; Yau, T; Yeh, KH; Zaatar, A | 1 |
| Amano, R; Fukuoka, T; Hirakawa, K; Ikeya, T; Iseki, Y; Kimura, K; Maeda, K; Matsutani, S; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tanaka, H; Toyokawa, T | 1 |
| Alvarez, R; Cubillo, A; de la Varga, LU; Garralda, E; Hidalgo, M; Lopéz-Casas, PP; López-Ríos, F; Pascual, JR; Perea, S; Prieto, SH; Sánchez, G; Sarno, F; Toledo, RA; Vega, E | 1 |
| Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T | 1 |
| Antunes, C; Bachet, JB; Cassinotto, C; Lucidarme, O; Pietrasz, D; Sa Cunha, A; Wagner, M; Zappa, M | 1 |
| Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS | 1 |
| Axilbund, J; Button, B; Chu, D; Cravero, K; Dalton, WB; Gocke, CD; Kyker-Snowman, K; Laheru, D; Lauring, J; Lee, J; Park, BH; Waters, I; Watkins, S | 1 |
| Allegrini, G; Aprile, G; Bergamo, F; Casagrande, M; Cillo, U; Cremolini, C; Falcone, A; Ferrari, L; Fontanini, G; Granetto, C; Loupakis, F; Marmorino, F; Masi, G; Milione, M; Moretto R, R; Pellegrinelli, A; Pietrantonio, F; Pilati, P; Sensi, E; Tomasello, G; Tonini, G; Urbani, L; Zucchelli, G | 1 |
| Benahim, E; Boige, V; de Baere, T; Deschamps, F; Ducreux, M; Goéré, D; Malka, D; Tselikas, L | 1 |
| Zaniboni, A | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Ahrendt, SA; Bahary, N; Bartlett, DL; Choudry, HA; Dhir, M; Hogg, ME; Holtzman, MP; Pingpank, JF; Singhi, AD; Zeh, HJ; Zureikat, AH | 1 |
| Beyer, G; Javed, MA; Kohlmann, T; Krug, S; Le, N; Neesse, A; Schober, M; Sund, M; Vinci, A | 1 |
| Al-Batran, SE; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Modest, DP; Moehler, M; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Einem, JC | 1 |
| Blanke, C; Cesas, A; Choi, MR; Croitoru, A; Decaestecker, J; Gibbs, P; Hotko, Y; Jassem, J; Klippel, Z; Kurteva, G; Morrow, PK; Novotny, J; O'Reilly, S; Pinter, T; Reiner, M; Salek, T; Whittaker, S | 1 |
| Atreya, C; Korn, WM; Parikh, A; Venook, AP | 1 |
| Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nakajima, J; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Tanaka, T; Watanabe, T; Yasuda, K | 1 |
| Bodoky, G; Harsanyi, L; Hegyi, P; Lakatos, G; Nehéz, L; Petranyi, A; Szűcs, A | 1 |
| Buonadonna, A; Cecchin, E; De Mattia, E; Giodini, L; Innocenti, F; Montico, M; Roncato, R; Solfrini, V; Toffoli, G | 1 |
| Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S | 1 |
| Modest, DP; Neumann, UP; Pratschke, J | 1 |
| Ando, M; Beier, F; Guenther, S; Ooki, A; Van Cutsem, E; von Hohnhorst, P; Yamaguchi, K | 1 |
| Baretta, Z; Bonfill Cosp, X; Hallum, S; Martin-Richard, M; Mocellin, S; Roqué I Figuls, M; Solà, I | 1 |
| Aomatsu, N; Hirakawa, T; Iwauchi, T; Morimoto, J; Nagashima, D; Nakazawa, K; Nishii, T; Takeuchi, K; Tei, S; Uchima, Y; Wang, E; Yamakoshi, Y | 1 |
| Doi, Y; Hatori, S; Kamiya, M; Masuda, M; Oshima, T; Rino, Y; Sato, T; Shirai, J; Suzuki, Y; Yamada, T; Yamamoto, N; Yoneyama, K; Yoshikawa, T; Yukawa, N | 1 |
| Ando, M; Hasegawa, H; Kadowaki, S; Komori, A; Masuishi, T; Mitani, S; Muro, K; Narita, Y; Taniguchi, H; Ura, T; Yatabe, Y | 1 |
| Byer, J; Chang, YD; Kim, DW; Kim, RD; Kothari, N; Mahipal, A | 1 |
| Loreni, G; Miele, V; Ramponi, S; Rastelli, M; Scevola, G; Sposato, S | 1 |
| Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA | 1 |
| Cho, SH; Chung, IJ; Han, HS; Hong, YS; Kang, HJ; Kang, JH; Kim, JE; Kim, JH; Kim, JW; Kim, KP; Kim, SY; Kim, TW; Lee, JH; Lee, KT; Lee, KW; Lee, MA; Nam, BH; Oh, HS; Park, SR; Park, YI; Park, YS; Shin, DB; Song, EK; Zang, DY | 1 |
| Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K | 1 |
| Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J | 1 |
| André, T; Asselain, B; Bennouna, J; Ducreux, M; Phelip, JM | 1 |
| Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M | 1 |
| Belk, KW; Kim, GP; Parisi, MF; Patel, MB; Pelletier, CL | 1 |
| Dawson, DW; Donahue, TR; Hines, OJ; Muthusamy, VR; Reber, HA; Sugimoto, M | 1 |
| Cho, DH; Kim, CW; Kim, JC; Kim, MB; Kim, TW; Roh, SA; Yoon, YS | 1 |
| Ahn, S; Hwang, JH; Kim, HW; Kim, J; Kim, JW; Kim, YH; Lee, J; Lee, JC; Paik, KH | 1 |
| Berger, MD; Cao, S; Cremolini, C; Falcone, A; Groshen, S; Hanna, DL; Heinemann, V; Lenz, HJ; Lonardi, S; Loupakis, F; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Stintzing, S; Suenaga, M; Sunakawa, Y; Yamauchi, S; Yang, D; Zhang, W | 1 |
| Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y | 1 |
| Barzi, A; Berger, MD; Cao, S; Falcone, A; Gopez, RF; Hanna, D; Heinemann, V; Lenz, HJ; Loupakis, F; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Stintzing, S; Suenaga, M; West, JD; Yang, D; Zhang, W | 1 |
| Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Matsunaga, T; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanda, N; Tsujino, T; Uchimoto, T; Yoshikawa, Y | 1 |
| Lamb, YN; Scott, LJ | 1 |
| Ferreira, FP; Leal, F; Sasse, AD | 1 |
| Al-Batran, SE; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Jagenburg, A; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Miller-Phillips, L; Modest, DP; Moehler, M; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM | 1 |
| Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Shimamura, T; Tokuhisa, M | 1 |
| Aoyama, H; Fukami, Y; Jinno, T; Kanamori, M; Kiriyama, M; Kobayashi, S; Kurumiya, Y; Miyamura, K; Mizuno, K; Mori, M; Nakashima, Y; Oiwa, T; Sekoguchi, E | 1 |
| Hashimoto, Y; Hirata, Y; Ishizaki, Y; Kitamura, S; Kuga, Y; Miwata, T; Mouri, T | 1 |
| Barni, S; Ghidini, M; Passalacqua, R; Petrelli, F; Russo, A; Tomasello, G | 1 |
| Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW | 1 |
| Akihito, T; Berger, MD; Cao, S; DePaolo, RW; Gopez, R; Heinemann, V; Ichikawa, W; Lenz, HJ; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Stintzing, S; Suenaga, M; Sunakawa, Y; West, JD; Yang, D; Zhang, W | 1 |
| Crispin, A; Fischer von Weikersthal, L; Giessen-Jung, C; Haas, M; Heinemann, V; Holch, JW; Jung, A; Kirchner, T; Kruger, S; Michl, M; Modest, DP; Neumann, J; Quietzsch, D; Schalhorn, A; Stahler, A; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Einem, J | 1 |
| Allegrini, G; Antoniotti, C; Aprile, G; Boni, L; Cremolini, C; Di Donato, S; Falcone, A; Lonardi, S; Loupakis, F; Marmorino, F; Masi, G; Passardi, A; Pietrantonio, F; Ricci, V; Ronzoni, M; Salvatore, L; Santini, D; Schirripa, M; Tamburini, E; Tomasello, G; Valsuani, C; Zagonel, V | 1 |
| Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P | 1 |
| Atkins, JN; Benson, AB; Berry, S; Bertagnolli, MM; Blanke, C; El-Khoueiry, AB; Fruth, B; Goldberg, RM; Greene, C; Hochster, HS; Innocenti, F; Lenz, HJ; Mayer, RJ; Meyerhardt, JA; Mulkerin, DL; Niedzwiecki, D; O'Neil, BH; O'Reilly, EM; Polite, BN; Schilsky, RL; Schrag, D; Venook, AP; Watson, P | 1 |
| Abad, A; Aranda, E; Carrato, A; Dueñas, R; Escudero, P; Gallego, J; García-Paredes, B; Gómez, A; González, E; Grávalos, C; Longo-Muñoz, F; Losa, F; Manzano, JL; Massuti, B; Pericay, C; Rivera, F; Safont, MJ; Valladares-Ayerbes, M | 1 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Aizawa, K; Furukawa, T; Kozakai, H; Mitsuboshi, S; Nagai, K; Yamada, H | 1 |
| Cinar, P; Ko, AH | 1 |
| Bilancia, D; Cascinu, S; Corsi, DC; Ferraú, F; Galli, F; Giordano, M; Iaffaioli, RV; Labianca, R; Leone, F; Lonardi, S; Marchetti, P; Nasti, G; Ronzoni, M; Rosati, G; Scartozzi, M; Zagonel, V; Zaniboni, A | 1 |
| Gao, L; Li, J; Niu, B; Wu, X; Ye, R; Zhao, Z | 1 |
| Gonzaga-López, A; Muñoz-Rodriguez, J; Ruiz-Casado, A | 1 |
| Guo, B; Li, J; Luo, L; Tang, D; Wang, D; Wang, J; Yang, Z | 1 |
| Peng, S; Shan, S; Wang, J; Wang, L; Wu, J; Xiao, N; Yu, K; Yu, S; Zheng, S | 1 |
| Cohen, D; Ghaffaripour, T; Stoner, P | 1 |
| Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O | 1 |
| Choi, YR; Han, JK; Hur, BY; Kim, JH; Park, SJ | 1 |
| Dochy, E; Lakomy, R; Macarulla, T; Magherini, E; Moiseyenko, VM; Papamichael, D; Prausova, J; Ruff, P; Soussan-Lazard, K; Van Cutsem, E; van Hazel, GA | 1 |
| Carvalho, T; Ferreira, MG; Figueiredo, N; Fior, R; Gomes, A; Mendes, RV; Póvoa, V | 1 |
| Funada, T; Kaiga, T; Kochi, M; Okada, S; Takayama, T; Yamazaki, S | 1 |
| Al-Batran, SE; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Holch, JW; Kahl, C; Kiani, A; Kullmann, F; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Seipelt, G; Stintzing, S; Vehling-Kaiser, U; von Einem, JC; Westphalen, CB | 1 |
| Avallone, A; Caraglia, M; Cassata, A; De Stefano, A; Nasti, G; Ottaiano, A | 1 |
| Liauw, SL | 1 |
| Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC | 1 |
| Allen, JN; Berger, D; Blaszkowsky, LS; Clark, JW; Collura, C; Deshpande, V; Ferrone, CR; Lillemoe, KD; Miller, CL; Murphy, JE; Parikh, AR; Qadan, M; Ryan, DP; Smalley, R; Tanabe, KK; Taylor, MS; Worthington, S | 1 |
| Costa, J; Duarte, GS; Marques, RP; Martins, AP; Pais, HL; Quintela, A; Sterrantino, C | 1 |
| Chalchal, H; Payette, E; Sarker, S | 1 |
| Cascinu, S; Cavanna, L; Codecà, C; Daniele, B; Ferrari, D; Germano, D; Giampieri, R; Labianca, R; Libertini, M; Lonardi, S; Pella, N; Puzzoni, M; Rosati, G; Scartozzi, M; Sozzi, P; Zagonel, V; Zampino, MG; Zaniboni, A | 1 |
| Bozkaya, Y; Demirci, NS; Erdem, GU; Ozdemir, NY; Yazici, O; Zengin, N | 1 |
| Biglietto, M; Bordonaro, R; Cardone, C; Ciardiello, F; Esposito Abate, R; Forgione, L; Giuliani, F; Iannaccone, A; Lambiase, M; Latiano, TP; Leo, S; Maiello, E; Martinelli, E; Normanno, N; Pisconti, S; Rachiglio, AM; Rinaldi, A; Rizzi, D; Sacco, A; Troiani, T | 1 |
| Bennouna, J; Bouché, O; Conroy, T; Desseigne, F; Gourgou, S; Jarlier, M; Juzyna, B; Robert, M; Ychou, M | 1 |
| Azoulay, D; Esposito, F; Fuentes, L; Lahat, E; Lim, C; Moussallem, T; Osseis, M; Salloum, C | 1 |
| Amar, Y; Berger, F; Bieche, I; Cacheux, W; Canet, J; Cartier, A; de Koning, L; Guimbaud, R; Guyetant, S; Lecomte, T; Lièvre, A; Mariani, O; Ouine, B; Selves, J | 1 |
| Azrumelashvili, T; Chikovani, T; Janikashvili, N; Kikodze, N; Mizandari, M; Paksashvili, N; Pantsulaia, I; Shanava, K | 1 |
| Gao, J; Gong, J; Li, J; Li, Y; Shen, L; Wang, X; Wei, Q | 1 |
| Berger, MD; Cao, S; Falcone, A; Heinemann, V; Lenz, HJ; Loupakis, F; Matsusaka, S; Miyamoto, Y; Ning, Y; Okazaki, S; Schirripa, M; Soni, S; Stintzing, S; Suenaga, M; Sunakawa, Y; Yang, D; Zhang, W | 1 |
| Aparicio, T; Baconnier, M; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; François, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Maillard, E; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J | 1 |
| Arita, S; Baba, E; Esaki, T; Kajitani, T; Makiyama, A; Oda, H; Shimokawa, H; Shirakawa, T | 1 |
| Barreto, R; Bonetto, A; Bonewald, LF; Colston, KC; Couch, KE; Couch, ME; Kitase, Y; Matsumoto, T; O'Connell, TM; Pin, F | 1 |
| Demonty, G; Köhne, CH; Koukakis, R; Peeters, M; Prenen, H; Rivera, F; Siena, S; Taieb, J | 1 |
| Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I | 1 |
| Allen, PJ; Balachandran, VP; Boucher, T; Capanu, M; Cercek, A; Chou, JF; D'Angelica, MI; DeMatteo, RP; Jarnagin, WR; Kemeny, NE; Kingham, TP; Pak, LM | 1 |
| Chen, L; Huang, L; Lin, X; Xie, Y; Zheng, Q | 1 |
| Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Held, S; Lang, H; Modest, DP; Modest, HI; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D | 1 |
| Bodoky, G; Ciuleanu, TE; Cohn, AL; Ferry, D; Garcia-Carbonero, R; Hozak, RR; Konrad, RJ; Melemed, SA; Muro, K; Nasroulah, F; Obermannova, R; Ouyang, H; Portnoy, DC; Prausová, J; Siegel, RW; Tabernero, J; Van Cutsem, E; Yoshino, T | 1 |
| Assenat, E; Bouarioua, N; Cadiot, G; Coriat, R; Dahan, L; Dubreuil, O; Elhajbi, F; Ferru, A; Gangloff, A; Granger, V; Hautefeuille, V; Hentic, O; Kurtz, JE; Le Malicot, K; Lepage, C; Lepere, C; Lievre, A; Lombard-Bohas, C; Malka, D; Roquin, G; Scoazec, JY; Smith, D; Walter, T | 1 |
| Akagi, Y; Baba, H; Emi, Y; Maehara, Y; Miyamoto, Y; Ogata, Y; Oki, E; Saeki, H; Sakamoto, Y; Shimokawa, M; Tanaka, T; Tokunaga, S | 1 |
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Fan, H; Jiang, Y; Li, G; Li, X; Song, G; Wang, F | 1 |
| Allegrini, G; Bergamo, F; Boni, L; Buonadonna, A; Chiara, S; Cremolini, C; Dell'Aquila, E; Di Donato, S; Falcone, A; Fea, E; Lonardi, S; Marmorino, F; Masi, G; Racca, P; Ronzoni, M; Santini, D; Schirripa, M; Stellato, M; Tomasello, G; Tomcikova, D; Tonini, G; Urbano, F; Zaniboni, A; Zeppola, T | 1 |
| Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S | 1 |
| Aoyagi, H; Higuchi, K; Ito, H; Ito, M; Koseki, K; Nihei, Z; Nishi, N; Suzuki, K; Tanaka, Y; Watanabe, I | 1 |
| Hagino, S; Miyata, T; Sakamoto, K | 1 |
| Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V | 1 |
| Baumann, AB; D'Anastasi, M; Heinemann, V; Hesse, N; Hofmann, FO; Holch, JW; Modest, DP; Reiser, MF; Ricard, I; Sommer, WH; Stintzing, S | 1 |
| Crathorne, L; Hoyle, M; Huxley, N; Napier, M; Snowsill, T; Tikhonova, IA; Varley-Campbell, J | 1 |
| Alberts, SR; Hartgers, ML; Hassan, M; Jin, Z; Mahipal, A; Muppa, P; Nagorney, DM; Sanhueza, CT; Shubert, CR; Smyrk, TC; Truty, MJ | 1 |
| Anan, C; Katada, E; Mitsui, A; Sasaki, S; Uematsu, N | 1 |
| Bando, H; Emi, Y; Iwamoto, S; Kagawa, Y; Kanazawa, A; Kato, T; Kotaka, M; Muro, K; Nakamura, M; Nakayama, G; Oki, E; Sakisaka, H; Taniguchi, H; Touyama, T; Tsuji, A; Yamaguchi, T; Yamanaka, T; Yamazaki, K; Yoshino, T | 1 |
| Aprile, G; Bergamo, F; Cardellino, GG; Cremolini, C; de Braud, F; Falcone, A; Fassan, M; Fontanini, G; Lonardi, S; Marmorino, F; Mazzaferro, V; Mennitto, A; Milione, M; Morano, F; Morelli, L; Pellegrinelli, A; Pietrantonio, F; Prisciandaro, M; Rossini, D; Schirripa, M; Urbani, L; Zucchelli, G | 1 |
| Al-Batran, SE; Galle, PR; Gehrke, N; Goepfert, K; Grimminger, P; Hegewisch-Becker, S; Maderer, A; Möhler, M; Nagel, M; Schattenberg, JM; Schulz, J; Thomaidis, T; Thuss-Patience, PC | 1 |
| Price, TJ | 1 |
| Geredeli, C; Yasar, N | 1 |
| Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K | 1 |
| Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C | 1 |
| Ariotti, R; Berardi, G; De Man, M; Geboes, K; Hoorens, A; Laurent, S; Smeets, P; Tomassini, F; Troisi, RI; van Dorpe, J; Varin, O | 1 |
| Ehara, S; Eizuka, M; Hasegawa, Y; Ishida, K; Kato, K; Nitta, H; Osakabe, M; Otsuka, K; Sasaki, A; Sugai, T; Tamura, A; Uesugi, N | 1 |
| Antoniotti, C; Astrow, SH; Berger, MD; Cremolini, C; Falcone, A; Hanna, DL; Lenz, HJ; Li, M; Loupakis, F; Matsusaka, S; Miyamoto, Y; Moran, M; Ning, Y; Salvatore, L; Schirripa, M; Yang, D; Zeger, G; Zhang, W | 1 |
| Fukunaga, M; Honda, S; Kobayashi, K; Konishi, K; Konishi, M; Matsuno, H; Nakai, S; Okada, K; Okamoto, A; Ota, H; Saito, A; Takeoka, T; Takiguchi, N; Yokoyama, S; Yukimoto, R | 1 |
| Conneely, JB; Greally, M; Linehan, A; McCaffrey, JA; O'Keane, C; Pilson, K; Shields, CJ | 1 |
| Aparicio, T; Ghebriou, D; Guetz, GD; Landre, T; Maillard, E; Taleb, C; Zelek, L | 1 |
| Evert, M; Fest, P; Fichtner-Feigl, S; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Munker, S; Ott, C; Reng, M; Schlitt, HJ; Schnoy, E; Stroszczynski, C; Teufel, A; Vogelhuber, M; Wiggermann, P | 1 |
| Bruno, R; Claret, L; Karovic, S; Maitland, ML; Pentafragka, C; Schwartz, LH; Zhao, B | 1 |
| Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T | 1 |
| Chen, J; Feng, J; Huang, L; Liu, B; Peng, P; Qiu, H; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Bi, F; Cao, D; Chen, Y; Gou, H; Li, Z; Peng, Y; Yang, Y; Zhang, X | 1 |
| André, T; Taieb, J | 1 |
| Aparicio, T; Baconnier, M; Barbier, E; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; Francois, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J | 1 |
| Barone, C; Bilancia, D; Calegari, MA; Cassata, A; Corsi, D; Damato, A; Daniele, B; Di Costanzo, F; Fenizia, F; Ferrau, F; Frassinetti, GL; Gori, S; Iaffaioli, RV; Maiello, E; Normanno, N; Orlandi, A; Pinto, C; Pisconti, S; Repetto, L; Soto Parra, H; Tamburini, E; Tonini, G; Zampino, MG; Zaniboni, A | 1 |
| Kopetz, S | 1 |
| Cao, S; Heinemann, V; Jelas, I; Lenz, HJ; McSkane, M; Naseem, M; Puccini, A; Stintzing, S | 1 |
| Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W | 1 |
| Harty, G; Jarrett, J; Jofre-Bonet, M | 1 |
| Burge, M; Dean, AP; Eastgate, M; Gibbs, P; Kosmider, S; Lee, B; Lee, M; Lok, SW; Ma, B; Semira, C; Shapiro, J; Steel, SA; Torres, J; Wong, HL; Wong, R; Zimet, AS | 1 |
| Abel, U; Apostolidis, L; Berger, AK; Dietrich, M; Freitag, A; Giesel, F; Grüllich, C; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lücke, S; Ose, J; Stange, A; Trierweiler, C; von Gall, C; Weber, TF | 1 |
| Beck, M; Denz, A; Fietkau, R; Grützmann, R; Haderlein, M; Hecht, M; Langheinrich, M; Lettmaier, S; Schmid, A; Schmidt, D; Semrau, S | 1 |
| Berlin, J; Das, S; Du, L; Idrees, K; Shi, C | 1 |
| Kodama, M; Kondo, S; Miyahara, Y; Yamazaki, K; Yokoyama, M; Yoshida, A | 1 |
| Ohara, H; Yamamoto, H | 1 |
| Chevalier, H; Neuzillet, C; Turpin, A | 1 |
| Abraham, I; Bartels, T; Eckstrom, J; Elquza, E; Hollings, J; Malangone, S; McBride, A; Patel, H; Scott, AJ | 1 |
| Chen, X; Lin, H; Shui, L; Shui, P; Sun, Q; Wu, YS | 1 |
| Gaston-Mathe, Y; Grisoni, ML; Heinemann, V; Jung, A; Laurent-Puig, P; Liebaert, F; Montestruc, F; Neureiter, D; Stintzing, S; Thiébaut, R | 1 |
| Ba, Y; Bai, Y; Bi, F; Fan, N; Li, J; Lim, R; Liu, T; Ma, B; Magherini, E; Pan, H; Qin, S; Shen, L; Shi, D; Tsuji, A; Wei, V; Xu, J; Xu, R; Yeh, KH; Zhang, S | 1 |
| Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J | 1 |
| Eskens, FALM; Groot Koerkamp, B; Nuyttens, JJ; Suker, M; van Eijck, CHJ | 1 |
| Abdalla, KC; Bondarenko, I; Del Campo García, A; Franke, F; Huerga, C; Melo Cruz, F; Mendonça Bariani, G; Millán, S; Ostwal, V; Paravisini, A; Peredpaya, S; Rahuman, SA; Ramesh, A; Roca, E; Romera, A; Shah, P; Shparyk, Y | 1 |
| Cai, Y; Deng, R; Deng, Y; Hu, H; Li, J; Ling, J; Wu, Z; Yang, L; Zhang, J | 1 |
| Bengrine, L; Collot, T; Fumet, JD; Ghiringhelli, F; Klopfenstein, Q; Vincent, J | 1 |
| Dote, S; Hira, D; Itakura, S; Kamei, K; Kobayashi, Y; Noda, S; Terada, T | 1 |
| Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W | 1 |
| Bodoky, G; Ciuleanu, T; Cohn, AL; García-Alfonso, P; Garcia-Carbonero, R; Grothey, A; Hozak, RR; Kim, TW; Lonardi, S; Muro, K; Nasroulah, F; O'Connor, J; Obermannová, R; Portnoy, DC; Prausová, J; Tabernero, J; Taieb, J; Van Cutsem, E; Wijayawardana, SR; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Freiberg-Richter, J; Giessen-Jung, C; Graeven, U; Heinemann, V; Held, S; Jung, A; Kirchner, T; Modest, DP; Peuser, B; Peveling Genannt Reddemann, C; Schenk, M; Schuch, G; Schwaner, I; Stahler, A; Stintzing, S; Uhlig, J; Vehling-Kaiser, U | 1 |
| Bendardaf, R; Pyrhönen, S; Sharif-Askari, FS; Sharif-Askari, NS; Syrjänen, K | 1 |
| Hsu, CW; Kuo, WT; Lin, HY | 1 |
| O'hara, H; Yamamoto, H | 1 |
| Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD | 1 |
| Adán, A; Castellà, C; Eixarch, A; Reguart, N; Saint-Jean, A; Sainz-de-la-Maza, M; Sánchez-Dalmau, B | 1 |
| Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS | 1 |
| Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Holch, JW; Jelas, I; Kahl, C; Kiani, A; Kullmann, F; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Vehling-Kaiser, U; von Einem, JC; Westphalen, CB | 1 |
| Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH | 1 |
| Miyagaki, T; Nonogaki, A; Oka, T; Sato, S; Senda, N; Shibata, S; Yoshizaki, A | 1 |
| Borelli, B; Masi, G | 1 |
| Pietrantonio, F | 3 |
| Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM | 1 |
| Aikawa, T; Akashi, K; Ariyama, H; Baba, E; Doi, Y; Esaki, T; Ito, M; Kobayashi, K; Kusaba, H; Makiyama, A; Mitsugi, K; Shimokawa, H; Takayoshi, K; Tsuchihashi, K; Uenomachi, M; Yoshihiro, T | 1 |
| Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O | 2 |
| Cai, J; Li, N; Sui, Y; Sun, H; Wei, X; Xu, C; Zhang, G; Zheng, B; Zhuang, J | 1 |
| Akbulut, H; Dost Gunay, FS; Ensari, A; İcli, F; Kırmızı, BA | 1 |
| Barreto, R; Bonetto, A; Couch, ME; O'Connell, TM; Pin, F | 1 |
| Aieta, M; Chiriacò, G; Conca, R; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G | 1 |
| Bjorklof, K; Buchler, T; Csoszi, T; Demonty, G; Hebart, H; Kafatos, G; Kiehl, M; Koukakis, R; Kuhn, A; Tomasek, J | 1 |
| Covela Rúa, M; de la Cámara Gómez, J; Fernández Montes, A; García Gómez, J; González Villaroel, P; Graña Suárez, B; Jorge Fernández, M; Luz Pellón Augusto, M; Martínez Lago, N; Méndez Méndez, JC; Quintero Aldana, G; Reboredo López, M; Salgado Fernández, M | 1 |
| Ahmed, A; Kozma, K; Patel, S; Rezkallah, KNM | 1 |
| Auby, D; Azzedine, A; Borget, I; Bouché, O; Denis, B; Ducreux, M; Etienne, PL; Gargot, D; Gasmi, M; Geoffroy, P; Lacas, B; Lepage, C; Lombard-Bohas, C; Michel, P; Pignon, JP; Texereau, P | 1 |
| Balestri, R; Bergamo, F; Buccianti, P; Castagna, M; Cremolini, C; Di Paolo, A; Falcone, A; Fontanini, G; Fornaro, L; Lonardi, S; Luca Urso, ED; Marcucci, L; Martignetti, A; Masi, G; Montrone, S; Musettini, G; Pasqualetti, F; Sainato, A; Sensi, E; Urbani, L; Vivaldi, C; Zagonel, V | 1 |
| Dai, G; Gou, M; Jia, J; Qian, N; Yang, F; Zhang, P | 1 |
| Aranda, E; Azuara, D; Bugés, C; Capellá, G; Durán, G; Élez, E; Falcó, E; García-Alfonso, P; López-López, C; Navarro, V; Páez, D; Robles-Díaz, L; Salazar, R; Salud, A; Santos, C; Valladares, M; Viéitez, JM | 1 |
| Arai, H; Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Liang, G; Lo, JH; Loupakis, F; Mancao, C; Millstein, J; Mumenthaler, SM; Naseem, M; Puccini, A; Salhia, B; Soni, S; Stintzing, S; Tokunaga, R; Weisenberger, DJ; Zhang, W | 1 |
| Abbati, F; Brandi, G; Brocchi, S; De Lorenzo, S; Frega, G; Palloni, A; Rizzo, A | 1 |
| Accordino, MK; Hershman, DL; Hillyer, GC; Keller, D; Kiran, RP; Lin, A; Neugut, AI; O'Neil, DS; Raab, GT; Wright, J | 1 |
| Gallego, I; García, G; García-Alfonso, P; Lloansí, A; Muñoz, A; Ortega, L; Sandoval, C; Torres, G | 1 |
| Çiçin, I; Demircan, NC; Erdoğan, B; Eslame, H; Gökyer, A; Hacıoğlu, MB; Köstek, O; Küçükarda, A; Solak, S; Sunal, BS; Tunçbilek, N; Uzunoğlu, S; Yılmaz, E | 1 |
| Chin, K; Ichimura, T; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K | 1 |
| Aparicio, T; Barbier, E; Ben Abdelghani, M; Bennouna, J; Boige, V; Borel, C; Bouché, O; Desseigne, F; Dohan, A; Faroux, R; François, E; Gallix, B; Genet, D; Ghiringhelli, F; Guiu, B; Hoeffel, C; Jacquot, S; Jouve, JL; Khemissa-Akouz, F; Le Malicot, K; Lepage, C; Phelip, JM; Reinhold, C; Rinaldi, Y; Seitz, JF; Soyer, P; Suc, E; Taieb, J; Texereau, P | 1 |
| Argilés Martínez, G; Carmona-Bayonas, A; Castañón López, C; Fernández Montes, A; Gallego Plazas, J; García Paredes, B; Gutiérrez Abad, D; Jiménez Fonseca, P; Juez Martel, I; Llorente Ayala, B; López Doldán, MC; López Flores, M; López López, C; López Muñoz, AM; Martínez de Castro, E; Páez López, D; Sánchez Cánovas, M; Tobeña Puyal, M | 1 |
| Ishigame, T; Kenjo, A; Kimura, T; Kofunato, Y; Marubashi, S; Muto, M; Okada, R; Sato, N; Shimura, T; Suzushino, S; Tsukida, S | 1 |
| Enomoto, M; Ishibashi, Y; Ishizaki, T; Katsumata, K; Kuwabara, H; Mazaki, J; Nagakawa, Y; Shigoka, M; Tsuchida, A; Wada, T | 1 |
| Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L | 1 |
| Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S | 1 |
| Doğanlar, O; Doğanlar, ZB; Güçlü, O; Yüksel, V | 1 |
| Han, Y; Li, YH; Liang, JY; Liu, W; Wang, K; Xing, BC | 1 |
| Berkhout, M; Gallego, J; Hofheinz, RD; Karthaus, M; Köhne, CH; Koukakis, R; Mineur, L; Thaler, J; Van den Eynde, M | 1 |
| Hayashi, S; Kojima, T; Matsuo, M; Nakahata, Y; Obora, A; Omatsu, T; Tanaka, O; Yagi, N; Yasuda, T; Yasuda, Y | 1 |
| Beckert, S; Horvath, P; Königsrainer, A; Königsrainer, I; Nadalin, S | 1 |
| Kanno, M; Kichikawa, K; Koyama, F; Marugami, N; Masada, T; Nishiofuku, H; Otsuji, T; Sato, T; Sho, M; Tanaka, T; Tatsumoto, S | 1 |
| Fuks, D; Gayet, B; Goumard, C; Okumura, S; Scatton, O | 1 |
| Andersen, CL; Demuth, C; Johansen, AFB; Knudsen, M; Krag, SRP; Kronborg, CS; Lyskjær, I; Rasmussen, MH; Rosenkilde, M; Spindler, KG; Sørensen, BS; Vang, S | 1 |
| Bafaloukos, D; Bamia, C; Bombolaki, I; Chatzopoulos, K; Chrisafi, S; Efstratiou, I; Fountzilas, G; Kafiri, G; Koliou, GA; Kotoula, V; Kourea, HP; Makatsoris, T; Mauri, D; Mavroeidis, L; Papadopoulou, K; Papakostas, P; Papatsibas, G; Pectasides, D; Pentheroudakis, G; Petraki, K; Samantas, E | 1 |
| Arai, K; Ariyoshi, N; Ishii, I; Kaneya, N; Matsubara, H; Miyauchi, H; Ohira, G; Suzuki, T; Yamamoto, K; Yamazaki, K; Yamazaki, S | 1 |
| Baijal, S; Chau, I; Cunningham, D; Ellis, R; Harrison, M; Khakoo, S; Ograbek, A; Pedley, I; Raouf, S; Ross, P; Steward, W; Tahir, S | 1 |
| Arango, MJ; Noonan, AM; Porter, K; Reardon, J; Tossey, JC; VanDeusen, JB | 1 |
| Allain, EP; Buonadonna, A; Cecchin, E; Couture, F; D'Andrea, M; De Mattia, E; Guillemette, C; Jonker, D; Labriet, A; Lévesque, É; Rouleau, M; Simonyan, D; Toffoli, G; Villeneuve, L | 1 |
| Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V | 1 |
| Higashijima, J; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Takasu, C; Yamada, S | 1 |
| Chiron, M; Denda, T; Esaki, T; Fujii, H; Hamaguchi, T; Itabashi, M; Kajiwara, T; Komatsu, Y; Kudo, T; Moriwaki, T; Nagashima, F; Nakajima, TE; Oki, E; Otsu, S; Sasaki, T; Sato, T; Sugimoto, N; Takahashi, S; Ura, T; Yamazaki, K; Yoshino, T | 1 |
| Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G | 1 |
| Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N | 1 |
| Amano, S; Aoyama, T; Ju, M; Komori, K; Maezawa, Y; Masuda, M; Morita, J; Mushiake, H; Numata, M; Oshima, T; Rino, Y; Sato, T; Sawazaki, S; Tamagawa, H; Yukawa, N | 1 |
| Artru, P; Auclin, E; Auvray, M; Coriat, R; Hammel, P; Hautefeuille, V; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Pernot, S; Sickersen, G; Taieb, J; Tougeron, D; Vernerey, D | 1 |
| Hopkins, AM; Karapetis, CS; Lim, HH; Rowland, A; Sorich, MJ; Yuen, HY | 1 |
| Alessandroni, P; Bergamo, F; Borelli, B; Catalano, V; Cremolini, C; Falcone, A; Giordani, P; Graziano, F; Intini, R; Lonardi, S; Mattioli, R; Negri, F; Rocchi, MBL; Rossini, D; Santini, D; Sarti, D; Stragliotto, S; Vincenzi, B; Zagonel, V | 1 |
| Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y | 1 |
| Berry, SR; Chan, KKW; Ko, YJ; Riesco-Martínez, M; Wong, WWL; Zargar, M | 1 |
| Chiron, M; Paccard, C; Tabernero, J; Van Cutsem, E | 1 |
| Antista, M; Barault, L; Corallo, S; de Braud, F; Di Bartolomeo, M; Di Maio, M; Di Nicolantonio, F; Farina, G; Fucà, G; Gori, S; Guarini, V; Lobefaro, R; Lonardi, S; Longarini, R; Macagno, M; Martinetti, A; Milione, M; Morano, F; Mosconi, S; Murgioni, S; Pagani, F; Palermo, F; Perrone, F; Petrelli, F; Pietrantonio, F; Raimondi, A; Randon, G; Rimassa, L; Sartore-Bianchi, A; Tamborini, E; Tomasello, G | 1 |
| Fukuyama, R; Ishigure, K; Mashita, N; Nakamura, M; Tobinaga, J; Watanabe, T | 1 |
| Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G | 1 |
| Crocetti, D; DE Felice, F; DE Toma, G; Fiori, E; Lamazza, A; Mingoli, A; Sapienza, P; Sterpetti, AV; Tarallo, M | 1 |
| Bi, F; Chen, H; Li, Q; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
| Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS | 1 |
| Cremolini, C; Dienstmann, R; Sveen, A | 1 |
| Aderka, D; Al-Batran, S; Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Jung, A; Kahl, C; Kaiser, F; Kiani, A; Kirchner, T; Kullmann, F; Lenz, HJ; Lerchenmüller, C; Modest, DP; Moehler, M; Neureiter, D; Scheithauer, W; Seipelt, G; Stintzing, S; Tejpar, S; Wirapati, P | 1 |
| Aucoin, N; Berry, S; Couture, F; Gillesby, B; Kavan, P; Kennecke, H; Maroun, J; Poulin-Costello, M | 1 |
| Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R | 1 |
| Becker, T; Boersch, K; Burmeister, G; Forster, M; Franke, A; Hendricks, A; Hinz, S; Röcken, C; Rosenstiel, P; Schafmayer, C | 1 |
| Li, J; Peng, L; Shi, Y; Tan, C; Wan, X | 1 |
| Decker, T; Fischer von Weikersthal, L; Heinemann, V; Heintges, T; Held, S; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Michl, M; Moehler, M; Scheithauer, W; Stintzing, S; von Einem, JC | 1 |
| Balcı, NC; İnan, N; Koyuncu Sökmen, B; Namal, E; Öz, A; Server, S | 1 |
| Chen, SC; Chiang, TY; Hsu, HC; Jane, SW | 1 |
| Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D | 1 |
| Alonso, V; Cabrera, JM; Escudero, P; González, B; González, E; Iranzo, P; Juez, I; López, C; Martínez, NP; Mata, E; Pericay, C; Rivera, F; Ruiz-Casado, A; Safont, MJ; Salgado, M; Vera, R | 1 |
| Cai, X; Chen, Y; Fang, H; Fang, W; Li, H; Li, Q; Lin, X; Ma, D; Nie, Y; Peng, C; Shen, L; Wang, N; Wang, W; Xu, R; Zhao, Q; Zhu, B; Zhu, L | 1 |
| Adachi, T; Eguchi, S; Enjoji, T; Hidaka, M; Inoue, Y; Ito, S; Kanetaka, K; Kobayashi, K; Kosaka, T; Kuba, S; Okada, S; Takatsuki, M; Tetsuo, H; Torashima, Y; Yamaguchi, S; Yamanouchi, K | 1 |
| Ajani, JA; Blum Murphy, M; Palmer, M; Rogers, JE; Trail, A; Xiao, L | 1 |
| Burge, M; Clarke, SJ; Feeney, K; Gibbs, P; Jones, K; Marx, G; Molloy, MP; Price, T; Reece, WHH; Segelov, E; Tebbutt, NC | 1 |
| Allen, A; Berlin, J; Das, S | 1 |
| Fukata, T; Fukuzaki, T; Hojo, S; Ito, Y; Nishida, H; Ohigashi, H; Okimura, S; Shingai, T; Takayama, O; Taniguchi, Y; Yoshioka, S | 1 |
| Aizawa, M; Endo, S; Isohata, N; Nemoto, D; Nemoto, T; Oshibe, I; Saito, T; Soeta, N; Takayanagi, D; Togashi, K; Utano, K | 1 |
| Hata, T; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Naito, A; Omura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
| Alvarez, R; Andel, J; Bendell, JC; Bennouna, J; Bessudo, A; Boetsch, C; Cervantes, A; Franjkovic, I; García-Alfonso, P; Gracián, AC; Heil, F; Hurwitz, H; Hussein, M; Krieter, O; Lahr, A; Lechner, K; López-López, C; Miron, ML; Montagut, C; Moons, V; Plezia, P; Rossomanno, S; Samuel, L; Sauri, T; van der Westhuizen, A; Vivas, CS | 1 |
| Glynne-Jones, R; Harrison, M | 1 |
| Kubo, S; Tomita, N; Yamano, T | 1 |
| Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Heinrich, K; Held, S; Lang, H; Modest, DP; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D; Stahler, A; Stintzing, S; von Einem, JC | 1 |
| Chen, S; Feng, C; Guo, C; Hua, L; Huang, H; Li, G; Lin, Z; Mo, Q; Shen, Y; Wei, M; Xu, J | 1 |
| Aranda, E; Balbín, M; Bando, I; Bellosillo, B; Calle, SG; Díaz-Rubio, E; García-Alfonso, P; Llovet, P; Lopez, C; Martínez, A; Mediero, B; Moral, VM; Orden, V; Ortiz-Morales, MJ; Palanca, S; Peligros Gomez, MI; Quintero, G; Salud, A; Sastre, J; Viéitez, JM | 1 |
| Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Hanna, DL; Heinemann, V; Lenz, HJ; Loupakis, F; Miyamoto, Y; Naseem, M; Ning, Y; Puccini, A; Schirripa, M; Soni, S; Stintzing, S; Suenaga, M; Tokunaga, R; Yang, D; Zhang, W | 1 |
| Chang, W; Cho, JY; Cho, S; Jheon, S; Kang, SB; Kim, DW; Kim, JH; Kim, JW; Kim, K; Kim, SA; Lee, KW; Oh, HK; Suh, KJ | 1 |
| Eguchi, S; Inoue, Y; Ito, S; Kanetaka, K; Kobayashi, K; Takatsuki, M; Torashima, Y; Yamaguchi, S | 1 |
| Akamatsu, H; Fujie, Y; Imasato, M; Kagawa, Y; Kawai, K; Murata, K; Naito, A; Nakaba, H; Ohtsuka, M; Suzuki, Y; Takeda, Y; Takeno, A | 1 |
| Ahn, JB; Baek, JY; Beom, SH; Cho, SH; Chu, CW; Chun, YJ; Hong, S; Jung, M; Kim, SG; Kim, TW; Lee, KW; Park, YS; Shin, SJ | 1 |
| Atzpodien, J; Buechner-Steudel, P; Ettrich, T; Florschütz, A; Geissler, M; Greeve, J; Heinemann, V; Held, S; Kanzler, S; Kurreck, A; Martens, UM; Modest, DP; Nörenberg, D; Reinacher-Schick, AC; Riera-Knorrenschild, J; Seidensticker, M; Seufferlein, T; Stintzing, S; Tannapfel, A; Wessendorf, S | 1 |
| Asaro, F; Fortuna, S; Garziera, M; Geremia, S; Scarabel, L; Toffoli, G | 1 |
| Chan, LF; Kamei, Y; Miyakita, H; Ogimi, T; Okada, K; Sadahiro, S; Saito, G; Suzuki, T | 1 |
| Cheng, Q; Liao, L; Pei, F; Ye, S; Zhu, G | 1 |
| Cai, Y; Deng, Y; Hu, H; Xie, X; Zhang, J | 1 |
| Avallone, A; Giuliani, F | 1 |
| Antoniotti, C; Cremolini, C; Falcone, A; Rossini, D | 1 |
| Ueno, M | 1 |
| Fujiwara, D; Hoshida, T; Mashimo, K; Morimoto, N; Nishida, S; Noda, A; Sakaguchi, K; Takeda, T; Tsubaki, M | 1 |
| Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E | 1 |
| Augustine, T; Chandy, C; Coffey, M; Fogel, E; Goel, S; Maitra, R; Parakrama, R; Tesfa, L | 1 |
| Aprile, G; Belfiore, A; Boccaccino, A; Brich, S; Cattaneo, L; Centonze, G; Cillo, U; Corallo, S; Cremolini, C; De Braud, F; Falcone, A; Fassan, M; Fontanini, G; Germani, MM; Lonardi, S; Loupakis, F; Marmorino, F; Milione, M; Morano, F; Morelli, L; Moretto, R; Pietrantonio, F; Prisciandaro, M; Rossini, D; Urbani, L | 1 |
| Kaci, R; Lo Dico, R; Mathonnet, M; Naneix, AL; Pocard, M; Taibi, A | 1 |
| Haihong, L; Jiamin, X; Quan, Q; Shuwen, H; Wei, W; Xi, Y; Yizhen, J; Yuefen, P | 1 |
| Kashiwa, M; Matsushita, R | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Fischer von Weikersthal, L; Fraccaroli, A; Haas, M; Heinemann, V; Heinrich, K; Held, S; Holch, JW; Jung, A; Kullmann, F; Modest, DP; Moehler, M; Scheithauer, W; Schulz, C; Stintzing, S; von Einem, JC | 1 |
| Aljubran, A; Alzahrani, A; Badran, A; Bazarbashi, S; Eldali, A; Elshenawy, MA; Rauf, MS | 1 |
| Abgral, R; Amrane, K; le Pennec, R; Metges, JP; Schick, U | 1 |
| Ahmed, SU; Dasari, A; Eng, C; Fogelman, D; Jácome, AA; Johnson, B; Kee, B; Kopetz, S; Mehdizadeh, A; Morris, V; Overman, M; Raghav, K; Rogers, J; Rothschild, N; Shureiqi, I; Wolff, R | 1 |
| Antoniotti, C; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Brunella, DS; Corallo, S; Cremolini, C; Falcone, A; Grassi, E; Lonardi, S; Marmorino, F; Morano, F; Moretto, R; Pietrantonio, F; Racca, P; Rossini, D; Salvatore, L; Tamberi, S; Tamburini, E; Tortora, G | 1 |
| Dorcaratto, D; Garcés-Albir, M; Huerta Álvaro, M; Muñoz-Forner, E; Pérez-Santiago, L; Roselló Keranën, S; Sabater, L | 1 |
| Fujiwara, Y; Nakane, M; Yamaguchi, T | 1 |
| Aranda, E; Élez, E; Gallego, J; González, E; Safont, MJ; Salgado, M; Vera, R | 1 |
| Bates, DDB; Capanu, M; Chatila, W; Chou, J; Hersch, J; Kelsen, D; Paroder, V; Schultz, N; Tang, L; Yaeger, R | 1 |
| Chen, JB; Chen, TL; Huang, CW; Huang, HY; Ke, TW; Lin, YW; Sung, YC; Tang, HC; Tsai, CS; Tsai, HL; Wang, HM; Wang, JH; Wang, JY; Wu, CC | 1 |
| Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G | 1 |
| Antonuzzo, L; Bergamo, F; Berselli, A; Bordonaro, R; Damato, A; Iachetta, F; Maiello, E; Nasti, G; Normanno, N; Pinto, C; Romagnani, A; Tonini, G; Zaniboni, A | 1 |
| Boige, V; Boilève, A; De Cuyper, A; Ducreux, M; Gelli, M; Larive, A; Mahjoubi, L; Malka, D; Najdawi, M; Pignon, JP; Smolenschi, C; Tazdait, M; Tselikas, L | 1 |
| Borg, C; Chevalier, H; Edeline, J; El Hajbi, F; Hammel, P; Lièvre, A; Meurisse, A; Neuzillet, C; Peugniez, C; Turpin, A; Vernerey, D; Vienot, A | 1 |
| Antonuzzo, L; Castiglione, F; Di Costanzo, F; Lastraioli, E; Lavacchi, D; Messerini, L; Palmieri, VE | 1 |
| Froelich, MF; Gesenhues, AB; Heinemann, V; Hesse, N; Hofmann, FO; Holch, JW; Modest, DP; Nörenberg, D; Petersen, EL; Sommer, WH; Stintzing, S | 1 |
| Kitagawa, C; Nishibori, R; Nozawa, K; Sato, M; Shiraishi, K; Sugiyama, K | 1 |
| Aparicio, T; Caroli-Bosc, FX; Dahan, L; Desrame, J; Doat, S; Lapeyre-Prost, A; Le Malicot, K; Lecomte, T; Lepage, C; Marthey, L; Mary, F; Pernot, S; Sigrand, J; Taieb, J | 1 |
| Auman, JT; Bertagnolli, MM; Blanke, CD; Casey, G; Etheridge, AS; Furukawa, Y; Howell, SD; Innocenti, F; Jiang, C; Kubo, M; Lenz, HJ; McLeod, HL; Ou, FS; Owzar, K; Parker, JS; Patil, SA; Plummer, SJ; Ratain, MJ; Sibley, AB; Venook, AP | 1 |
| Baba, H; Denda, T; Hyodo, I; Izawa, N; Kondoh, C; Makiyama, A; Masuishi, T; Moriwaki, T; Muro, K; Nakajima, TE; Nakamura, M; Nishina, T; Okuda, H; Shitara, K; Sunakawa, Y; Yamaguchi, H; Yamanaka, T; Yamazaki, K; Yonesaka, K; Yoshino, T | 1 |
| Balachandran, VP; Boerner, T; Buisman, FE; D'Angelica, MI; Drebin, JA; Gonen, M; Jarnagin, WR; Kemeny, NE; Kingham, TP; Narayan, RR; Seier, K; Srouji, RM; Wei, A | 1 |
| Antoniotti, C; Aprile, G; Bergamo, F; Boccaccino, A; Bordonaro, R; Buonadonna, A; Caponnetto, S; Cremolini, C; Cupini, S; Falcone, A; Fea, E; Grande, R; Lonardi, S; Marmorino, F; Moretto, R; Pietrantonio, F; Rossini, D; Santini, D; Tamburini, E; Tomasello, G; Zaniboni, A; Zucchelli, G | 1 |
| Li, Q; Liao, W; Wang, X; Wu, Q; Zhang, M; Zhang, P | 1 |
| Chen, B; Han, G; Huang, C; Ye, J; Yu, W; Zheng, D; Zhuang, J | 1 |
| Antoniotti, C; Bergamo, F; Buonadonna, A; Caponnetto, S; Cremolini, C; Ermacora, P; Falcone, A; Germani, MM; Latiano, TP; Lonardi, S; Masi, G; Moretto, R; Pietrantonio, F; Rapisardi, S; Ricci, V; Ritorto, G; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A | 1 |
| Fujiwara, T; Inukai, M; Kikuchi, T; Kobayashi, M; Kurisu, Y; Matsumoto, T; Miguchi, M; Moriyama, I; Nagano, H; Nagasaka, T; Nasu, J; Nishina, T; Nozaka, K; Shinozaki, K; Shiraishi, T; Tanioka, H; Tsuchihashi, K; Yamada, T; Yoshida, R; Yuasa, Y | 1 |
| Farma, J; Hall, MJ; Jain, R; Luo, B; McGillivray, E; Savage, M | 1 |
| Foster, L; Lamarca, A; Satyadas, T; Siriwardena, A; Valle, JW | 1 |
| Kanto, S; Kawabe, A; Okamura, M; Sakikubo, M; Takeji, S; Tatsumi, K; Yasuda, S | 1 |
| Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Held, S; Jung, A; Kahl, C; Kaiser, F; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Miller-Phillips, L; Modest, DP; Moehler, M; Scheithauer, W; Seipelt, G; Stintzing, S; von Weikersthal, LF | 1 |
| Al-Rajabi, R; Carroll, E; Diab, O; Kasi, A; Melancon, T; Rawlley, B | 1 |
| Carneiro, BA; El-Deiry, WS; Marks, EI; Matera, R; Olszewski, AJ; Safran, H; Yakirevich, E | 1 |
| Antoniotti, C; Bendell, JC; Boccaccino, A; Boni, L; Borelli, B; Corallo, S; Cremolini, C; de Braud, F; Di Bartolomeo, M; Falcone, A; Fucà, G; Lonardi, S; Marmorino, F; Masi, G; Morano, F; Niger, M; Pietrantonio, F; Raimondi, A; Rossini, D; Schmoll, HJ | 1 |
| Chin, K; Kamiimabeppu, D; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Sato, T; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K | 1 |
| Almuradova, E; Çakar, B; Doğanavşargil, B; Gürsoy, P; Harman, M; Karabulut, B; Karateke, M; Sezak, M | 1 |
| Aparicio, T; Bibeau, F; Bouché, O; Chibaudel, B; Desrame, J; Evrard, C; Fiore, FD; Gonzalez, D; Guimbaud, R; Hajbi, FE; Kim, S; Laurent-Puig, P; Lecomte, T; Lepage, C; Lièvre, A; Louvet, C; Malicot, KL; Pierre, S; Sokol, H; Tougeron, D; Zaanan, A | 1 |
| Fujii, H; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K | 1 |
| Köstek, O | 1 |
| Teng, HW | 1 |
| Loree, JM; Yu, IS | 1 |
| Endo, I; Homma, Y; Matsuyama, R; Takei, S | 1 |
| Cai, Z; Kagawa, Y; Makiyama, A; Piao, Y; Satake, H; Shinozaki, E; Tanizawa, Y | 1 |
| Chen, Z; Guo, W; Huang, M; Li, W; Qiu, L; Wang, C; Wang, Y; Yang, Y; Zhang, W; Zhang, X; Zhang, Z; Zhao, X; Zhu, X | 1 |
| Al-Jumayli, M; Miller, K; Park, R; Saeed, A | 1 |
| Ayukawa, H; Endo, S; Furuse, J; Furuta, T; Hirano, R; Kaneko, S; Kawai, K; Kobayashi, T; Minowa, Y; Nagashima, F; Naruge, D; Okano, N; Shibasaki, H; Yokokawa, A | 1 |
| Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R | 1 |
| Habib, M; Jorns, C; Nilsson, PJ; Nordenvall, C; Sparrelid, E; Villard, C | 1 |
| Kang, J; Kim, SY; Kim, TW; Lee, JS; Morita, S; Muro, K; Park, YS; Sakamoto, J; Xu, RH | 1 |
| Antoniotti, C; Bergamo, F; Boccaccino, A; Borelli, B; Cremolini, C; Falcone, A; Fontana, E; Fontanini, G; Giordano, M; Lonardi, S; Maiello, E; Morano, F; Nyamundanda, G; Passardi, A; Pella, N; Pietrantonio, F; Sadanandam, A; Santini, D; Tamburini, E; Ugolini, C; Zaniboni, A; Zucchelli, G | 1 |
| Bartolini, G; Crudi, L; Donati, C; Foca, F; Frassineti, GL; Masini, C; Matteucci, L; Monti, M; Pagan, F; Passardi, A; Rapposelli, I; Ruscelli, S; Sbaffi, S; Sullo, F; Valgiusti, M | 1 |
| Ahmed, S; Bhatti, T; Chalchal, H; Gill, D; Le, D; Moser, M; Shaw, J; Souied, O; Tan, KT; Zaidi, A | 1 |
| Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF | 1 |
| Bachet, JB; Bouvier, AM; Jooste, V; Lepage, C; Mas, L | 1 |
| Aoki, K; Hamano, T; Makishima, M; Oki, E; Sano, F; Yamanaka, T; Yamazaki, K; Yuki, S | 1 |
| Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M | 1 |
| Capanu, M; Chatila, WK; Chou, JF; Connell, LC; D'Angelica, MI; Jarnagin, WR; Kemeny, NE; Kingham, TP; Sanchez-Vega, F; Shi, H | 1 |
| Anger, F; Germer, CT; Kelm, M; Klein, I; Kunzmann, V; Löb, S; Schlegel, N; Schollbach, J; Wiegering, A | 1 |
| Aalbers, AGJ; Bakkers, C; Boerma, D; Brandt-Kerkhof, ARM; Bremers, AJA; Buffart, TE; Burger, JWA; Creemers, GM; de Groot, DJA; de Hingh, IHJT; de Reuver, PR; Dijkgraaf, MGW; Fijneman, RJA; Hemmer, PHJ; Kok, NFM; Koopman, M; Kranenburg, O; Kruijff, S; Kusters, M; Lahaye, MJ; Los, M; Madsen, EVE; Nederend, J; Nienhuijs, SW; Punt, CJA; Rovers, KP; Snaebjornsson, P; Tanis, PJ; Thijs, AMJ; Tuynman, JB; van 't Erve, I; van Grevenstein, WMU; van Meerten, E; Verheul, HMW; Versteeg, KS; Wiezer, MJ; Witkamp, AJ | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
| Baraibar, I; Cuadra-Urteaga, JL; Élez, E; Marmolejo, D; Mulet, N; Ros, J; Salvà, F; Saoudi Gonzalez, N; Tabernero, J; Valdivia, A | 1 |
| Aprile, G; Bertolini, AS; Boccaccino, A; Clavarezza, M; Conca, V; Cremolini, C; Falcone, A; Fontanini, G; Frassoldati, A; Germani, MM; Giordano, M; Granetto, C; Lonardi, S; Masi, G; Moretto, R; Passardi, A; Pietrantonio, F; Poma, AM; Tomasello, G; Ugolini, C | 1 |
| Jin, L; Shinozaki, E; Tanizawa, Y | 1 |
| Armansyah, A; Endarti, D; Khoe, LC; Kristin, E; Sastroasmoro, S; Taroeno-Hariadi, KW; Trijayanti, C | 1 |
| Anami, S; Furihata, S; Ohno, R; Takamatsu, N; Yatsu, N | 1 |
| Bando, H; Iino, S; Kadowaki, S; Kageyama, R; Kawazoe, A; Masuishi, T; Muro, K; Taniguchi, H; Yoshino, T | 1 |
| Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ | 1 |
| Alig, AHS; Decker, T; Fischer, LE; Heinemann, V; Heinrich, K; Holch, JW; Jelas, I; Jung, A; Kaiser, F; Kiani, A; Kirchner, T; Modest, DP; Moehler, M; Schlieker, L; Stahler, A; Stintzing, S; von Einem, JC; von Weikersthal, LF; Weiss, L; Westphalen, CB | 1 |
| Ahn, JB; Bai, L; Cho, SH; Fang, WJ; Han, SW; Hong, YS; Iwasa, S; Kim, TW; Kotaka, M; Lee, KW; Matsuoka, H; Morita, S; Muro, K; Nakamura, M; Nishina, T; Park, YS; Sakamoto, J; Yamada, Y; Yuan, XL; Yuan, Y; Zhang, DS | 1 |
| Barra, WF; Burbano, RMR; da Costa Silva, AL; da Costa, DF; de Assumpção, PB; de Assumpção, PP; Dobbin, EAF; Dos Santos, NPC; Dos Santos, SEB; Fernandes, MR; Modesto, AAC; Pastana, LF; Rodrigues, JCG | 1 |
| Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF | 1 |
| Alvi, R; Beca, JM; Chan, KKW; Cheung, WY; Dai, WF; Dvorani, E; Earle, CC; Gavura, S; Isaranuwatchai, W; Pataky, RE; Peacock, S; Tran, D | 1 |
| Ichikawa, D; Iino, H; Okamoto, H; Shiba, S; Sudoh, M | 1 |
| Callan, B; Callan, JF; Gao, J; Griffith, DM; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M | 1 |
| Anhut, P; Busse, D; Eckstein, M; Grützmann, R; Hartmann, A; Kersting, S; Merkel, S; Neufert, C; Neurath, MF; Ostermeier, N; Roth, JP; Schreiner, W; Siebler, J; Stoehr, R; Uder, M; Vitali, F; Wein, A; Wolff, K | 1 |
| Antonuzzo, A; Boccaccino, A; Borelli, B; Buonadonna, A; Caponnetto, S; Conca, V; Cremolini, C; Daniel, F; Falcone, A; Lonardi, S; Marmorino, F; Masi, G; Pietrantonio, F; Raimondi, A; Rossini, D; Santini, D; Sbrana, A; Tomasello, G; Zaniboni, A | 1 |
| Arai, H; Battaglin, F; Jayachandran, P; Kawanishi, N; Lenz, HJ; Mancao, C; Millstein, J; Mumenthaler, SM; Parikh, AR; Salhia, B; Soni, S; Wang, J; Xiao, Y; Zhang, W | 1 |
| Boku, N; Esaki, T; Izawa, N; Kawakami, K; Kawakami, T; Komoda, M; Makiyama, A; Masuishi, T; Mitani, S; Moriwaki, T; Nagashima, K; Nakajima, TE; Okuda, H; Tsuji, Y; Yamamoto, S; Yamamoto, Y; Yamazaki, K | 1 |
| Fujii, H; Kadono, T; Kimura, H; Nakatsugawa, Y; Nishimura, T; Okuyama, Y; Sato, H; Tomatsuri, N; Urata, Y; Yamada, S | 1 |
| Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N | 1 |
| Jung, A; Kirchner, T; Klauschen, F; Kumbrink, J; Li, P; Pók-Udvari, A | 1 |
| Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A | 1 |
| Bang, SM; Jung, EH; Kim, JH; Kim, JW; Kim, KJ; Kim, SA; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Nam, M; Park, H; Suh, KJ; Sung, JH | 1 |
| Ahn, JB; Beom, SH; Byun, HK; Chang, JS; Kim, HS; Kim, K; Kim, MS; Koom, WS; Lee, J; Park, EJ; Shin, SJ; Yang, G | 1 |
| Bedon, L; Buonadonna, A; Cecchin, E; Dal Bo, M; Fabbiani, E; Polano, M; Toffoli, G | 1 |
| Aranda, E; Díaz, IA; Élez, E; García-Alfonso, P; Gómez-España, MA; Graña, B; Grávalos, C; Losa, F; Martínez de Castro, E; Ortiz-Morales, MJ; Polo, E; Riesco, MDC; Rodriguez-Ariza, A; Ruiz-Casado, A; Safont, MJ; Salgado, M; Salud, A; Tabernero, J; Toledano-Fonseca, M; Valladares-Ayerbes, M | 1 |
| Ajani, JA; Rogers, JE; Trail, A; Wang, X | 1 |
| Chau, I; Lau, DK; Mencel, J | 1 |
| Adam, R; Adenis, A; Aparicio, T; Assenat, E; Audemar, F; Bouché, O; Chauvenet, M; Fonck, M; Francois, E; Galais, MP; Ghiringhelli, F; Guimbaud, R; Houyau, P; Jouffroy, C; Khemissa, F; Kianmanesh, R; Lopez-Crapez, E; Mercier-Blas, A; Mineur, L; Rivoire, M; Thezenas, S; Ychou, M | 1 |
| Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J | 1 |
| Hazama, S; Iida, M; Ioka, T; Matsui, H; Matsukuma, S; Nagano, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tomochika, S; Ueno, T; Watanabe, Y; Yamada, K; Yoshida, S | 1 |
| Iga, N; Ishizaki, M; Kawai, H; Miyauchi, S; Mizuno, D; Nishi, H; Suemori, K; Uno, F; Yamashita, K; Yoshida, R | 1 |
| Fujitani, K; Hata, T; Inoue, A; Kagawa, Y; Kato, T; Kawai, K; Komatsu, H; Miyazaki, Y; Motoori, M; Murata, K; Naito, A; Nishizawa, Y; Ohta, T; Takeda, Y; Tomokuni, A | 1 |
| Deng, YX; Hou, ZL; Lin, JZ; Lu, ZH; Pan, ZZ; Peng, JH; Zhang, LJ; Zhang, WL; Zhou, C | 1 |
| Dai, WP; Jiao, XD; Li, XN; Liu, K; Qin, BD; Qin, WX; Sun, L; Wang, MM; Wang, Z; Ye, CY; Yuan, LY; Zang, YS | 1 |
| Atkins, JN; Bainter, TM; Blanke, CD; Fuchs, CS; Goldberg, RM; Hochster, HS; Innocenti, F; Lenz, HJ; Ma, C; Mayer, RJ; McCleary, NJ; Meyerhardt, JA; Ng, K; Niedzwiecki, D; O'Neil, BH; O'Reilly, EM; Ou, FS; Polite, BN; Venook, AP; Zhang, S | 1 |
| Chang, TK; Chen, PJ; Chen, YC; Huang, CW; Li, CC; Su, WC; Tsai, HL; Wang, JY; Yin, TC | 1 |
| Copur, MS; Horn, AJ; Kelly, JR; Lintel, N; Ly, Q; Riley, B; Rodriguez, P; Schroeder, CW; Tun, SM; Wedel, W | 1 |
| Bai, LY; Chan, DC; Chen, JS; Chen, LT; Chen, YY; Cheng, FM; Chiang, NJ; Chiu, SC; Chiu, TJ; Chou, WC; Chuang, SC; Hsueh, SW; Li, CP; Peng, CM; Shan, YS; Su, YY; Yang, SH; Yen, CJ | 1 |
| Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Bekaii-Saab, TS | 1 |
| Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H | 1 |
| Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY | 1 |
| Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S | 1 |
| Allegrini, G; Antoniotti, C; Boccaccino, A; Borelli, B; Buonadonna, A; Conca, V; Cremolini, C; Dell'Aquila, E; Germani, MM; Lonardi, S; Maddalena, G; Marmorino, F; Masi, G; Passardi, A; Pietrantonio, F; Randon, G; Rossini, D; Zaniboni, A | 1 |
| Al-Batran, SE; Decker, T; Denzlinger, C; Fischer, LE; Giessen-Jung, C; Heinemann, V; Heinrich, K; Heintges, T; Held, S; Jung, A; Kahl, C; Kaiser, F; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Modest, DP; Peuser, B; Scheithauer, W; Seipelt, G; Stahler, A; Stauch, M; Stintzing, S; Uhlig, J; von Weikersthal, LF; Weiss, L | 1 |
| Alonso de Castro, B; Cameselle García, S; Carmona Campos, M; Cousillas Castiñeiras, A; De la Cámara Gómez, JC; Fernández-Montes, A; Gómez-Randulfe Rodríguez, MI; González Villarroel, P; Martínez-Lago, N; Méndez Méndez, JC; Romero Reinoso, C; Salgado Fernández, M; Vidal Insua, Y | 1 |
| Antoniotti, C; Brodskiy, P; Calegari, MA; Carullo, M; Conca, V; Corti, F; Cremolini, C; Elliott, A; Fassan, M; Intini, R; Korn, M; Lenz, HJ; Lonardi, S; Masi, G; Mauri, G; Moretto, R; Pella, N; Pietrantonio, F; Rasola, C; Rossini, D; Salati, M; Sartore-Bianchi, A; Scartozzi, M; Shields, A | 1 |
| Fukushima, T; Hamaguchi, T; Kobayashi, S; Morimoto, M; Nagashima, S; Oishi, R; Shin, M; Tezuka, S; Ueno, M; Yamachika, Y | 1 |
| Arai, H; Battaglin, F; Heinemann, V; Jayachandran, P; Kawanishi, N; Lenz, HJ; Millstein, J; Soni, S; Stintzing, S; Wang, J; Yang, Y; Zhang, W | 1 |
| Liu, JY; Liu, X; Long, YX; Qiu, M; Zhou, YW | 1 |
| Akazawa, N; Ando, T; Hirata, K; Kagawa, Y; Kato, T; Maeda, H; Mishima, H; Nagasaka, T; Nagata, N; Oba, K; Sakamoto, J; Shiozawa, M; Watanabe, J; Yamada, T; Yokota, M | 1 |
| Arai, H; Battaglin, F; Cremolini, C; Falcone, A; Heinemann, V; Jayachandran, P; Kawanishi, N; Lenz, HJ; Liu, T; Loupakis, F; Mancao, C; Millstein, J; Shen, L; Soni, S; Stintzing, S; Wang, J; Xiao, Y; Yang, Y; Zhang, W | 1 |
| Aparicio, J; Capdevila, J; Gallego, RÁ; Galván, P; García de Albeniz, X; Hernandez-Yagüe, X; Hernando, J; Maurel, J; Muñoz Boza, F; Oliveres, H; Páez, D; Richart, P; Riesco-Martinez, MC; Serrano, S; Vera, R; Virgili Manrique, AC | 1 |
| Iwai, M; Kimura, M; Usami, E; Yoshimura, T | 1 |
| Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S | 1 |
| Giuliani, J | 1 |
| Auberger, B; Auclin, E; Bernard-Tessier, A; Botsen, D; Bouche, O; Bourgeois, V; Bureau, M; Darbas, T; Doat, S; Dubreuil, O; Gignoux, P; Gluszak, C; Godet, T; Goujon, G; Grados, L; Hammel, P; Jaffrelot, M; Lambert, A; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Nassif, E; Neuzillet, C; Palmieri, LJ; Pernot, S; Perret, A; Perrier, M; Randrian, V; Roth, G; Saint, A; Sefrioui, D; Stouvenot, M; Taieb, J; Torregrosa, C; Tournigand, C; Trager, S; Turpin, A; Vaflard, P | 1 |
| Banerjee, A; Chrabaszcz, S; Dhiman, A; Gamblin, TC; Johnston, FM; Klooster, B; Rajeev, R; Turaga, KK; Witmer, HDD | 1 |
| Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H | 1 |
| Kashihara, H; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Tokunaga, T; Wada, Y; Yamashita, S; Yoshikawa, K; Yoshimoto, T | 1 |
| Blaney, M; Cubillo, A; Kozloff, M; Liang, JT; Lowe, T; Matrana, M; Naumovski, L; Sahtout, M; Strickler, JH; Wainberg, ZA | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S | 1 |
| Afable, M; Gathirua-Mwangi, W; Khan, T; Wu, Y; Yang, T | 1 |
| Aalbers, AGJ; Berbée, M; Bloemen, JG; Buffart, TE; Burger, JWA; Creemers, GJM; de Groot, JWB; de Wilt, JHW; Marijnen, CAM; Melenhorst, J; Nederend, J; Nieuwenhuijzen, GAP; Peters, NAJB; Peulen, HMU; Roef, MJ; Roodhart, JML; Rutten, HJT; Schaap, DP; Simkens, LHJ; Snaebjornsson, P; van 't Veer, M; van den Berg, K; van Lijnschoten, IG; van Westreenen, HL; Verheul, HMW; Verhoef, C; Vincent, J; Voogt, ELK; Werter, IM; Willems, JMWE | 1 |
| García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P | 1 |
| Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A | 1 |
| Jiang, W; Liu, Q; Yang, D; Yang, SB | 1 |
| Kazama, H; Terazawa, T; Uetake, H; Watanabe, J; Yamane, S; Yoshino, T | 1 |
| Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S | 1 |
| Hassan, MA; Khalil, KA; Mahmoud, IA; Musallam, HS | 1 |
| Bassali, F; Book, A; Bruckner, HW; De Jager, R; Dusowitz, E; Gurell, D | 1 |
| Barber, PR; Forsyth, S; Gao, F; Hackett, LD; Hartley, JA; Hochhauser, D; Lopes, A; Lowe, HL; Ng, TT; Pearce, S; Propper, DJ; Sarker, D; Saunders, MP; Spanswick, VJ; Weitsman, GE; White, L | 1 |
| Betrian, S; Brac De La Perriere, C; Chaltiel, L; Delord, JP; Sarradin, V | 1 |
| Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M | 1 |
| Bendell, J; Cervantes, A; Chiu, VK; Fakih, M; Falcone, A; Fontaine, M; Grothey, A; Hitron, M; Oh, SC; Shah, MA; Tabernero, J; Taieb, J; Tebbutt, NC; Tomasek, J; Van Cutsem, E; Wu, C; Xu, B; Xu, RH; Yamaguchi, K; Yoshino, T | 1 |
| Acar, R; Akbas, S; Akinci, MB; Araz, M; Arslan, C; Artac, M; Bahceci, A; Bilgetekin, I; Bilici, A; Cakir, E; Celik, E; Cilbir, E; Cincin, I; Dede, DS; Demirkiran, A; Deniz, GI; Dogan, I; Erdem, D; Erdogan, AP; Eren, OO; Erol, C; Garbioglu, DB; Gulmez, A; Hacibekiroglu, I; Hamdard, J; Hizal, M; Inal, A; Kahraman, S; Kaya, AO; Koca, S; Kubilay, P; Kucukarda, A; Kut, E; Mandel, NM; Menekse, S; Nayir, E; Oksuzoglu, B; On, S; Oyman, A; Ozyukseler, DT; Paydas, S; Sakin, A; Sen, E; Sendur Mehmet, AN; Sevinc, A; Taskaynatan, H; Tastekin, D; Turhal, S; Uncu, D; Yalcin, B; Yildirim, ME | 1 |
| Chen, BS; Cheng, TC; Chiang, CH; Chiu, JH; Hsieh, CL; Luan, YZ; Ma, KS; Peng, CM | 1 |
| Fushiki, K; Hamauchi, S; Kawakami, T; Onozawa, Y; Oshima, K; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Alés Díaz, I; Aranda, E; Élez, E; García-Alfonso, P; García-Ortiz, MV; Gómez-España, MA; Graña, B; Grávalos, C; Losa, F; Polo, E; Riesco, MC; Rivera, F; Rodríguez, R; Rodríguez-Ariza, A; Ruiz-Casado, A; Safont, MJ; Salgado, M; Salud, A; Tabernero, JM; Toledano-Fonseca, M; Valladares-Ayerbes, M | 1 |
| Abad, LP; Aguilera, MJS; Bonastre, MTT; Hernández, IB; Pérez, IP; Raga, MG; Rodríguez, PL; Sosa, MM; Urtasun, JA; Veiga, RC | 1 |
| Fujimura, T; Nakura, M; Nojima, K; Sasaki, S; Takenaka, S; Takeshita, M; Watanabe, T; Yamazaki, H | 1 |
| Bergamo, F; Conca, V; Cremolini, C; Di Donato, S; Fanotto, V; Fontanini, G; Germani, MM; Giordano, M; Latiano, TP; Lonardi, S; Masi, G; Moretto, R; Niccoli, C; Passardi, A; Pietrantonio, F; Prisciandaro, M; Proietti, A; Tamburini, E; Ugolini, C; Zaniboni, A | 1 |
| Asaoka, T; Furukawa, K; Hyuga, S; Imasato, M; Iwamoto, K; Mizushima, T; Moon, J; Naito, A; Nakahara, Y; Ohashi, T; Takeda, M | 1 |
| Hara, T; Hasegawa, J; Hata, T; Imamoto, H; Kim, Y; Okano, M; Takayama, O; Tanizaki, K | 1 |
| Antoniotti, C; Bensi, M; Bergamo, F; Boccaccino, A; Boquet, I; Catteau, A; Conca, V; Cremolini, C; Galon, J; Giordano, M; Leonetti, S; McGregor, K; Morano, F; Murgioni, S; Nielsen, TJ; Papiani, G; Passardi, A; Pietrantonio, F; Ross, DT; Rossini, D; Salvatore, L; Schweitzer, BL; Seitz, R; Tamburini, E; Varga, MG | 1 |
| Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M | 1 |
| Beppu, N; Hirata, M; Ikeda, M; Ikeuchi, H; Kataoka, K; Kimura, K; Kuribayashi, M; Nishimura, Y; Nomura, K; Ohashi, E; Song, J; Takenaka, Y; Uchino, M; Yanagawa, T; Yarimizu, A | 1 |
| Chorawala, MR; Patel, RS; Thakur, A | 1 |
| Azuma, K; Dote, S; Fujii, R; Fukui, R; Goto, E; Hayasaka, D; Hayashi, Y; Hirabatake, M; Hirata, T; Honda, S; Ikesue, H; Itakura, S; Ito, K; Kataoka, N; Kobayashi, A; Kobayashi, Y; Kohno, E; Makihara, K; Mashimo, K; Meguro, Y; Miyake, M; Miyata, H; Morimoto, N; Nakao, M; Nakata, Y; Negoro, Y; Nishiuma, S; Odaira, N; Shigemori, M; Shimato, A; Shiwaku, E; Suzuki, S; Takagi, M; Takahashi, K; Takahashi, M; Takahashi, Y; Tasaka, M; Tokutome, A; Watanabe, H; Yagisawa, K; Yamaguchi, D; Yamamoto, Y; Yokomizo, A; Yoshino, M | 1 |
| Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C | 1 |
| Boccaccino, A; Bustreo, S; Carullo, M; Clavarezza, M; Cremolini, C; Cupini, S; Daniel, F; Libertini, M; Lonardi, S; Morano, F; Niger, M; Palermo, F; Pietrantonio, F; Procaccio, L; Raimondi, A; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A | 1 |
| Burkart, C; Eucker, J; Fischer von Weikersthal, L; Heinemann, V; Heinrich, K; Kahl, C; Kaiser, F; Karthaus, M; Kasper-Virchow, S; Krammer-Steiner, B; Modest, DP; Müller, C; Pihusch, R; Prager, GW; Reinacher-Schick, A; Schwaner, I; Stauch, M; Stintzing, S; Taieb, J; Tougeron, D | 1 |
| Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K | 1 |
| Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K | 1 |
| Chang, W; Cui, Y; Ding, K; Fan, J; Feng, Q; He, G; Liang, F; Liang, L; Lin, Q; Ren, L; Tang, W; Wang, H; Wang, J; Wang, X; Wei, Y; Xu, J; Ye, F; Ye, Q; Zhao, R; Zhou, G; Zhu, D | 1 |
| Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Kimura, M; Kotani, M; Nakabori, T; Nozaki, K; Ohkawa, K; Seiki, Y; Takada, R; Takagi, M; Uehara, H; Urabe, M; Watsuji, K; Yagi, T; Yamai, T | 1 |
| Armansyah, A; Khoe, LC; Megraini, A; Nadjib, M; Nugraha, RR; Permanasari, VY; Putri, S; Saldi, SRF; Santatiwongchai, B; Sastroasmoro, S; Setiawan, E | 1 |
| Fukuda, H; Hamaguchi, T; Hashimoto, T; Hironaka, S; Kanemitsu, Y; Kataoka, T; Mizusawa, J; Otsu, S; Takashima, A; Tsukamoto, S | 1 |
| Hansen, TF; Havelund, BM; Jensen, LH; Lindebjerg, J; Rafaelsen, SR; Raunkilde, L; Thomsen, CB | 1 |
| Anchisi, S; Bohanes, P; Derigs, HG; Geffriaud-Ricouard, C; Grünberger, B; Gueldner, M; Hofheinz, RD; Piringer, G; Scholten, F; Schwarz, L; Thaler, J; von Moos, R | 1 |
| Imai, H; Ishioka, C; Kasahara, Y; Kawamura, Y; Komine, K; Ouchi, K; Saijo, K; Sasaki, K; Shirota, H; Takahashi, M; Takenaga, N; Taniguchi, SH; Yoshida, Y | 1 |
244 review(s) available for camptothecin and levoleucovorin
| Article | Year |
|---|---|
Chemotherapy of advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Digestive System Neoplasms; Double-Blind Method; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Immunologic Factors; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 1994 |
Role of chemotherapy for advanced colorectal cancer: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 1996 |
[Recent advance in chemotherapy for advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Quinazolines; Remission Induction; Thiophenes; Thymidylate Synthase | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
[New anti-cancer drugs for gastrointestinal cancers].
Topics: Amino Acids; Antidotes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Irinotecan; Leucovorin; Paclitaxel; Taxoids | 1997 |
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Hospitalization; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; North America | 1998 |
European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Therapy, Combination; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycins | 1998 |
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Salvage Therapy | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Europe; Fluorouracil; Irinotecan; Japan; Leucovorin; Mitomycin; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors; Treatment Outcome; United States | 1998 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Fluorouracil; Humans; Irinotecan; Leucovorin; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
[Adjuvant chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2000 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Leucovorin; Lymphatic Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2000 |
The role of irinotecan in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Patient Selection; Topoisomerase I Inhibitors; Treatment Outcome | 1999 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxonic Acid; Pyridines; Tegafur | 2000 |
Irinotecan in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Paclitaxel; Topoisomerase I Inhibitors | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2000 |
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2000 |
Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2000 |
Second-line therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2000 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Efficacy of oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Treatment Outcome | 2000 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis; Treatment Outcome | 2001 |
Adjuvant therapy of colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
[Standard therapy of CPT-11 for colorectal cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Therapeutic advances in the management of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Methotrexate; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2001 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fluorouracil; Humans; Indoles; Irinotecan; Leucovorin; Male; Neovascularization, Pathologic; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2002 |
Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2001 |
Review of the role of CPT-11 in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2001 |
Adjuvant therapy of colon cancer: a review.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging | 2002 |
Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome | 2002 |
[Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Levamisole; Palliative Care; Quality-Adjusted Life Years; Quinazolines; Thiophenes | 2003 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inhibitors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Palliative Care; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Treatment Outcome; Uracil | 2003 |
[Chemotherapy for colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2003 |
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Survival Rate; Treatment Outcome | 2003 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Neovascularization, Pathologic; Predictive Value of Tests; Prognosis; Survival Analysis | 2003 |
Campto effective and flexible chemotherapy for advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index | 2003 |
Colorectal cancer: integrating oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
Alternative schedules with irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin | 2003 |
[Controversy of treatment for advanced colorectal cancer--intermedisine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pyridines; Tegafur | 2003 |
Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis | 2003 |
[Chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2003 |
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; United States | 2003 |
[Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Prognosis; United States | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Pyridines; Tegafur; United States; Uracil | 2003 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Nausea; Stomatitis; Thrombocytopenia; Vomiting | 2003 |
[Guidance and informed consent in colon cancer therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluorouracil; Humans; Informed Consent; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local | 2003 |
[Chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2003 |
Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Survival Analysis; Survival Rate; United States | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2004 |
[Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
Current status of adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Europe; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; United States | 2004 |
Developments in combination chemotherapy for colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Tegafur; Uracil | 2004 |
Intergroup trial fails to demonstrate a benefit with the addition of irinotecan to bolus 5-fluorouracil/leucovorin in stage III colon cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate | 2004 |
[CPT-11 combined chemotherapy for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
Which drug combination for colorectal cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2004 |
[Second-line chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Quality of Life; Survival Rate; Tegafur; Uracil | 2005 |
Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2004 |
Adjuvant therapy of colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2005 |
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Quinazolines; Thiophenes; United Kingdom | 2005 |
Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
New chemotherapeutic strategies in colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2005 |
Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2005 |
Perioperative adjunctive treatment in the management of operable gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2005 |
Adjuvant therapy in colon cancer: which treatment in 2005?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2005 |
[Chemotherapy of patients with colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Incidence; Irinotecan; Leucovorin; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis | 2005 |
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Drug Delivery Systems; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2004 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2005 |
Metastatic colorectal cancer: is there one standard approach?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Vitamin B Complex | 2005 |
[Drug therapy of patients with metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Practice Guidelines as Topic; Prognosis; Survival Rate | 2005 |
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Pyrimidines; Treatment Outcome | 2005 |
[Progression of adjuvant chemotherapy for colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2005 |
[Recent progress of chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Rate | 2005 |
The role of bevacizumab as first-line therapy for colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic | 2005 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Uracil; Vitamin B Complex | 2005 |
[The modern treatment of colorectal cancer. Present and future].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Immunologic Factors; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2006 |
Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; History, 20th Century; History, 21st Century; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Randomized Controlled Trials as Topic | 2006 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Oxonic Acid; Survival Rate; Tegafur | 2006 |
[FOLFIRI regimen for metastatic or recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2006 |
[IFL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
[Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Postoperative Care; Treatment Outcome | 2006 |
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Vaccines; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Humans; Hungary; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Methotrexate; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2007 |
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Survival Analysis | 2006 |
[Up to date chemotherapy for colon cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Survival Rate | 2007 |
[Standard chemotherapy for colonic neoplasms].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Uracil | 2007 |
Adjuvant treatment of colon cancer: past, present and future.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Europe; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Staging; Oxonic Acid; Practice Guidelines as Topic; Rectal Neoplasms; Tegafur; United States; Uracil | 2007 |
[Surgery and chemotherapy for colorectal cancer: current status and perspective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonoscopy; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Lymph Node Excision; Organoplatinum Compounds; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic | 2007 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Treatment Outcome | 2007 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Approval; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fluorouracil; Humans; Hypertension; Kidney Neoplasms; Leucovorin; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2007 |
The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2007 |
[Progress of chemotherapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds | 2007 |
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Survival Rate | 2008 |
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2007 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A; Vitamin B Complex | 2008 |
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2008 |
Colon cancer: update on adjuvant therapy.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2008 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2008 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Glass; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Microspheres; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Yttrium Radioisotopes | 2009 |
[Colorectal carcinoma--primary treatment in case of advanced metastization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Leucovorin; Organoplatinum Compounds; Primary Health Care; Treatment Outcome | 2008 |
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fatty Liver; Floxuridine; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Risk Factors | 2009 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Treatment of colorectal liver metastases: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2009 |
A novel K-ras mutation in colorectal cancer. A case report and literature review.
Topics: Adenocarcinoma, Mucinous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Tumor Suppressor Protein p53 | 2009 |
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Genes, MCC; Humans; Leucovorin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2010 |
Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Precision Medicine; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
[Neoadjuvant chemotherapy and pancreatoduodenectomy for locally advanced colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreaticoduodenectomy | 2009 |
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2011 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Oxaloacetates; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Surgical therapies in metastatic colorectal cancer with a potential for cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Hyperthermia, Induced; Infusions, Parenteral; Leucovorin; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Peritoneal Neoplasms; Pneumonectomy | 2011 |
[Transition of chemotherapy for metastatic colorectal cancer and recent advances].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Rate | 2010 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2010 |
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Vitamin B Complex | 2010 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2011 |
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2011 |
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Approval; Europe; Fluorouracil; Humans; Irinotecan; Leucovorin; Mutation; Organoplatinum Compounds; United States; United States Food and Drug Administration | 2010 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Prodrugs; Radiotherapy, Adjuvant | 2010 |
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2010 |
Chemotherapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2010 |
Adjuvant treatment of colon cancer: what is next?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Common side effects and interactions of colorectal cancer therapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Complementary Therapies; Deoxycytidine; Drug Interactions; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2011 |
Evolution of systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2011 |
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; DNA Copy Number Variations; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Leucovorin; Pemetrexed; Treatment Outcome | 2011 |
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Forecasting; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Rectal Neoplasms; Time Factors; Treatment Outcome | 2011 |
[A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dysarthria; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Sigmoid Neoplasms | 2011 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Mutation; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2012 |
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; France; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2011 |
[Neoadjuvant therapy concepts for liver metastases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Prognosis; Randomized Controlled Trials as Topic | 2011 |
Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic | 2012 |
[A case of mucinous cystadenocarcinoma of the appendix with abdominal wall abscess successfully treated by percutaneous drainage and systemic chemotherapy-a case report].
Topics: Abdominal Abscess; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Biopsy; Camptothecin; Cystadenocarcinoma, Mucinous; Drainage; Female; Fluorouracil; Humans; Leucovorin; Tomography, X-Ray Computed | 2011 |
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2011 |
A preclinical and clinical review of aflibercept for the management of cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2012 |
[A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Organoplatinum Compounds; Panitumumab; Tomography, X-Ray Computed | 2012 |
Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Molecular Targeted Therapy; Organoplatinum Compounds; Survival Rate | 2012 |
[FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Liver Neoplasms; Lung Neoplasms; Middle Aged; Rectal Neoplasms; Recurrence | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2012 |
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Codon; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Treatment Outcome | 2012 |
Colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Treatment Outcome | 2013 |
Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Guidelines as Topic; Humans; Leucovorin; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Duodenal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Multiple Organ Failure; Nausea; Organoplatinum Compounds; Severity of Illness Index; Vomiting | 2013 |
Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Meta-Analysis as Topic; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2013 |
Oncological management of unresectable liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Panitumumab; Time Factors | 2012 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Coronary Angiography; Diagnostic Errors; Docetaxel; Electric Countershock; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Myocardial Infarction; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Takotsubo Cardiomyopathy; Taxoids; Ventricular Fibrillation | 2013 |
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2013 |
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Retrospective Studies; Treatment Outcome | 2013 |
[A case of recurrent colon cancer involved in multiple organs maintaining complete response over the long-term after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Recurrence; Time Factors | 2013 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
The evolving role of oxaliplatin in the management of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2003 |
FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Treatment Outcome | 2013 |
Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate; Treatment Outcome | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2014 |
Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Treatment Outcome | 2014 |
Role of cetuximab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Ligands; Liver Neoplasms; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Randomized Controlled Trials as Topic; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Disseminated intravascular coagulation as clinical manifestation of colorectal cancer: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Oxaloacetates; Paraneoplastic Syndromes; Sigmoid Neoplasms | 2014 |
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Precision Medicine; Treatment Outcome | 2014 |
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Vascular Endothelial Growth Factor A | 2014 |
TroVax in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Carcinoembryonic Antigen; Carcinoma, Renal Cell; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Kidney Neoplasms; Leucovorin; Membrane Glycoproteins; Organoplatinum Compounds; Vaccination; Vaccines, DNA; Vaccinia virus | 2014 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Publication Bias | 2015 |
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Fluorouracil; Health Care Costs; Humans; Kaplan-Meier Estimate; Leucovorin; Models, Economic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Camptothecin; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Neoplasms; Organoplatinum Compounds; Tegafur | 2015 |
Pancreatic cancer and FOLFIRINOX: a new era and new questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Care Planning; Postoperative Care; Preoperative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2015 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Multicenter Studies as Topic; Oxaloacetates; Oxonic Acid; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2015 |
Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Treatment Outcome | 2015 |
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2015 |
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quality-Adjusted Life Years; Treatment Outcome; United States | 2016 |
[A Case of Descending Colon Adenocarcinoma with Neuroendocrine Differentiation Successfully Treated with FOLFIRI plus Bevacizumab].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Colon, Descending; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Prognosis | 2016 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Leucovorin; Maintenance Chemotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds | 2016 |
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genes, ras; Humans; Leucovorin; Maintenance Chemotherapy; Mutation; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacokinetics; Proto-Oncogene Proteins B-raf | 2016 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Nanoparticles; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Leucovorin; Pancreatic Neoplasms; Sucrose; Treatment Outcome | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2016 |
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Prognosis | 2016 |
Liver Metastases in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds | 2016 |
Localized Pancreatic Cancer: Multidisciplinary Management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Radiosurgery | 2016 |
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Survival Rate | 2016 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2016 |
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Precision Medicine; Translational Research, Biomedical; Vascular Endothelial Growth Factor A | 2016 |
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Unresectable liver metastases in colorectal cancer: review of current strategies.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Management; Embolization, Therapeutic; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2016 |
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Treatment Outcome | 2016 |
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms; Drug Carriers; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2017 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Second-line systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2017 |
Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gentamicins; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Practice Guidelines as Topic; Treatment Outcome; United States | 2017 |
Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Network Meta-Analysis; Organoplatinum Compounds; Software; Survival Analysis; Treatment Outcome | 2018 |
The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colon, Sigmoid; Colonoscopy; Colorectal Neoplasms; Embolization, Therapeutic; Female; Fluorouracil; Hepatectomy; Humans; Hypertrophy; Laparoscopy; Leucovorin; Ligation; Liver; Liver Neoplasms; Liver Regeneration; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Portal Vein; Prognosis; Treatment Outcome; Vascular Surgical Procedures | 2017 |
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2017 |
Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis | 2017 |
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2018 |
Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies | 2018 |
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Databases, Factual; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neutropenia; Organoplatinum Compounds; Proportional Hazards Models; Risk; Survival Rate; Treatment Outcome | 2018 |
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Progression-Free Survival; Randomized Controlled Trials as Topic; Signal Transduction | 2019 |
FOLFOXIRI plus biologics in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2019 |
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment | 2020 |
The actual management of colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Electroporation; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Liver Transplantation; Margins of Excision; Microwaves; Organoplatinum Compounds; Prognosis; Radiofrequency Ablation; Reoperation | 2020 |
Controversies in the treatment of RAS wild-type metastatic colorectal cancer.
Topics: Advisory Committees; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colon, Ascending; Colon, Transverse; Colonic Neoplasms; Colorectal Neoplasms; Consensus; Delphi Technique; ErbB Receptors; Fluorouracil; Genes, ras; Genotype; Humans; Leucovorin; Liquid Biopsy; Maintenance Chemotherapy; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Retreatment | 2021 |
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
Topics: Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Substitution; Fluorouracil; Genes, ras; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2021 |
Up-to-date role of aflibercept in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2021 |
[FOLFIRI plus Ramucirumab Treatment for Metastatic Colorectal Cancer-Narrative Review of Real-World Evidence in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Japan; Leucovorin; Neoplasm Metastasis; Ramucirumab | 2021 |
Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; British Columbia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Retrospective Studies | 2022 |
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Febrile Neutropenia; Female; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2021 |
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2022 |
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Placenta Growth Factor; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Leucovorin; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic | 2022 |
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms | 2022 |
Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin | 2022 |
The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Supplements; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic | 2022 |
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Placenta Growth Factor; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2023 |
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Prospective Studies; Rectal Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D | 2023 |
642 trial(s) available for camptothecin and levoleucovorin
| Article | Year |
|---|---|
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms | 1996 |
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 1998 |
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction | 1999 |
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 1999 |
UFT plus calcium folinate/irinotecan in colorectal cancer.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Humans; Irinotecan; Leucovorin; Tegafur; Topoisomerase I Inhibitors; Treatment Outcome; Uracil | 1999 |
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Severity of Illness Index; Survival Rate; Treatment Outcome | 1999 |
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Topics: Adult; Aged; Animals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Radioimmunotherapy | 1999 |
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 1999 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Quality of Life; Stomatitis; Survival Analysis | 2000 |
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2000 |
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2000 |
UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Treatment Outcome; Uracil | 2000 |
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Uracil | 2000 |
Irinotecan and UFT/leucovorin in patients with advanced cancers.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Tegafur; Uracil | 2000 |
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Quinazolines; Thiophenes; Treatment Failure | 2000 |
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2001 |
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2001 |
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life | 2001 |
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2001 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2001 |
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2001 |
[Preliminary clinical comparison of HLF and ELF regimen in the treatment of advanced gastric carcinoma in middle-aged and elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms | 2000 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Remission Induction; Survival Analysis | 2002 |
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Treatment Outcome | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Salvage Therapy; Secondary Prevention; Thiophenes; Treatment Outcome | 2002 |
Chronotherapy of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rats | 2002 |
Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Resistance, Neoplasm; Female; Fluorouracil; Health Status; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Compliance; Quality of Life; Survival Analysis | 2002 |
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2002 |
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; England; Fluorouracil; Humans; Irinotecan; Leucovorin | 2002 |
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Italy; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Analysis; Treatment Outcome | 2002 |
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival; Treatment Outcome | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia | 2002 |
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Failure | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Stomatitis; Treatment Outcome | 2002 |
Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Probability; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Pyridines; Survival Analysis | 2002 |
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Probability; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Salvage Therapy; Survival Analysis; Treatment Failure | 2002 |
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; United States | 2003 |
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydroxyurea; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2003 |
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2003 |
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome; United Kingdom; Uracil | 2003 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2003 |
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2003 |
Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pilot Projects; Prospective Studies; Stomach Neoplasms | 2003 |
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Rectal Neoplasms; Topoisomerase I Inhibitors | 2003 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2003 |
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2004 |
Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Tegafur; Treatment Outcome; Uracil | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis | 2003 |
FDA drug approval summaries: oxaliplatin.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Random Allocation; Recurrence; United States; United States Food and Drug Administration | 2004 |
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Dehydrogenase (NADP); Middle Aged; Neoplasms; Polymorphism, Genetic; Tablets; Tegafur; Treatment Outcome; Uracil | 2004 |
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2004 |
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2004 |
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease Progression; Epothilones; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Failure | 2004 |
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Survival Analysis | 2004 |
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Gene Expression Profiling; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Multivariate Analysis; Prognosis; Thymidylate Synthase; Treatment Outcome | 2004 |
The toxicity rates of two different regimens of irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Topoisomerase I Inhibitors | 2003 |
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Shock, Septic; Stomatitis; Survival Rate | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Quality of Life; Remission Induction; Treatment Outcome | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Stomatitis; Survival Analysis; Survival Rate | 2004 |
Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2004 |
Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2004 |
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2004 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome | 2004 |
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2004 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Israel; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Time Factors; Treatment Outcome | 2004 |
Bevacizumab for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Approval; Fluorouracil; Humans; Leucovorin; Treatment Outcome; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factors | 2004 |
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2005 |
Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prospective Studies; Treatment Outcome | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Selection; Treatment Outcome | 2005 |
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2005 |
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Placebos; Quality of Life; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors; Treatment Outcome | 2005 |
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2005 |
Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Uracil | 2005 |
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucose; Hemodilution; Humans; Hyperthermia, Induced; Hypoalbuminemia; Infusions, Parenteral; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Period; Prospective Studies; Red-Cell Aplasia, Pure; Treatment Outcome | 2005 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2005 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusion Pumps; Irinotecan; Leucovorin; Male; Neoplasms; Neutropenia; Pharmacogenetics; Promoter Regions, Genetic; Thymidylate Synthase; Treatment Outcome | 2005 |
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2005 |
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronobiology Phenomena; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2005 |
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Korea; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Glutamine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Survival Analysis | 2005 |
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; CD3 Complex; CD4 Antigens; CD8 Antigens; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Flow Cytometry; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-A2 Antigen; Humans; Immunodominant Epitopes; Immunotherapy; Interferon-gamma; Interleukin-2; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Prospective Studies; T-Lymphocytes; Treatment Outcome | 2005 |
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Survival Rate; Tegafur; Uracil; Vomiting, Anticipatory | 2005 |
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Weight Loss | 2005 |
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2006 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2005 |
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis | 2006 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Survival Analysis | 2006 |
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Time Factors; Treatment Outcome | 2005 |
FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2005 |
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds | 2005 |
Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Digestive System Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Saliva; Tissue Distribution | 2006 |
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2006 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Health Status; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis | 2005 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2006 |
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Administration Schedule; Enteroendocrine Cells; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2006 |
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2006 |
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2006 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers; Body Composition; Camptothecin; Colorectal Neoplasms; Cytokines; Dietary Proteins; Dietary Supplements; Eicosapentaenoic Acid; Energy Intake; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Male; Malnutrition; Middle Aged; Nutritional Status; Nutritional Support; Phospholipids; Quality of Life; Treatment Outcome; Vitamin B Complex | 2007 |
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2007 |
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Paris; Prospective Studies; Time Factors; Treatment Outcome | 2007 |
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Italy; Kaplan-Meier Estimate; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Positron-Emission Tomography; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2007 |
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines | 2007 |
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Tegafur; Uracil | 2007 |
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pelvic Neoplasms; Rectal Neoplasms; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronates; Humans; Intestinal Mucosa; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Mucositis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 2007 |
Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Camptothecin; Carcinoma; Female; Fluorouracil; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Vitamin B Complex | 2007 |
[Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Pyrimidines; Rectal Neoplasms; Remission Induction; Treatment Failure | 2006 |
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Health Status; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Patient Compliance; Quality of Life; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome | 2007 |
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Sample Size; Survival Rate; Treatment Failure | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Recurrence; Survival Analysis | 2007 |
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Compliance | 2007 |
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Vitamin B Complex | 2007 |
Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Treatment Outcome | 2007 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis | 2007 |
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Odds Ratio; Rectal Neoplasms; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2007 |
Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Tegafur; Treatment Outcome; Uracil | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2007 |
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2007 |
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Floxuridine; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2007 |
Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Palliative Care; Prospective Studies; Survival Rate | 2007 |
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Retrospective Studies; Treatment Outcome | 2007 |
Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost of Illness; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2007 |
[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Leucovorin; Male; Middle Aged; Neutropenia; Treatment Outcome | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2007 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neutropenia; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2007 |
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2008 |
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2007 |
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Nausea; Salvage Therapy; Stomach Neoplasms; Stomatitis; Survival Rate; Treatment Outcome | 2007 |
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Safety | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival; Time Factors; Treatment Outcome | 2007 |
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Vaccines, DNA | 2008 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Thrombospondins; Vascular Endothelial Growth Factor A | 2007 |
Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2007 |
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2008 |
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis | 2008 |
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
Topics: Adult; Aged; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organic Chemicals; Proliferating Cell Nuclear Antigen | 2008 |
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Palliative Care; Survival Analysis | 2008 |
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2007 |
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Diarrhea; Disease-Free Survival; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Myocardial Ischemia; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Patient Compliance; Prospective Studies; Quality of Life; Radiotherapy, Adjuvant; Survival Analysis | 2008 |
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; gamma-Glutamyl Hydrolase; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Tandem Repeat Sequences; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Tegafur; Uracil | 2009 |
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Maximum Allowable Concentration; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms | 2008 |
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Radiotherapy, Adjuvant; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Quinazolines | 2008 |
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; T-Lymphocytes; Treatment Outcome; Viral Vaccines | 2008 |
Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Treatment Outcome | 2008 |
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chelating Agents; Colorectal Neoplasms; Copper; Cytokines; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Molybdenum; Neoplasm Metastasis; Pilot Projects | 2009 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Spain; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Rectal Neoplasms; Remission Induction; Survival Rate; Vomiting; Young Adult | 2008 |
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Selection; Proportional Hazards Models; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2008 |
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Survival Analysis; Treatment Outcome | 2008 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2008 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
[Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Tomography, X-Ray Computed | 2008 |
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Genotype; Haplotypes; Humans; Inactivation, Metabolic; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Linkage Disequilibrium; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Metastasis; Polymorphism, Single Nucleotide | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2008 |
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2008 |
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Placebos; Retrospective Studies; Survival Rate | 2009 |
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Tegafur; Uracil | 2009 |
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Predictive Value of Tests | 2009 |
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure; Treatment Outcome | 2009 |
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Simvastatin | 2009 |
Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Recurrence; Risk Assessment | 2009 |
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Tegafur; Tissue Distribution; Treatment Outcome | 2009 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Digestive System Neoplasms; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome; Vitamin B Complex | 2010 |
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Analysis; Young Adult | 2009 |
Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Young Adult | 2009 |
[Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Vomiting | 2009 |
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Young Adult | 2009 |
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Drug Interactions; Female; Fluorouracil; Gastrointestinal Tract; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2009 |
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging | 2009 |
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Treatment Outcome | 2009 |
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Frequency; Genotype; Glucuronosyltransferase; Glutathione Transferase; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Patient Selection; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Predictive Value of Tests; Stomach Neoplasms; Thymidylate Synthase; Time Factors; Treatment Outcome | 2009 |
A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Feasibility Studies; Female; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Survival Rate; Tegafur; Uracil | 2009 |
Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Time Factors | 2010 |
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Patient Compliance; Treatment Outcome | 2009 |
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Palliative Care; Quality of Life; Stomach Neoplasms; Young Adult | 2009 |
[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate | 2009 |
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Time Factors | 2009 |
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Camptothecin; Colorectal Neoplasms; Disease Progression; DNA; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Proportional Hazards Models; Risk Assessment; Time Factors; Treatment Outcome; United States; White People; Young Adult | 2009 |
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Complementarity Determining Regions; Female; Fluorouracil; Genes, T-Cell Receptor beta; Hematuria; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Proteinuria; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Disease Progression; Early Diagnosis; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Pulmonary Embolism; Risk Factors; Thrombophilia; Ultrasonography, Doppler; Vena Cava, Superior; Venous Thromboembolism; Young Adult | 2010 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Salvage Therapy; Survival Rate; Vomiting; Young Adult | 2009 |
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2010 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Treatment Outcome | 2010 |
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Glutathione Transferase; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Predictive Value of Tests; Probability; Survival Analysis; Thymidylate Synthase; Time Factors; Treatment Outcome | 2009 |
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austria; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Germany; Hepatectomy; Humans; Leucovorin; Linear Models; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Odds Ratio; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Risk Assessment; Time Factors; Tomography, Spiral Computed; Treatment Outcome | 2010 |
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Cytokines; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2010 |
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Hyperthermia, Induced; Leucovorin; Organoplatinum Compounds; Peritoneum; Pneumonectomy; Stomach Neoplasms; Survival Rate | 2009 |
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Recombinant Proteins; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Survival; Vomiting; Young Adult | 2011 |
Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Confidence Intervals; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Vitamin B Complex | 2010 |
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease Progression; Double-Blind Method; Female; Fever; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Odds Ratio; Organoplatinum Compounds; Polyethylene Glycols; Recombinant Proteins; Risk Factors; Young Adult | 2010 |
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2010 |
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Chronotherapy; ErbB Receptors; Female; Fluorouracil; Gene Amplification; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Rectal Neoplasms; Time Factors; Treatment Outcome | 2010 |
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2010 |
[Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Rate | 2010 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prodrugs; Tegafur | 2010 |
Treatment of colorectal cancer with and without bevacizumab: a phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2010 |
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Lymphocyte Culture Test, Mixed; Male; Middle Aged; T-Lymphocytes; Time Factors; Treatment Outcome | 2012 |
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Statistics as Topic; Stomach Neoplasms; Surveys and Questionnaires; Survival Analysis; Taxoids; Time Factors; Vitamin B Complex | 2010 |
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Panitumumab; Predictive Value of Tests; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2010 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2010 |
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged | 2011 |
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Young Adult | 2011 |
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2010 |
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Blood Chemical Analysis; Camptothecin; Disease Progression; Docetaxel; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prognosis; Taxoids; Upper Gastrointestinal Tract | 2010 |
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Intra-Abdominal Fat; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Levoleucovorin; Male; Middle Aged; Treatment Outcome | 2011 |
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2011 |
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Proportional Hazards Models; Remission Induction; Sample Size; Treatment Outcome | 2011 |
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prospective Studies; Survival Rate; Treatment Outcome; Tumor Burden | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2010 |
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib | 2011 |
Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Recombinant Proteins; Remission Induction | 2011 |
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Greece; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Young Adult | 2011 |
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index; Topoisomerase I Inhibitors; Treatment Outcome | 2011 |
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; Organoplatinum Compounds; Pharmacogenetics; Thrombospondin 1; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2012 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis | 2011 |
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Vitamin B Complex | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Research Design; Treatment Outcome | 2011 |
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Young Adult | 2011 |
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Vitamin B Complex | 2012 |
Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Radiographic Image Enhancement; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Rectal Neoplasms | 2012 |
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Contrast Media; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome | 2012 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
[Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Recurrence; Splenic Neoplasms; Treatment Outcome | 2011 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cell Count; Colorectal Neoplasms; Deoxycytidine; Endothelial Cells; Endothelium, Vascular; Female; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Treatment Outcome | 2011 |
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome; Tumor Burden | 2012 |
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Real-Time Polymerase Chain Reaction; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drugs, Chinese Herbal; Female; Fluorouracil; Half-Life; Humans; Irinotecan; Leucovorin; Male; Mice; Middle Aged; Phytotherapy | 2011 |
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Models, Statistical; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2011 |
[Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Stomach Neoplasms | 2011 |
Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Thymidylate Synthase | 2011 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Survival Rate; Young Adult | 2011 |
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Panitumumab | 2012 |
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Polymerase Chain Reaction; Premedication; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Skin Diseases; Survival Rate; Young Adult | 2011 |
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2012 |
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2011 |
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins B-raf | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Peritoneal Neoplasms; Prospective Studies | 2012 |
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Treatment Failure; Treatment Outcome | 2012 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Withholding Treatment | 2012 |
FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Pilot Projects; Prospective Studies; Stomach Neoplasms | 2011 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Vitamin B Complex | 2012 |
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2012 |
Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH-cortisol and renin-angiotensin-aldosterone.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Angiotensins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Case-Control Studies; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hydrocortisone; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Renin | 2012 |
Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: preliminary results of a prospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Early Detection of Cancer; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Imaging, Three-Dimensional; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Organoplatinum Compounds; Perfusion Imaging; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2012 |
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2012 |
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Organoplatinum Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2013 |
Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Republic of Korea | 2012 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteopontin; Treatment Outcome | 2012 |
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2012 |
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Genes, ras; Germany; Humans; Leucovorin; Mutation; Neoplasm Metastasis | 2012 |
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds | 2012 |
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Survival Rate; Treatment Outcome | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Randomized Controlled Trials as Topic | 2012 |
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Young Adult | 2013 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Young Adult | 2012 |
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Evaluation of predictive markers for patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; C-Reactive Protein; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Linear Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prealbumin; Predictive Value of Tests; Prognosis; Receptors, Albumin; Sensitivity and Specificity; Serum Amyloid A Protein; Sweden; Tissue Inhibitor of Metalloproteinase-1; Tissue Polypeptide Antigen | 2012 |
Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2012 |
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Mutation; Panitumumab; Quality of Life; Skin; Skin Diseases; Young Adult | 2012 |
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Treatment Outcome | 2013 |
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Colorectal Neoplasms; Disease Progression; Drug Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2013 |
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 18; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Loss of Heterozygosity; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Research Design; Smad4 Protein | 2012 |
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Prospective Studies; Survival Rate | 2013 |
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pilot Projects; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2012 |
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2013 |
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; bcl-2-Associated X Protein; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged | 2013 |
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2013 |
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tissue Distribution | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; International Agencies; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate; Young Adult | 2013 |
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Markers; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index | 2013 |
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; In Vitro Techniques; Leucovorin; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Treatment Outcome; Vomiting | 2013 |
Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; Treatment Outcome; Young Adult | 2013 |
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Inflammation; Leucovorin; Lymphocytes; Male; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Reproducibility of Results | 2013 |
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Genotype; Humans; Insulin-Like Growth Factor Binding Proteins; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Treatment Outcome | 2013 |
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Rate | 2013 |
Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Research Design; Treatment Outcome | 2013 |
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glutamates; Guanine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2013 |
Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2013 |
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Sex Factors; Survival Rate; Young Adult | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptothecin; Dexamethasone; Drug Combinations; Female; Fluorouracil; Haloperidol; Humans; Leucovorin; Male; Metoclopramide; Morpholines; Nausea; Organoplatinum Compounds; Pancreatic Neoplasms; Vomiting | 2013 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Disease Progression; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Quinazolines; Thiophenes; Treatment Outcome | 2013 |
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; UDP-Glucuronosyltransferase 1A9 | 2013 |
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Placebos; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Treatment Outcome; Young Adult | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Japan; Leucovorin; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomatitis; Survival Analysis | 2013 |
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Prospective Studies; Proto-Oncogene Proteins B-raf; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Young Adult | 2013 |
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Young Adult | 2013 |
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Young Adult | 2014 |
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Microsatellite Instability; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Demography; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Fluorouracil; Genotype; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Methotrexate; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA-Binding Proteins; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Glutathione S-Transferase pi; Humans; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Republic of Korea; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2014 |
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adiponectin; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; PPAR gamma; Thiazolidinediones; Treatment Outcome | 2014 |
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Panitumumab; Quality of Life; Skin Diseases; Treatment Outcome | 2014 |
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2013 |
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Interactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome | 2014 |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Glucuronosyltransferase; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Prospective Studies; Survival Rate | 2014 |
Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gastrointestinal Neoplasms; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Withholding Treatment | 2014 |
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Postoperative Period; Preoperative Period; Stomach; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Treatment Outcome | 2014 |
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Proportional Hazards Models; Treatment Outcome | 2014 |
FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies | 2014 |
Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2014 |
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Tumor Burden | 2014 |
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2014 |
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Humans; Leucovorin; Stomach Neoplasms; Taxoids | 2014 |
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Demography; Disease-Free Survival; Female; Fluorouracil; Genotyping Techniques; Humans; Leucovorin; Male; Multivariate Analysis; Polymorphism, Genetic; Treatment Outcome | 2014 |
Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Panitumumab; Treatment Outcome; Young Adult | 2014 |
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; CpG Islands; Disease-Free Survival; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Phenotype; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Treatment Outcome; Young Adult | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Maximum Tolerated Dose; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Gastrectomy; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Stomach Neoplasms | 2014 |
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Pericytes; Predictive Value of Tests; Retrospective Studies; Treatment Outcome | 2015 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2014 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Survival Rate; Tegafur | 2015 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Female; Fluorouracil; Follow-Up Studies; Genetic Association Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; MRE11 Homologue Protein; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome; Young Adult | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds | 2014 |
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Microsatellite Instability; Microsatellite Repeats; Neoplasm Recurrence, Local | 2015 |
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Leucovorin; Logistic Models; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index; Thrombocytopenia; Valine; Vomiting | 2014 |
Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Evidence-Based Medicine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United Kingdom | 2015 |
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Proportional Hazards Models | 2015 |
A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Republic of Korea; Young Adult | 2015 |
Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy Dosage; Rectal Neoplasms; Salvage Therapy; Survival Analysis | 2015 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Granisetron; Humans; Leucovorin; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Prospective Studies; Remission Induction; Republic of Korea; Safety; Vomiting | 2015 |
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; China; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Young Adult | 2015 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2015 |
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2015 |
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Genetic Testing; GTP Phosphohydrolases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2015 |
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Oligonucleotides; Toll-Like Receptor 9 | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2015 |
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Italy; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden | 2015 |
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Italy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Middle Aged; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Panitumumab; Young Adult | 2015 |
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; GTP Phosphohydrolases; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Organoplatinum Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2015 |
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase | 2015 |
Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Endostatins; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Recombinant Proteins; Survival Rate | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Ramucirumab | 2015 |
Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin | 2015 |
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Deoxycytidine; Electrochemotherapy; Female; Fluorouracil; Humans; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult | 2015 |
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prospective Studies | 2015 |
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Panitumumab; Treatment Outcome | 2015 |
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Survival Rate | 2015 |
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Quality of Life; Stomatitis; Young Adult | 2015 |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2015 |
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Implants; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; RNAi Therapeutics | 2015 |
The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intralesional; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2016 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fatigue; Female; Fluorouracil; Humans; Hypertension; Leucovorin; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Survival Rate; Thrombosis; Vomiting | 2016 |
Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Ramucirumab | 2015 |
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Hypersensitivity; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2015 |
Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome | 2015 |
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2015 |
Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Insulin-Like Growth Factor I; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Somatostatin; Survival Analysis | 2015 |
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Genes, ras; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Intention to Treat Analysis; Irinotecan; Italy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Time Factors; Treatment Outcome | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; Exons; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; Retreatment; Survival Analysis; Treatment Outcome | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Quality of Life; Tegafur; Young Adult | 2015 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Hedgehog Proteins; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome; Veratrum Alkaloids; Vomiting | 2016 |
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multivariate Analysis; Proportional Hazards Models; Treatment Outcome | 2016 |
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic | 2015 |
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Republic of Korea; Simvastatin; Survival Analysis; Treatment Outcome | 2015 |
Phase II study of computed tomography-guided (125)I-seed implantation plus chemotherapy for locally recurrent rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Humans; Iodine Radioisotopes; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Image-Guided; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2016 |
A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Rectal Neoplasms; Tegafur | 2015 |
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Analysis; Treatment Outcome | 2016 |
High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2016 |
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Retreatment; Sucrose; Treatment Outcome | 2016 |
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Outcome Assessment, Health Care; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies | 2016 |
Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradiotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Radiotherapy Dosage; Treatment Outcome | 2016 |
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Interleukin-6; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Prognosis; STAT3 Transcription Factor | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2016 |
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Costs and Cost Analysis; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2016 |
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Macrophages; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Pyrrolidines; Receptors, CCR2 | 2016 |
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Recurrence; Tegafur; Treatment Failure; Treatment Outcome | 2016 |
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proportional Hazards Models; Treatment Outcome | 2016 |
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Exons; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras) | 2016 |
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate | 2016 |
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Quality of Life; Treatment Outcome | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors; Treatment Failure | 2016 |
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiation Injuries; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2016 |
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Ramucirumab | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Response Evaluation Criteria in Solid Tumors; Tomography, X-Ray Computed | 2016 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pyrroles; Stomach Neoplasms; Sunitinib | 2016 |
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins B-raf; ras Proteins; Retreatment; Treatment Outcome | 2016 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Ramucirumab | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2017 |
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Liquid Biopsy; Male; Membrane Proteins; Neoplasm Metastasis; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Treatment Outcome | 2017 |
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Proto-Oncogene Proteins p21(ras); Remission Induction; Treatment Outcome | 2017 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-V
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Febrile Neutropenia; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Humans; Incidence; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Young Adult | 2017 |
Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2017 |
Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Panitumumab; Retrospective Studies; Treatment Outcome | 2017 |
EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; ErbB Receptors; Female; Florida; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Panitumumab; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2017 |
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemoprevention; Colorectal Neoplasms; Doxycycline; Drug Eruptions; Exanthema; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Ointments; Skin Care; Treatment Outcome; Vitamin K 1 | 2017 |
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2017 |
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Humans; Hypertension; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Protein-Tyrosine Kinases | 2017 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate | 2017 |
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Genetic Association Studies; Humans; Insulin Receptor Substrate Proteins; Leucovorin; Male; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Sequence Analysis, DNA; Signal Transduction; Somatomedins; Survival Analysis | 2017 |
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Exons; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Treatment Outcome | 2017 |
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retreatment; Treatment Outcome | 2017 |
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neuregulin-1; Organoplatinum Compounds; Oxaliplatin; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Retrospective Studies | 2017 |
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Prospective Studies; Research Design; Treatment Outcome | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Canada; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genes, ras; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome; United States | 2017 |
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Panitumumab; Spain; Survival Analysis | 2017 |
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2017 |
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2018 |
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leucovorin; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Risk Factors; Time Factors; Treatment Outcome | 2017 |
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2017 |
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liquid Biopsy; Mutation; Neoplasm Metastasis; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2018 |
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2017 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Population Groups; Prognosis; Protein Serine-Threonine Kinases; Survival Rate | 2017 |
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Survival Rate | 2018 |
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxyuridine; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2018 |
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care | 2018 |
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Progression-Free Survival; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D | 2018 |
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Neuroendocrine; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Intestinal Neoplasms; Leucovorin; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Research Design; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Organoplatinum Compounds; Prognosis; Retrospective Studies | 2018 |
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Double-Blind Method; Doxycycline; Exanthema; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Patient Compliance; Pharmaceutical Vehicles; Quality of Life; Skin Cream; Vitamin K 1; Young Adult | 2018 |
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Young Adult | 2018 |
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Progression-Free Survival | 2018 |
Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Keratin-18; Leucovorin; Male; Middle Aged; Peptide Fragments; Placebos; Pyrroles; Stomach Neoplasms; Sunitinib | 2018 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur | 2018 |
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Hypertension; Italy; Leucovorin; Male; Middle Aged; Neutropenia; Progression-Free Survival; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Stomatitis; Surveys and Questionnaires | 2018 |
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Models, Biological; Neoplasm Staging; Nonlinear Dynamics; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Tumor Burden | 2018 |
UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Survival Rate; Young Adult | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2018 |
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quality of Life; Treatment Outcome; Young Adult | 2018 |
Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Height; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Prognosis; Progression-Free Survival; Prospective Studies; Rectum | 2018 |
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines | 2018 |
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
Topics: Adult; Aged; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Prospective Studies | 2018 |
Repeating of local therapy of distant metastases increases overall survival in patients with synchronous metastasized rectal cancer-a monocentric analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Progression-Free Survival; Rectal Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Leucovorin; MicroRNAs; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Young Adult | 2019 |
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Treatment Outcome | 2018 |
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Aged; Antibodies; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Biosimilar Pharmaceuticals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intention to Treat Analysis; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Progression-Free Survival; Therapeutic Equivalency | 2018 |
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Mutation; Neoplasm Metastasis; Neovascularization, Pathologic; Prognosis; Proto-Oncogene Proteins c-raf; Ramucirumab; ras Proteins; Survival Rate | 2019 |
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Leucovorin; Male | 2019 |
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival | 2019 |
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Progression-Free Survival; Ramucirumab; Retrospective Studies; Treatment Outcome | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms; Survival Rate | 2019 |
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Costs; Female; Fluorouracil; France; Health Status; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2019 |
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Rectal Neoplasms; Treatment Outcome | 2019 |
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Fluorouracil; Genotype; GTP Phosphohydrolases; Humans; Leucovorin; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Panitumumab; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate | 2019 |
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Patient Reported Outcome Measures; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Severity of Illness Index; Treatment Outcome; Young Adult | 2019 |
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Panitumumab; Retrospective Studies | 2019 |
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cohort Studies; Colorectal Neoplasms; Drug Dosage Calculations; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Survival Analysis | 2019 |
A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Incidence; Leucovorin; Male; Middle Aged; Young Adult | 2019 |
ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; United Kingdom | 2019 |
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Membrane Proteins; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Radiosurgery; Risk Assessment; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Progression-Free Survival; Sex Characteristics; Treatment Outcome; Vomiting | 2019 |
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Oxaliplatin; Placenta Growth Factor; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Rate; Vascular Endothelial Growth Factor A | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Proto-Oncogene Proteins p21(ras); Quality of Life; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2020 |
Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal Cancer: A Dilemma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Humans; Intestinal Obstruction; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Prospective Studies; Rectal Neoplasms; Self Expandable Metallic Stents; Survival Rate | 2019 |
Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Markov Chains; Middle Aged; Organoplatinum Compounds; Quality-Adjusted Life Years; Stomach Neoplasms; Treatment Outcome; Young Adult | 2020 |
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Phenylurea Compounds; Precision Medicine; Prodrugs; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Time Factors; Young Adult | 2019 |
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Decision-Making; Colon; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Prognosis; Progression-Free Survival; Rectum | 2019 |
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2020 |
Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Diffusion Magnetic Resonance Imaging; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pilot Projects; Prospective Studies | 2020 |
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nivolumab; Prognosis; Progression-Free Survival; Retrospective Studies; Stomach Neoplasms | 2020 |
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Inflammation; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prognosis; Translational Research, Biomedical | 2020 |
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2020 |
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Bone Neoplasms; Camptothecin; Cell Count; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; ras Proteins; Risk Assessment; Young Adult | 2020 |
A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Perioperative Period; Postoperative Complications; Progression-Free Survival; Prospective Studies; Tomography, X-Ray Computed | 2020 |
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panit
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins B-raf; ras Proteins; Treatment Outcome | 2020 |
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Oxonic Acid; Progression-Free Survival; Survival Rate; Tegafur; Young Adult | 2020 |
Immune characterization of metastatic colorectal cancer patients post reovirus administration.
Topics: Adult; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothecin; Colon; Colorectal Neoplasms; Combined Modality Therapy; Cytokines; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Intestinal Mucosa; Leucovorin; Lymphocyte Activation; Male; Middle Aged; Mutation; Oncolytic Virotherapy; Oncolytic Viruses; Proto-Oncogene Proteins p21(ras); T-Lymphocytes; Treatment Outcome | 2020 |
Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Japan; Leucovorin; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypercalciuria; Irinotecan; Leucovorin; Magnesium; Male; Nephrocalcinosis; Prognosis; Renal Tubular Transport, Inborn Errors; Retrospective Studies; Survival Rate | 2020 |
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Prognosis; Young Adult | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Italy; Leucovorin; Microsatellite Instability; Organoplatinum Compounds; Prospective Studies | 2020 |
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Polymorphism, Genetic; Proto-Oncogene Proteins p21(ras) | 2020 |
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Nivolumab; Organoplatinum Compounds; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Vascular Endothelial Growth Factor A; Young Adult | 2020 |
Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden | 2020 |
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Progression-Free Survival; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2020 |
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Genome-Wide Association Study; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Risk Assessment; Young Adult | 2021 |
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Panitumumab; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2020 |
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Progression-Free Survival; Tumor Burden; Young Adult | 2020 |
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Progression-Free Survival; Salvage Therapy; Treatment Outcome | 2021 |
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2021 |
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Genes, ras; Humans; Intention to Treat Analysis; Leucovorin; Middle Aged; Progression-Free Survival | 2021 |
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; France; Humans; Leucovorin; Male; Stomach Neoplasms; Treatment Outcome | 2021 |
A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2021 |
Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proton Pump Inhibitors | 2021 |
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; China; Double-Blind Method; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Nausea; Organoplatinum Compounds; Stomach Neoplasms; Vomiting | 2021 |
Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Topoisomerase I Inhibitors | 2021 |
A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Panitumumab; Proto-Oncogene Proteins p21(ras) | 2021 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Fluorouracil; Humans; Hyperthermic Intraperitoneal Chemotherapy; Leucovorin; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Perioperative Period; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors | 2021 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Dietary Supplements; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Pilot Projects; Prospective Studies; Protective Agents; Silymarin; Treatment Outcome; Young Adult | 2021 |
Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Bevacizumab; Camptothecin; Colorectal Neoplasms; Humans; Japan; Leucovorin; Naphthoquinones | 2021 |
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2021 |
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Prognosis; Progression-Free Survival; Topoisomerase I Inhibitors; Treatment Outcome; Young Adult | 2021 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Prognosis; Prospective Studies; Retrospective Studies; Risk Factors; Survival Rate; Weight Loss | 2022 |
A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPA
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Male; Membrane Proteins; Middle Aged; Palliative Care; Precision Medicine; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2 | 2022 |
Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cell Cycle Proteins; Colonic Neoplasms; DNA Replication; DNA-Binding Proteins; Female; Fluorouracil; Germ-Line Mutation; Humans; Intracellular Signaling Peptides and Proteins; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Survival Rate | 2022 |
Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Leucovorin; Machine Learning; Male; Maximum Tolerated Dose; Retrospective Studies | 2022 |
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2022 |
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 2022 |
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Proto-Oncogene Proteins B-raf; Vemurafenib | 2022 |
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Rectal Neoplasms; Retrospective Studies | 2023 |
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Germ Cells; Humans; Leucovorin; Rectal Neoplasms | 2022 |
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell-Free Nucleic Acids; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mutation; Panitumumab; Proto-Oncogene Proteins B-raf; Rectal Neoplasms | 2022 |
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating Tumor DNA; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Leucovorin; Panitumumab; Proto-Oncogene Proteins B-raf; Rectal Neoplasms | 2022 |
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms | 2022 |
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Rectal Neoplasms | 2022 |
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Second Primary; Organoplatinum Compounds; Quality of Life; Rectal Neoplasms; Treatment Outcome | 2022 |
Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies | 2022 |
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms | 2023 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Middle Aged; Rectal Neoplasms; Retrospective Studies | 2022 |
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prognosis; Rectal Neoplasms | 2023 |
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms; Transcriptome | 2023 |
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Panitumumab; Rectal Neoplasms | 2023 |
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies; Proto-Oncogene Proteins B-raf; Rectal Neoplasms | 2023 |
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms | 2023 |
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Middle Aged; Oxaliplatin; Rectal Neoplasms; Tocotrienols; Young Adult | 2023 |
980 other study(ies) available for camptothecin and levoleucovorin
| Article | Year |
|---|---|
[A case of recurrent advanced colon cancer treated with CPT-11 for second-line chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 1997 |
Irinotecan-induced immune thrombocytopenia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Thrombocytopenia | 1998 |
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Survival; Deoxyuracil Nucleotides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Thymidylate Synthase; Thymine Nucleotides; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Second line therapies move to the forefront in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms | 1999 |
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Sigmoid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
[A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged | 2000 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis; Value of Life | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality of Life | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretation, Statistical; Fluorouracil; Humans; Irinotecan; Leucovorin; Quality of Life | 2001 |
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colonic Neoplasms; Drug Interactions; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole | 2001 |
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin | 2001 |
[Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2001 |
Researchers urge caution with standard regimen for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Analysis | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2001 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Fluorouracil; Gastrointestinal Diseases; Guidelines as Topic; Irinotecan; Leucovorin; Mortality; Randomized Controlled Trials as Topic; Risk Factors; Syndrome; Time Factors; Vascular Diseases | 2001 |
[Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2001 |
Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; France; Humans; Leucovorin; Treatment Outcome | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2001 |
Toxicity of irinotecan in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin | 2001 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiovascular Diseases; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Syndrome; Thrombosis | 2002 |
[Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
[A case of recurrent rectal cancer responding to weekly low-dose CPT-11/isovorin/5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Recurrence, Local; Rectal Neoplasms | 2002 |
Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.
Topics: Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Treatment Outcome | 2002 |
ERBITUX as a single agent and in combination in colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2002 |
[Three patients with advanced nonresectable and recurrent gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by CPT-11 administration].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Cisplatin; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Tegafur | 2002 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2001 |
Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Retrospective Studies; Survival Analysis; United States; United States Food and Drug Administration | 2002 |
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Product Surveillance, Postmarketing; Survival Analysis; United States; United States Food and Drug Administration | 2002 |
Lessons learned from the Saltz and Mayo Clinic regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration | 2002 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Tegafur; Uracil | 2002 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome | 2002 |
[A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colectomy; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Sigmoid Neoplasms | 2002 |
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Europe; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2002 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Fluorouracil; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Life Tables; Lymphokines; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Nitrates; Nitric Oxide; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Salvage Therapy; Time Factors | 2002 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Middle Aged; Nausea; Pilot Projects; Rectal Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome; Vomiting, Anticipatory | 2003 |
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bacitracin; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Neomycin | 2003 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; Colonic Neoplasms; Drug Evaluation; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2003 |
Is liver disease an octreotide side effect?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Agents; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Octreotide | 2003 |
[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2003 |
Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2003 |
[Effect of the change of caspase-3 activity on the neoadjuvant chemotherapy-induced apoptosis of large-intestinal carcinoma cells].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Caspase 3; Caspases; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged | 2003 |
Validation of the role of angiogenesis as a chemotherapeutic target.
Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Fluorouracil; Humans; Irinotecan; Leucovorin; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Survival Analysis; Wound Healing | 2003 |
Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Endothelial Growth Factors; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Leucovorin; Lymphokines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Vomiting | 2003 |
[A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Spinal Neoplasms | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Rectal Neoplasms; Tegafur; Uracil | 2003 |
[A case of unresectable liver metastases from rectosigmoid colon cancer with survival for over 3 years after multidisciplinary treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Mitomycin; Rectal Neoplasms; Sigmoid Neoplasms | 2003 |
[Long-term survival after neck lymph node metastases from sigmoid colon cancer--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Neck; Sigmoid Neoplasms; Survivors; Tegafur; Uracil | 2003 |
Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Folic Acid; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Postoperative Complications; Retrospective Studies | 2003 |
Presentations from the Walter Reed Army Medical Center. Case 1: rectal carcinoma.
Topics: Adenocarcinoma, Mucinous; Adult; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Patient Care Planning; Rectal Neoplasms; Rectum; Ultrasonography | 2003 |
Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Survival Analysis | 2003 |
[Principles of postoperative therapy in rectal carcinoma].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rectal Neoplasms; Time Factors | 2004 |
First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Health Care Costs; Hepatic Artery; Humans; Immunosuppressive Agents; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Patient Selection; Treatment Outcome | 2004 |
Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ploidies; Predictive Value of Tests; Treatment Outcome | 2004 |
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Tumor Cells, Cultured | 2004 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pleurisy; Quality of Life; Tegafur; Uracil | 2004 |
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Survival Analysis; Treatment Outcome | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Blood Transfusion; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2004 |
[A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Quality of Life | 2004 |
Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Fluorouracil; Hepatitis C; Humans; Immunocompromised Host; Irinotecan; Leucovorin; Male; Recurrence | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2004 |
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Topics: Administration, Oral; Anti-Bacterial Agents; Antidiarrheals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Loperamide; Neomycin | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver; Liver Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies | 2004 |
[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Remission Induction | 2004 |
Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Taiwan | 2004 |
[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheters, Indwelling; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male | 2004 |
Bevacizumab in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Quality-Adjusted Life Years; Research Design | 2004 |
[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cecal Neoplasms; Combined Modality Therapy; Floxuridine; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoplasm Seeding; Peritoneal Neoplasms; Reoperation | 2004 |
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contraindications; Enzyme Inhibitors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Topoisomerase I Inhibitors | 2004 |
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2004 |
Treatment of a Gilbert's syndrome patient with irinotecan, leucovorin and 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gilbert Disease; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Mutation; Syndrome; Treatment Outcome | 2005 |
Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Quality of Life | 2005 |
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
[Systemic therapy for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
[Improving longevity in advanced intestinal cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Randomized Controlled Trials as Topic | 2005 |
Rectal cancer clinical practice guidelines in oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Medical Oncology; Neoplasm Staging; Organoplatinum Compounds; Radiotherapy, Adjuvant; Rectal Neoplasms | 2005 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Camptothecin; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Female; Fluorouracil; Galanin; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Leucovorin; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Octreotide; Organoplatinum Compounds; Oxaliplatin; Platelet Endothelial Cell Adhesion Molecule-1; Poly(ADP-ribose) Polymerases; Serotonin; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Thymidylate Synthase | 2005 |
Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate | 2005 |
[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2005 |
Regression of colorectal adenomas with intravenous cytotoxic chemotherapy in a patient with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2005 |
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2005 |
[A case of colon cancer with liver and lung metastases-efficacy of CPT-11/5-FU/l-LV (IFL) as part of ambulatory treatment].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Quality of Life; Sigmoid Neoplasms | 2005 |
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylesterase; Chromatography, High Pressure Liquid; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Irinotecan; Kinetics; Leucovorin; Leukocytes, Mononuclear; Male; Middle Aged; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2005 |
In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Leucovorin; Male; Middle Aged; Mitomycin; Taxoids | 2005 |
[A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cecal Neoplasms; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged | 2005 |
[A case of rectal cancer treated by preoperative chemoradiation].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colostomy; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Preoperative Care; Rectal Neoplasms; Rectum; Remission Induction; Tegafur; Uracil | 2005 |
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local | 2005 |
[Radiofrequency ablation (RFA) in colorectal cancer with hepatic metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Tomography, X-Ray Computed | 2005 |
[Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged | 2005 |
Thyroid metastasis from colorectal cancer: role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy; Rectal Neoplasms; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2005 |
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Veins; Humans; Irinotecan; Leucovorin; Liver; Liver Neoplasms; Liver Regeneration; Male; Rectal Neoplasms; Vena Cava, Inferior | 2006 |
Unresectable hepatic colorectal metastases: need for new surgical strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2006 |
Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies | 2005 |
Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2005 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Tegafur; Thiophenes; Treatment Outcome; Uracil | 2005 |
Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Health Care Costs; Health Services; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Retrospective Studies | 2006 |
[Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2006 |
[New chances in therapy of gastrointestinal tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Randomized Controlled Trials as Topic | 2005 |
[Outpatient based colorectal cancer treatment--the current status, challenges and future outlook].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Home Care Services, Hospital-Based; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Quality of Life | 2006 |
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Leucovorin; Leukopenia; Lung Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Neutropenia; Remission Induction; Tegafur; Uracil; Vomiting, Anticipatory | 2006 |
[Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report].
Topics: Adenocarcinoma; Administration, Oral; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Colostomy; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Omentum; Peritoneal Neoplasms; Rectal Neoplasms; Remission Induction; Tegafur; Uracil | 2006 |
Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bevacizumab; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Thromboembolism; Tomography, X-Ray Computed | 2006 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Tegafur; Uracil | 2006 |
Turning point for colorectal cancer clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2006 |
Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glutathione Transferase; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
Case-based discussion for the management of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Monitoring; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Patient Care Planning; Practice Guidelines as Topic; Salvage Therapy | 2006 |
Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Gene Expression Profiling; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2006 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Quality of Life; Rectal Neoplasms | 2006 |
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Bevacizumab; Blindness, Cortical; Blood Vessels; Camptothecin; Carcinoma; Cognition Disorders; Colonic Neoplasms; Dementia, Vascular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Occipital Lobe; Parietal Lobe; Vascular Endothelial Growth Factor A | 2006 |
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Fatty Liver; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Retrospective Studies; Treatment Outcome | 2007 |
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fatty Liver; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Portal Vein; Venous Thrombosis | 2006 |
Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2006 |
[A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colostomy; Drug Administration Schedule; Fluorouracil; Humans; Ileus; Irinotecan; Leucovorin; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms | 2006 |
[What happened during these 12 years since CPT-11 was launched in Japan ?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Approval; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Crohn Disease; Duodenal Neoplasms; Female; Humans; Ileal Neoplasms; Intestine, Small; Irinotecan; Jejunal Neoplasms; Leucovorin; Male; Remission Induction; Survival Analysis | 2006 |
Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Time Factors | 2006 |
Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Male; Rectal Neoplasms; Treatment Outcome | 2007 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neutropenia; Quality of Life; Rectal Neoplasms | 2007 |
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Irinotecan; Leucovorin; Male; Middle Aged | 2007 |
[Chemotherapy for elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vomiting, Anticipatory | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies | 2007 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate | 2007 |
[A case of effective regimen of tegafur and uracil (UFT)/leucovorin (LV) plus irinotecan (CPT-11) for advanced rectal carcinoma with severe pelvic infiltration to be performed curative resection].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Pelvic Neoplasms; Quality of Life; Rectal Neoplasms; Tegafur; Uracil | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Rectal Neoplasms; Vitamin B Complex | 2007 |
[Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].
Topics: Anastomosis, Surgical; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colectomy; Colitis, Ischemic; Colonic Neoplasms; Female; Fluorouracil; Humans; Ileostomy; Ileum; Intestinal Perforation; Ischemia; Leucovorin; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Reoperation; Surgical Wound Dehiscence; Tomography, X-Ray Computed | 2008 |
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lewis X Antigen; Male; Middle Aged; Oligosaccharides; Orotate Phosphoribosyltransferase; Prognosis; Sialyl Lewis X Antigen; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Vitamin B Complex | 2007 |
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Postoperative Complications | 2007 |
[Outpatient chemotherapy of an advanced or metastatic colorectal cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Critical Pathways; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantable; Leucovorin; Organoplatinum Compounds | 2006 |
[Present status of home therapy cancer patients using an infusor].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Home Care Services; Humans; Infusion Pumps; Infusion Pumps, Implantable; Leucovorin; Organoplatinum Compounds; Risk Management | 2006 |
[Our outpatient cases for home anti-cancer chemotherapy using a CV port and a portable pump system].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Home Care Services, Hospital-Based; Home Infusion Therapy; Humans; Infusion Pumps; Infusion Pumps, Implantable; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Outpatients; Quality of Life | 2006 |
[The future of chemotherapy at home--from outpatient chemotherapy to chemotherapy at home].
Topics: Ambulatory Care; Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Home Infusion Therapy; Humans; Infusion Pumps, Implantable; Leucovorin; Organoplatinum Compounds; Quality of Life; Risk Management | 2006 |
[A case report of a patient with advanced rectal cancer who was administered chemotherapy in collaboration with a clinical pathway and visiting nursing care].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Community Health Nursing; Cooperative Behavior; Critical Pathways; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms | 2006 |
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Leukemia, Myeloid, Acute; Male; Prognosis; Recurrence; Remission Induction | 2007 |
Bevacizumab in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Receptors, Cell Surface; Treatment Outcome | 2007 |
Panitumumab in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Epidermal Growth Factor; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Panitumumab | 2007 |
[Comparisons of standard treatments for colorectal cancer between Japan and Western Countries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Japan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Practice Guidelines as Topic; Radiotherapy, Adjuvant; United Kingdom; United States | 2007 |
Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Polymorphism, Genetic | 2007 |
Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Palliative Care | 2007 |
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Gene Expression Profiling; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies | 2008 |
[Long survival of a colon cancer case with multiple liver metastases cured by multidisciplinary therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Sigmoid Neoplasms; Survivors; Tegafur | 2007 |
Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; HIV Infections; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis | 2007 |
Chemotherapy-induced mucositis: focusing on diarrhea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Camptothecin; Dehydration; Diarrhea; Fluorouracil; Gastric Mucosa; Gastrointestinal Tract; Humans; Infusions, Intravenous; Intestinal Absorption; Intestinal Mucosa; Irinotecan; Leucovorin; Loperamide; Mice; Mucositis; Organoplatinum Compounds; Rats | 2007 |
Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colitis, Ischemic; Colonoscopy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Rectal Neoplasms | 2007 |
Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethics, Medical; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukemia; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Uncertainty | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2007 |
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Injections, Intravenous; Japan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Retrospective Studies; Survival Analysis; Treatment Outcome; Vomiting | 2007 |
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Gene Expression; Gene Expression Profiling; Humans; Irinotecan; Leucovorin; Mutation; Oligonucleotide Array Sequence Analysis; Tumor Cells, Cultured; Up-Regulation | 2007 |
Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery Systems; ErbB Receptors; Evidence-Based Medicine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Practice Guidelines as Topic; Vascular Endothelial Growth Factor A | 2007 |
Bevacizumab-associated reversible hypotension.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Humans; Hypotension; Leucovorin; Liver Neoplasms; Middle Aged; Rectal Neoplasms | 2007 |
Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Ileal Neoplasms; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2006 |
Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
Topics: Adenocarcinoma; Amyotrophic Lateral Sclerosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged | 2007 |
Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Catheter Ablation; Chemotherapy, Adjuvant; Cohort Studies; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Laparoscopy; Leucovorin; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Rectal Neoplasms; Risk Factors; Survival Rate; Treatment Outcome; Vitamin B Complex | 2007 |
[A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Rectal Neoplasms; Tegafur; Uracil | 2007 |
Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diabetes Mellitus, Type 1; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Renal Dialysis; Treatment Outcome | 2007 |
[Systemic treatment of peritoneal metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Peritoneal Neoplasms; Prognosis; Quality of Life | 2007 |
[A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms | 2007 |
Central venous access port-related complications in outpatient chemotherapy for colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Female; Fluorouracil; Humans; Incidence; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome | 2007 |
Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome | 2007 |
[Long- term remission survival with a case of rectal carcinoid tumor with metastasis in the soft tissue effectively treated with the combination therapy of irinotecan/5-fluorouracil/levofolinate followed by resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoid Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Rectal Neoplasms; Rectum; Remission Induction; Soft Tissue Neoplasms; Time Factors; Treatment Outcome | 2007 |
Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Cryptogenic Organizing Pneumonia; Female; Fluorouracil; Glucocorticoids; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prednisone; Radiotherapy, Adjuvant; Rectal Neoplasms; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2007 |
[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
[A case report--combination chemotherapy with oral UFT and CPT-11, 5-FU, l-LV by hepatic arterial infusion for multiple hepatic metastasis from sigmoid colon cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Sigmoid Neoplasms; Tegafur; Uracil | 2007 |
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; ErbB Receptors; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2007 |
Treatment of metastatic urachal carcinoma in an elderly woman.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Cystectomy; Diagnosis, Differential; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Neoplasm Recurrence, Local; Pelvic Neoplasms; Radiotherapy, Adjuvant; Urachus; Urinary Bladder Neoplasms | 2008 |
Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Tumor Lysis Syndrome | 2008 |
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Length of Stay; Leucovorin; Liver; Liver Neoplasms; Logistic Models; Male; Middle Aged; Morbidity; Organoplatinum Compounds; Preoperative Care; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis | 2008 |
Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Survival Rate | 2008 |
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Transaminases; Tumor Cells, Cultured | 2008 |
Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Retrospective Studies; Survival Analysis | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Survival Rate | 2008 |
A case of late-onset severe cardiotoxicity from 5-fluorouracil therapy resulting in death.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fatal Outcome; Fluorouracil; Heart Arrest; Humans; Leucovorin; Male | 2007 |
[A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colonoscopy; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Markers; Haplotypes; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Salvage Therapy; Signal Transduction | 2008 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Leucovorin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Philadelphia Chromosome; Quinazolines; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes | 2008 |
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2008 |
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Determination of anticarcinogenic and rescue therapy drugs in urine by photoinduced spectrofluorimetry using multivariate calibration: comparison of several second-order methods.
Topics: Anticarcinogenic Agents; Calibration; Camptothecin; Fluorometry; Humans; Hydrogen Peroxide; Hydrogen-Ion Concentration; Irinotecan; Leucovorin; Molecular Structure; Photochemistry; Salvage Therapy | 2008 |
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Retrospective Studies | 2008 |
[Non-resectable metastases from colorectal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Eruptions; ErbB Receptors; Female; Fluorouracil; Humans; Hypertension; Leucovorin; Middle Aged; Neoplasm Metastasis; Treatment Failure | 2008 |
Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Middle Aged; Stomach Neoplasms | 2008 |
[A case of advanced rectal cancer responding to neoadjuvant chemotherapy with CPT-11, 5-FU and l-LV after coronary artery bypass graft].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Coronary Artery Bypass; Coronary Stenosis; Fluorouracil; Humans; Leucovorin; Male; Rectal Neoplasms | 2008 |
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2009 |
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Treatment Outcome | 2008 |
Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Camptothecin; Colorectal Neoplasms; Fluorouracil; HIV Infections; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Treatment Outcome | 2008 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
[A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2008 |
[Combination chemotherapy composed of mFOLFOX 6, FOLFIRI 2 and surgery and radiation therapy for locoregional recurrences and multiple lung metastases from rectal cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Positron-Emission Tomography; Rectal Neoplasms; Recurrence; Tomography, X-Ray Computed | 2008 |
Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Mice; Middle Aged; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin | 2008 |
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Analysis; Treatment Outcome | 2008 |
FLEX data, KRAS and ERCC1 testing in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; DNA-Binding Proteins; Drug Delivery Systems; Drug Resistance, Neoplasm; Endonucleases; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2008 |
[Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Constipation; Diarrhea; Female; Fluorouracil; Health Surveys; Humans; Leucovorin; Male; Middle Aged; Pamphlets | 2008 |
KRAS status predicts response to cetuximab for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA, Neoplasm; Fluorouracil; Gene Frequency; Humans; Leucovorin; Mutation; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2008 |
New lessons from "old" chemotherapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pyrimidines | 2008 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Models, Statistical; Placebos; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Salvage Therapy; Tomography, X-Ray Computed | 2008 |
Effects of nutritional support in patients with colorectal cancer during chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Body Mass Index; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Nutritional Status; Nutritional Support; Quality of Life; Retrospective Studies; Weight Loss | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Morbidity; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
[Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Feasibility Studies; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Phlebitis; Time Factors; Venules | 2008 |
[A case of metastatic lung and liver tumors from rectal cancer treated with oral UFT and CPT-11 by hepatic arterial infusion followed by FOLFOX and FOLFIRI].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2008 |
Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Infusions, Intravenous; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Prodrugs; Retrospective Studies; Survival Rate; Treatment Outcome; Vitamin B Complex | 2008 |
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2009 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Mass Screening; Medical Oncology; Neoplasms; Organoplatinum Compounds; Societies, Medical | 2008 |
Sequential or combination chemotherapy for a patient with mCRC?
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male | 2008 |
Recurrent disease four years after surgery and adjuvant chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Organoplatinum Compounds | 2008 |
[Complete response of advanced rectal cancer with combined therapy of S-1 + chemo-radiation plus FOLFIRI--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Proctoscopy; Rectal Neoplasms; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2008 |
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Leucovorin; Male; Matrix Metalloproteinase 7; Middle Aged; Organoplatinum Compounds | 2009 |
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Small; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Vitamin B Complex | 2009 |
A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Markov Chains; Models, Econometric; Neoplasm Staging; Organoplatinum Compounds; Quality of Life; Quality-Adjusted Life Years; Sensitivity and Specificity; Treatment Outcome | 2009 |
[Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Rectal Neoplasms; Vomiting | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pneumonectomy; Treatment Outcome | 2009 |
[The optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disposable Equipment; Drug Dosage Calculations; Fluorouracil; Home Care Services; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Organoplatinum Compounds; Solutions; Time Factors | 2009 |
[Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Quality of Life; Surveys and Questionnaires; Taste Disorders | 2009 |
[A case of ascending colon cancer with local recurrence responding completely to alternating modified-FOLFOX6 and FOLFIRI regimens(modified-FIREFOX regimen)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Positron-Emission Tomography; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2009 |
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Hypertrophy; Leucovorin; Ligation; Liver; Liver Circulation; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Organoplatinum Compounds; Portal Vein; Preoperative Care; Prospective Studies; Young Adult | 2009 |
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Glucuronosyltransferase; Haplotypes; Humans; Leucovorin; Linkage Disequilibrium; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2009 |
Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Camptothecin; Cell Line, Tumor; Drug Therapy, Combination; Fluorouracil; Gene Expression; Humans; Irinotecan; Leucovorin; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Stomach Neoplasms | 2009 |
Perforating dermatosis in a patient receiving bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Skin Diseases; Treatment Outcome | 2009 |
Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Treatment Outcome | 2009 |
Cetuximab, chemotherapy and KRAS status in mCRC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Glycolysis; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Proteome; Pyruvate Kinase; Reproducibility of Results; Up-Regulation | 2009 |
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Leucovorin; Male; Polymorphism, Genetic | 2009 |
[A case of hyperammonemia with encephalopathy related to FOLFIRI chemotherapy for advanced colon cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Consciousness Disorders; Fluorouracil; Humans; Hyperammonemia; Irinotecan; Leucovorin; Male; Middle Aged | 2009 |
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fever; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Retrospective Studies; Stomach Neoplasms; Taxoids; Young Adult | 2010 |
Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; CA-19-9 Antigen; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Health Status Indicators; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Predictive Value of Tests; Retrospective Studies; Serum Albumin; Survival Analysis; Treatment Outcome | 2009 |
Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging | 2009 |
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Vitamin B Complex | 2009 |
Metastatic colorectal cancer: is surgery necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Research Design; Retrospective Studies; SEER Program; Unnecessary Procedures | 2009 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Odds Ratio; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Injections, Intraperitoneal; Irinotecan; Leucovorin; Mice; Mice, Nude; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Prognosis; Receptor, IGF Type 1; Stomach Neoplasms; Survival Rate | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Child; Colonic Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectal Neoplasms; Remission Induction; Young Adult | 2009 |
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Predictive Value of Tests | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pneumonectomy; Survival Rate; Treatment Outcome | 2009 |
Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies | 2009 |
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonoscopy; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Mass Screening; Middle Aged; Neoplasm Staging; Occult Blood; Organoplatinum Compounds; SEER Program; Selection Bias; Sigmoidoscopy; Survival Rate; United States | 2009 |
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Retrospective Studies; Young Adult | 2009 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
[Metachronous metastasis from rectal adenocarcinoma to the penis--case report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Diagnosis, Differential; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Palliative Care; Penile Neoplasms; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome | 2009 |
NCCN guideline updates: colon and rectal cancers, version 1.2004.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Rectal Neoplasms | 2004 |
The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Retrospective Studies; Survival Analysis; Vitamin B Complex | 2010 |
[A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Quality of Life; Rectal Neoplasms; Recurrence; Salvage Therapy | 2009 |
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2009 |
Improved first-line chemotherapy: a better chance for surgery?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Patient Selection; Time Factors; Treatment Outcome | 2010 |
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
[A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Sigmoid Neoplasms | 2009 |
Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2010 |
Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Random Allocation; Treatment Outcome; Vitamin B Complex | 2010 |
[The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Hypersensitivity; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis | 2009 |
[Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds | 2009 |
[A case report of metastatic liver tumor from rectosigmoid colon cancer demonstrating a pathological complete response with FOLFOX and FOLFIRI treatment].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Rectal Neoplasms; Sigmoid Neoplasms | 2009 |
[A case report of multiple liver metastases from colorectal cancer effectively treated with systemic chemotherapy and hepatic arterial infusion].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Hepatectomy; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Sigmoid Neoplasms; Tegafur; Uracil | 2009 |
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Portal Vein | 2009 |
[A case of advanced right colonic cancer successfully treated by surgery and post operative chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Combined Modality Therapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Postoperative Period; Tegafur | 2009 |
[Extended lymphadenectomy for gastric regional lymph node metastasis from transverse colon cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Transverse; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Stomach | 2009 |
[Treatment for intrapelvic recurrence of rectal cancer--resection versus chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Pelvis; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2009 |
[Ovarian metastasis after complete response of colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Hysterectomy; Leucovorin; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy | 2009 |
En bloc resection for right colon cancer directly invading duodenum or pancreatic head.
Topics: Adult; Aged; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Duodenal Neoplasms; Duodenum; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2009 |
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Validation study of KRAS mutation in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genes, ras; Genetic Predisposition to Disease; Genetic Testing; Humans; Leucovorin; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pathology, Molecular; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2009 |
[Evaluation of bevacizumab for advanced colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds | 2010 |
[Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Palliative Care; Pulmonary Embolism | 2010 |
[A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Rectal Neoplasms | 2010 |
[Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Sigmoid Neoplasms; Tegafur | 2010 |
[Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Recurrence; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2010 |
A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Duodenal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds | 2010 |
Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; Drug Administration Schedule; Fluorouracil; Humans; Japan; Leucovorin; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2010 |
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Male; Middle Aged; Neck Dissection; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Recombinant Proteins; Tongue Neoplasms | 2010 |
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Exanthema; Fluorouracil; Folliculitis; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Panitumumab; Tomography, X-Ray Computed | 2010 |
[A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Combinations; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxonic Acid; Salvage Therapy; Tegafur; Tomography, X-Ray Computed | 2010 |
Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Duodenal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Ileal Neoplasms; Intestine, Small; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2010 |
Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
Topics: Aneurysm; Angiogenesis Inhibitors; Angiomyolipoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kidney Neoplasms; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasms, Second Primary; Tomography, X-Ray Computed | 2010 |
Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Mutation; Panitumumab; Predictive Value of Tests; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2010 |
The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Disease Progression; Fluorouracil; Green Fluorescent Proteins; Humans; Leucovorin; Lymphatic Metastasis; Mice; Mice, Nude; Survival Rate; Treatment Outcome; Whole Body Imaging; Xenograft Model Antitumor Assays | 2010 |
[A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Leucovorin; Male; Oxonic Acid; Sigmoid Neoplasms; Tegafur; Uracil | 2010 |
[A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Lymphangitis; Male; Middle Aged; Organoplatinum Compounds; Sigmoid Neoplasms | 2010 |
[Optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients (2nd report)-influence of temperature on outflow speed of the medicinal solution].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disposable Equipment; Fluorouracil; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Organoplatinum Compounds; Regression Analysis; Solutions; Temperature; Time Factors; Viscosity | 2010 |
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Survey on the compliance of patients with continuous infusion of 5-fluorouracil via portable infusion pumps].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Seasons; Surveys and Questionnaires | 2010 |
[A case of fluoropyrimidine-resistant recurrent colon cancer successfully treated with weekly administration of irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoplasm Staging; Recurrence; Tegafur; Tomography, X-Ray Computed; Uracil | 2010 |
Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Indocyanine Green; Irinotecan; Leucovorin; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Recovery of Function; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression; Humans; Immunoprecipitation; Lentinan; Leucovorin; Receptors, Calcium-Sensing; Transcription, Genetic; Transfection | 2010 |
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fibrin Fibrinogen Degradation Products; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Sensitivity and Specificity; Sepsis; Venous Thromboembolism | 2010 |
[Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hospitals, General; Hospitals, Public; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Osteoarthropathy, Secondary Hypertrophic; Treatment Outcome | 2011 |
The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coculture Techniques; Colon; Colonic Neoplasms; Cytokines; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Nitric Oxide; Reactive Oxygen Species; Spheroids, Cellular | 2010 |
Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Camptothecin; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Laparoscopy; Length of Stay; Leucovorin; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Melanoma; Middle Aged; Organoplatinum Compounds; Postoperative Complications; Retrospective Studies; Tissue and Organ Harvesting | 2011 |
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Gastrectomy; Humans; Leucovorin; Liver Neoplasms; Male; Neoplasm Staging; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2011 |
[Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Salvage Therapy; Survival Rate | 2010 |
[A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colonoscopy; Combined Modality Therapy; Fatal Outcome; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Organoplatinum Compounds; Tomography, X-Ray Computed | 2010 |
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neoplasms; Cetuximab; Colectomy; Combined Modality Therapy; Diagnosis, Differential; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Peritoneal Neoplasms; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pseudomyxoma Peritonei; ras Proteins; Whole Body Imaging | 2010 |
Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost Analysis; Disease-Free Survival; Dose-Response Relationship, Drug; Fee Schedules; Fluorouracil; Japan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome | 2010 |
[A case of colon cancer with multiple lung metastases responding completely to FOLFIRI and FOLFOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Organoplatinum Compounds; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
[A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Peritoneal Neoplasms; Sigmoid Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dietary Supplements; Drug-Related Side Effects and Adverse Reactions; Fatty Liver; Female; Fluorouracil; Glycine; Immunohistochemistry; Irinotecan; Kupffer Cells; Leucovorin; Liver; Microcirculation; Neoadjuvant Therapy; Nitric Oxide Synthase Type II; Organoplatinum Compounds; Oxaliplatin; Phagocytosis; Rats; Rats, Sprague-Dawley; Transaminases | 2011 |
Outcomes in the management of obstructive unresectable stage IV colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Colostomy; Comorbidity; Emergencies; Female; Fluorouracil; Humans; Intestinal Obstruction; Kaplan-Meier Estimate; Length of Stay; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Quality of Life; Retrospective Studies; Stents; Treatment Outcome | 2010 |
Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Carcinoembryonic Antigen; Colorectal Neoplasms; Dendritic Cells; Female; Fluorouracil; Leucovorin; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory | 2010 |
EGFR antibodies in colorectal cancer: where do they belong?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Leucovorin; Multicenter Studies as Topic; Mutation; Organoplatinum Compounds; Panitumumab; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins | 2010 |
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Disease Progression; Drug Tolerance; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms; Retrospective Studies; Safety; Spain; Treatment Outcome | 2010 |
[A case of high CEA colon cancer responding to neoadjuvant chemotherapy with FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction | 2010 |
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Association Studies; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Japan; Leucovorin; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prodrugs; Retrospective Studies; Survival Analysis; Topoisomerase I Inhibitors | 2011 |
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Research Design; Survival Rate; Tomography, X-Ray Computed | 2010 |
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Focal Nodular Hyperplasia; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2011 |
Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pain; Palliative Care; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
[Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Organoplatinum Compounds; Patient Care Team; Treatment Outcome | 2010 |
[Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Rectal Neoplasms | 2010 |
Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Incidence; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nasal Septum; Nose Diseases; Organoplatinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Palliative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Professional Practice; Standard of Care; Treatment Outcome; Young Adult | 2011 |
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; HCT116 Cells; Humans; Imidazoles; Immunohistochemistry; Irinotecan; Isoenzymes; Leucovorin; MAP Kinase Signaling System; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Xenograft Model Antitumor Assays | 2011 |
[A case of liver metastases from rectal cancer showed a complete response by FOLFIRI and bevacizumab chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms; Treatment Outcome | 2010 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Germany; Health Status Indicators; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Female; Fluorouracil; Humans; Indocyanine Green; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Survival Rate; Treatment Outcome | 2011 |
[Prehepatectomy chemotherapy using hepatic artery infusion plus systemic chemotherapy for liver metastases from colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 2010 |
[An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds | 2010 |
[A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male | 2010 |
[A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Sigmoid Neoplasms; Stomach Neoplasms | 2010 |
[A case with liver resection of metastasis from rectal cancer after bevacizumab treatment].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Reoperation | 2010 |
[The efficacy of cetuximab for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Rectal Neoplasms; Sigmoid Neoplasms | 2010 |
[A case of multiple lung and liver metastases from colon cancer treated with clinical benefit by hepatic arterial infusion chemotherapy plus cetuximab mono-therapy after standard chemotherapy failure].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Sigmoid Neoplasms | 2010 |
[A case of sigmoid colon cancer with synchronous multiple liver and lung metastases, who survived 25-month after combination of chemotherapy and metastasectomy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colectomy; Colon, Sigmoid; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Sigmoid Neoplasms | 2010 |
[A long-term survival case of rectal cancer with Virchow's lymph node metastasis by multimodality therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Tegafur; Uracil | 2010 |
[A case of recurrent sigmoid colon cancer with adrenal and para-aortic lymph node metastasis successfully treated by operation and chemotherapy].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Sigmoid Neoplasms; Tegafur; Uracil | 2010 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Oxonic Acid; Tegafur; Tumor Burden | 2010 |
[Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Salvage Therapy | 2010 |
[A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Pelvis; Rectal Neoplasms; Tegafur; Vitamin B Complex | 2010 |
[An experience of curative resection of local recurrent rectal cancer with high-level sacrectomy after preoperative chemo-radiation therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Humans; Irinotecan; Length of Stay; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Rectal Neoplasms; Sacrum; Tegafur; Uracil; Vitamin B Complex | 2010 |
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bevacizumab; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Platelet Count; Radiography; Retrospective Studies; Splenomegaly | 2011 |
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Pharmacogenetics; Pilot Projects; Polymerase Chain Reaction; Survival Rate; Thymidylate Synthase; Treatment Outcome; Young Adult | 2011 |
R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Preoperative Period; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Time Factors | 2012 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Epistaxis; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxonic Acid; Proteinuria; Retrospective Studies; Tegafur; Thrombosis; Treatment Outcome | 2011 |
Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Japan; Leucovorin; Lung Diseases, Interstitial; Male; Medical Records Systems, Computerized; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pulmonary Fibrosis; Retrospective Studies; Severity of Illness Index; Smoking; Tomography, X-Ray Computed | 2011 |
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients.
Topics: Angiography; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms; Combined Modality Therapy; Embolization, Therapeutic; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 2011 |
Mediastinal infusion with tracheal necrosis: an unusual complication of Port-a-cath devices.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bronchoscopy; Camptothecin; Catheters, Indwelling; Equipment Design; Equipment Failure; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Necrosis; Sigmoid Neoplasms; Surgical Flaps; Thoracotomy; Tomography, X-Ray Computed; Trachea; Tracheal Diseases | 2011 |
[A case of drug-induced lung injury associated with chemotherapy (FOLFOX6, FOLFIRI, Bevacizumab) for an advanced colon cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Lung Injury; Neoplasm Staging; Organoplatinum Compounds; Tomography, X-Ray Computed | 2011 |
[Effective cetuximab monotherapy for a case of recurrence rectal cancer after multiple previous chemotherapy treatment (FOLFOX, FOLFIRI)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Recurrence; Salvage Therapy | 2011 |
Three-drug combination regimen in pancreatic cancer treatment: are we there yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Retrospective Studies | 2011 |
Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Retreatment | 2011 |
Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Decision Trees; Fluorouracil; Genetic Testing; Genotype; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Models, Economic; Neutropenia; Polymorphism, Genetic; Severity of Illness Index | 2010 |
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Palliative Care; Prognosis; Radionuclide Imaging; Stomach Neoplasms; Treatment Outcome | 2011 |
Successful treatment of an intra-abdominal desmoid tumor with irinotecan, fluorouracil, and leucovorin plus bevacizumab in a patient with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fibromatosis, Abdominal; Fibromatosis, Aggressive; Fluorouracil; Humans; Irinotecan; Leucovorin; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Topics: Adenocarcinoma; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Surgical Wound Dehiscence | 2011 |
Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Preoperative Care; Rectal Neoplasms; Retrospective Studies; Tumor Burden | 2012 |
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2011 |
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Risk; Survival Analysis; Vitamin B Complex | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Delivery Systems; Fluorouracil; Follow-Up Studies; Genes, ras; Germany; Humans; Leucovorin; Liver Neoplasms; Models, Economic; Models, Statistical; Organoplatinum Compounds; Survival Rate | 2011 |
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Models, Statistical; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factors | 2011 |
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Statistics as Topic | 2011 |
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Research Design | 2011 |
Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression; Humans; Leucovorin; Male; Microarray Analysis; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Thymidylate Synthase; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2011 |
Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Treatment Outcome | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Treatment Outcome | 2011 |
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Quality of Life; Surveys and Questionnaires; Tegafur | 2011 |
Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
[Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Blood Pressure; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Forecasting; Humans; Hypertension; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Ipilimumab; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Comparative Effectiveness Research; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Retrospective Studies; SEER Program; Survival Analysis; Treatment Outcome; United States | 2011 |
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; National Cancer Institute (U.S.); Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Reference Standards; United States | 2012 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Japan; Leucovorin; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Patient Selection | 2011 |
Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Body Surface Area; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Precision Medicine | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; ErbB Receptors; Fluorouracil; Genetic Testing; Germany; Humans; Irinotecan; Leucovorin; Markov Chains; Monte Carlo Method; Mutation; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States | 2012 |
FOLFIRINOX: a small step or a great leap forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Sequential chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds | 2011 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
[A case of undifferentiated colon cancer responding to FOLFIRI therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fatal Outcome; Fluorouracil; Humans; Leucovorin; Male; Tomography, X-Ray Computed | 2011 |
[A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens].
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Panitumumab; Sigmoid Neoplasms | 2011 |
[Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Skin Ulcer; Tomography, X-Ray Computed | 2011 |
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Fluorouracil; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polycomb Repressive Complex 2; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Transcription Factors; Treatment Outcome | 2012 |
Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Routes; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2011 |
Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Topics: Abdominal Neoplasms; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Fluorouracil; Gastrectomy; Gene Expression Regulation, Neoplastic; Humans; Leucovorin; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Receptor, ErbB-2; Reoperation; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab; Ultrasonography | 2011 |
The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Radiotherapy, Adjuvant; Rectal Neoplasms; Retrospective Studies | 2012 |
Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Fluorouracil; Health Care Costs; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quality-Adjusted Life Years; Survival Analysis | 2012 |
[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Forecasting; Humans; Leucovorin; Logistic Models; Male; Middle Aged; Nausea; Organoplatinum Compounds; Retrospective Studies; Risk Factors; Sex Factors; Vomiting | 2011 |
Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Alleles; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Creatinine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Fluorouracil; Genetic Association Studies; Glycine Hydroxymethyltransferase; Homocysteine; Humans; Hypertension; INDEL Mutation; Leucovorin; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Genetic; Prognosis; Thymidylate Synthase; Treatment Outcome | 2012 |
Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diagnosis, Differential; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; Nephrolithiasis; Tomography, X-Ray Computed | 2011 |
The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2012 |
Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Europe; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome; Young Adult | 2012 |
[Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Mucositis; Nausea; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Vomiting | 2011 |
Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: 3' Flanking Region; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Dosage; Genetic Association Studies; Glucuronosyltransferase; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Retrospective Studies; Survival Analysis | 2012 |
Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pelvic Exenteration; Peritoneal Neoplasms; Young Adult | 2011 |
[A case of recurrent rectal cancer with paraaortic lymph node metastasis treated by FOLFIRI therapy leading to complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Middle Aged; Rectal Neoplasms; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2011 |
[mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Middle Aged; Organoplatinum Compounds; Peritoneal Dialysis; Peritoneal Neoplasms | 2011 |
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2012 |
[Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2011 |
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distribution; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Ultrasonography | 2012 |
[Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothecin; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Quality of Life; Rectal Neoplasms; Tomography, X-Ray Computed | 2012 |
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Fluorouracil; Genotype; Humans; Leucovorin; Middle Aged; Polycomb Repressive Complex 2; Polymorphism, Single Nucleotide; Prognosis; Risk Assessment; Survival Analysis; Transcription Factors | 2012 |
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Republic of Korea; Retrospective Studies; Treatment Outcome | 2012 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Colorectal Neoplasms; Cryosurgery; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Proportional Hazards Models; Retrospective Studies; Tumor Burden; Young Adult | 2012 |
Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Catheterization, Central Venous; Catheters, Indwelling; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outpatients | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Complete calcification of colorectal liver metastases on imaging after chemotherapy does not indicate sterilization of disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Tomography, Spiral Computed; Treatment Outcome; Ultrasonography | 2012 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Neutropenia; Polypharmacy; Retrospective Studies | 2013 |
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2012 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Young Adult | 2012 |
Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation Disorders; Blood Coagulation Tests; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Thrombelastography | 2012 |
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Electrocoagulation; ErbB Receptors; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Microwaves; Molecular Targeted Therapy; Neoadjuvant Therapy; Organoplatinum Compounds; Quality of Life; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2012 |
FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2012 |
Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Propensity Score; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Isoquinolines; Leucovorin; Male; Middle Aged; Nausea; Organoplatinum Compounds; Palonosetron; Quinuclidines; Retrospective Studies; Vomiting | 2012 |
[A case of colon cancer with chronic renal dysfunction responding to effective retreatment with FOLFIRI].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Male; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salvage Therapy; Tomography, X-Ray Computed | 2012 |
In vivo real-time imaging of chemotherapy response on the liver metastatic tumor microenvironment using multiphoton microscopy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Green Fluorescent Proteins; HT29 Cells; Humans; Leucovorin; Liver; Liver Neoplasms; Luminescent Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microscopy, Confocal; Neoplasm Transplantation; Organoplatinum Compounds; Red Fluorescent Protein; Transplantation, Heterologous; Tumor Microenvironment | 2012 |
Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Fluorouracil; Hospitalization; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Office Visits; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Palliative Care; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Retrospective Studies; Scandinavian and Nordic Countries; Sweden | 2012 |
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Neuroendocrine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Pelvic Neoplasms; Platinum; Treatment Outcome | 2012 |
The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Current stages of adjuvant treatment of colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Survival Analysis | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Periodontitis; Prednisone; Retrospective Studies; Treatment Outcome; Vindesine | 2013 |
Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Device Approval; Drug Approval; Fluorouracil; Genetic Testing; Humans; Leucovorin; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States; United States Food and Drug Administration | 2012 |
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Tomography, X-Ray Computed; Uterine Perforation | 2012 |
Progress in pancreatic cancer: moving beyond gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neutropenia; Platinum Compounds; Remission Induction; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2012 |
[A case of unresectable multiple hepatic metastases from ascending colon cancer successfully treated with panitumumab and FOLFIRI(5-FU/LV/irinotecan)therapy].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Panitumumab; Tomography, X-Ray Computed | 2012 |
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms | 2013 |
Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Topoisomerases, Type I; DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; National Cancer Institute (U.S.); Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Real-Time Polymerase Chain Reaction; Retrospective Studies; RNA, Messenger; Tegafur; United States; Up-Regulation | 2012 |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Topics: Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; Humans; Irinotecan; Leucovorin; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Retrospective Studies; Survival Analysis | 2013 |
Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2012 |
Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
[A clinical case of recurrent small intestinal cancer successfully treated with FOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Jejunal Neoplasms; Leucovorin; Male; Neoplasm Staging; Organoplatinum Compounds; Recurrence | 2012 |
[Predictive value of Köhne's index on the efficacy of FOLFIRI regimen in the treatment of unresectable liver metastatsis of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Retrospective Studies | 2012 |
[A case report of recurrent lung metastasis after surgery for rectal cancer for which lung radiofrequency ablation therapy and long-term administration of FOLFIRI were effective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Rectal Neoplasms; Recurrence; Time Factors | 2012 |
Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies | 2013 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2013 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cesarean Section; Colectomy; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Gestational Age; Humans; Infant, Newborn; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Failure | 2012 |
Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Histocytochemistry; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2013 |
Aflibercept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Placenta Growth Factor; Pregnancy Proteins; Protein Binding; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2013 |
Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; CD3 Complex; Cetuximab; Colorectal Neoplasms; Cytokines; Female; Fluorouracil; Humans; Leucovorin; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Phenotype; T-Lymphocytes, Regulatory | 2013 |
ALPPS procedure with the use of pneumoperitoneum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Ligation; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Pneumoperitoneum, Artificial; Portal Vein | 2013 |
Advancements in the management of pancreatic cancer: 2013.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Models, Biological; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms | 2013 |
[Panitumumab-induced trichomegaly].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Eyelashes; Female; Fluorouracil; Hair Diseases; Humans; Leucovorin; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Panitumumab | 2013 |
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2013 |
[A case of locally advanced sigmoid colon cancer curatively resected after neoadjuvant chemotherapy with FOLFIRI plus panitumumab].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sigmoid Neoplasms | 2013 |
Extracorporeal hepatic venous bypass during en bloc resection of right trisection, caudate lobe, and inferior vena cava: a novel technique to avoid hypothermic perfusion.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cold Ischemia; Extracorporeal Circulation; Female; Fluorouracil; Hepatectomy; Hepatic Veins; Humans; Jugular Veins; Leucovorin; Liver Circulation; Liver Neoplasms; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Organoplatinum Compounds; Sigmoid Neoplasms; Treatment Outcome; Vena Cava, Inferior | 2013 |
High-dose FOLFIRI, surgery, and radiofrequency ablation for patients with unresectable liver metastases from colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Update: NCCN colon and rectal cancer clinical practice guidelines.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradiotherapy; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Rectal Neoplasms | 2004 |
Selecting regimens in advanced colon cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2004 |
Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
[Changes of lymphocyte subsets before and after chemotherapy in colorectal carcinoma patients].
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lymphocyte Subsets; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2013 |
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Longitudinal Studies; Male; Models, Biological; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome; Tumor Burden | 2013 |
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies | 2013 |
FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?
Topics: Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camptothecin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Tissue Scaffolds; Xenograft Model Antitumor Assays | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins B-raf; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mutation; Neoplasm Metastasis; Precision Medicine; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Treatment of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver; Liver Neoplasms; Organoplatinum Compounds | 2013 |
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Fluorouracil; Gastroscopy; Humans; Leucovorin; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Recurrence; Silicates; Stomach Neoplasms; Titanium; Tomography, X-Ray Computed | 2013 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Polymorphism, Genetic; Severity of Illness Index; Treatment Outcome | 2013 |
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Gene Expression; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
[Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis | 2013 |
[A case of hyperammonemic encephalopathy related to 5-FU in an aged patient with recurrent colon cancer treated with FOLFIRI therapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Brain Diseases, Metabolic; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Hyperammonemia; Leucovorin; Male; Recurrence | 2013 |
Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Survival; Drug Delivery Systems; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Leucovorin; Nanofibers; Nanotechnology; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tumor Cells, Cultured | 2013 |
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Carcinoma; Cohort Studies; Drug Monitoring; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Secondary Prevention; Severity of Illness Index; Survival Analysis | 2013 |
Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Failure; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Remission Induction; Tomography, X-Ray Computed | 2013 |
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Staging; Oligonucleotides; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Variation; Genotype; Humans; Irinotecan; Leucovorin; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Neoplasm Metastasis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Approval; Europe; Fluorouracil; Humans; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2013 |
Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Placenta Growth Factor; Pregnancy Proteins; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Salvage Therapy; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Dysarthria; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Recurrence; Time Factors | 2014 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2013 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2013 |
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Colectomy; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases | 2013 |
[A case of hepatitis B virus reactivation in a patient with prior resolved hepatitis B infection during bevacizumab plus FOLFIRI treatment].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Hepatitis B; Hepatitis B virus; Humans; Leucovorin; Male; Rectal Neoplasms; Virus Activation | 2013 |
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Topics: Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sex Characteristics; Treatment Outcome | 2014 |
Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Organoplatinum Compounds; Radiosurgery; Treatment Outcome | 2014 |
[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Hemorrhage; Humans; Hypertension; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Proteinuria; Rectal Neoplasms; Remission Induction; Young Adult | 2013 |
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Taxoids | 2013 |
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Digestive System Fistula; Female; Fluorouracil; Hematoma; Humans; Hyperthermia, Induced; Length of Stay; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Peritoneal Neoplasms; Wound Healing | 2014 |
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; Humans; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaloacetates; Pharmacogenetics; Polymorphism, Single Nucleotide; Recurrence; Retrospective Studies | 2014 |
A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Hypertension, Portal; Immunohistochemistry; Leucovorin; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platelet Endothelial Cell Adhesion Molecule-1; Splenomegaly; Thrombocytopenia; Tomography, X-Ray Computed | 2013 |
Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2014 |
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
[A case of multiple skin metastases from cancer of the descending colon responding to FOLFIRI/cetuximab therapy].
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Skin Neoplasms | 2014 |
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cholangitis; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Sepsis | 2014 |
Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum | 2014 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Precision Medicine; Retrospective Studies | 2014 |
Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prognosis; Vitamin B Complex | 2014 |
FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Retrospective Studies; Survival Analysis | 2014 |
Irinotecan-induced immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Platelet Count; Thrombocytopenia | 2014 |
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prognosis; Radiography, Thoracic; Retrospective Studies | 2014 |
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Gene Frequency; Genetic Variation; Genotype; HLA Antigens; HLA-B Antigens; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptors, KIR; Receptors, KIR3DL1; Treatment Outcome | 2014 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Rest; Weight Loss | 2014 |
The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Retrospective Studies | 2014 |
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colonic Neoplasms; Colonoscopy; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Neoadjuvant Therapy; Positron-Emission Tomography | 2014 |
FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Health Status; Humans; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Sample Size; Severity of Illness Index; Skin; Surveys and Questionnaires | 2014 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Treatment Outcome | 2014 |
Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Prospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
FOLFIRINOX: from the ACCORD study to 2014.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Intestinal Obstruction; Intestinal Perforation; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Factors | 2014 |
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Leucovorin; Liver Neoplasms; Male; Middle Aged | 2014 |
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Rectum; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2014 |
Caring for one of our own.
Topics: Camptothecin; Caregivers; Diphosphonates; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nurses; Organoplatinum Compounds; Oxaliplatin; Pain; Pain Management; Pancreatic Neoplasms; Patient-Centered Care; Physician-Patient Relations | 2014 |
Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Hemoglobins; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Odds Ratio; Organoplatinum Compounds; Prognosis; Retrospective Studies | 2014 |
A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Renal Dialysis | 2014 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Survival Rate | 2014 |
Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Denmark; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vitamin B Complex | 2014 |
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Fluorouracil; GTP Phosphohydrolases; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Sequence Analysis, DNA; Tumor Suppressor Protein p53 | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
Colon cancer, version 3.2014.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Liver Neoplasms; Membrane Proteins; Organoplatinum Compounds; Oxaloacetates; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fecal Incontinence; Female; Fluorouracil; Humans; Ileostomy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Prospective Studies; Rectal Neoplasms; Risk Factors; Surveys and Questionnaires; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2014 |
FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Camptothecin; Canada; Colorectal Neoplasms; Diarrhea; Drug Screening Assays, Antitumor; Europe; Female; Fluorouracil; Humans; Immunologic Factors; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prevalence; Quality of Life; Risk Assessment; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; United States | 2014 |
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Community Health Services; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States; Young Adult | 2014 |
Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Liver Cirrhosis; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin | 2014 |
Cetuximab or bevacizumab in metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male | 2014 |
Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and ci
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Febrile Neutropenia; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2014 |
Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nutrition Assessment; Nutritional Status; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2015 |
[The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Retrospective Studies | 2014 |
[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Markov Chains; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2014 |
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Analysis; Treatment Outcome | 2014 |
Fatal outcome of posterior "reversible" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Middle Aged; Neoplasm Staging; Posterior Leukoencephalopathy Syndrome | 2014 |
Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; China; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome; Young Adult | 2014 |
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Camptothecin; Carboxylesterase; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Thymidylate Synthase; Treatment Outcome | 2014 |
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Combinations; ErbB Receptors; Fluorouracil; Guideline Adherence; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Metastasectomy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Oxonic Acid; Panitumumab; Practice Guidelines as Topic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Rectal Neoplasms; Tegafur; Tomography, X-Ray Computed | 2014 |
Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Differentiation; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mice; Myeloid Cells; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Young Adult | 2015 |
Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Neoplasm Recurrence, Local; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Failure | 2014 |
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neutropenia; Organoplatinum Compounds; Pilot Projects; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Salvage Therapy; Survival Rate | 2017 |
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Burden | 2015 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Prospective Studies; Sex Factors; Treatment Outcome | 2015 |
FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2015 |
Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Hypersensitivity; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasms; Organoplatinum Compounds | 2015 |
FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2014 |
Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation.
Topics: Adult; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Organ Sparing Treatments; Organoplatinum Compounds; Pelvis; Rectal Neoplasms; Rectum; Retrospective Studies | 2015 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Capecitabine; Carcinoma; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2014 |
Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta-Thromboglobulin; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Receptors, CXCR4; Receptors, Interleukin-8B; Signal Transduction | 2015 |
Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Signet Ring Cell; Cetuximab; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Retrospective Studies; Survival Rate; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
Expanded RAS: refining the patient population.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Codon; ErbB Receptors; Fluorouracil; GTP Phosphohydrolases; Humans; Leucovorin; Membrane Proteins; Molecular Targeted Therapy; Mutation; Organoplatinum Compounds; Panitumumab; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouracil; Humans; Imaging, Three-Dimensional; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Spiral Cone-Beam Computed Tomography; Treatment Outcome | 2015 |
Neoadjuvant therapy for localized pancreatic cancer: support is growing?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Always look at the bright side of drugs?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2015 |
Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Bevacizumab; Camptothecin; Capecitabine; Carcinoid Tumor; Carcinoma, Signet Ring Cell; Cytoreduction Surgical Procedures; Deoxycytidine; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Retrospective Studies | 2015 |
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds | 2015 |
Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis | 2015 |
[After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms | 2015 |
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic | 2015 |
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Panitumumab | 2015 |
Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Collateral Circulation; Colorectal Neoplasms; Disease Progression; Enoxaparin; Fatal Outcome; Female; Fibrinolytic Agents; Fluorouracil; Humans; Leucovorin; Middle Aged; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Venous Thromboembolism | 2015 |
Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Outcome and Process Assessment, Health Care; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Tumor Burden; United Kingdom | 2015 |
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[A case of long-term survival following chemotherapy after laparoscopic resection of sigmoid colon cancer with multiple liver metastases].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Humans; Laparoscopy; Leucovorin; Liver Neoplasms; Middle Aged; Sigmoid Neoplasms; Time Factors | 2014 |
[A case of liver metastasis from sigmoid colon cancer treated effectively by second-line chemotherapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Sigmoid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Treatment Outcome | 2015 |
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prospective Studies | 2015 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Malaysia; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Postoperative Period; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
[Management for adverse events associated with FOLFIRI plus cetuximab or panitumumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Panitumumab | 2015 |
[Tumor lysis syndrome after FOLFIRI+cetuximab for ascending colon cancer].
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colon, Ascending; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Tumor Lysis Syndrome | 2015 |
Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Prognosis; Retreatment; Retrospective Studies; Survival Rate; Turkey | 2015 |
[FOLFIRINOX, nab-paclitaxel + gemcitabine].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Organoplatinum Compounds; Pancreaticoduodenectomy; Pylorus; Retrospective Studies; Treatment Outcome | 2015 |
Inferior mesenteric artery chemoembolization and chemotherapy for advanced rectal cancer: report of a clinical case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Mesenteric Artery, Inferior; Microspheres; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Treatment Outcome; Tumor Burden | 2015 |
Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cytochrome P-450 Enzyme System; Disease-Free Survival; Female; Fluorouracil; Gene Frequency; Genotype; Humans; Leucovorin; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies | 2015 |
Colorectal cancer: to stack or sequence therapy?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Sequence Analysis, DNA; Treatment Outcome | 2015 |
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Down-Regulation; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Predictive Value of Tests; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Endostatins; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Recombinant Proteins; Survival Rate | 2015 |
Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Czech Republic; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Rectal Neoplasms; Survival Rate; Treatment Outcome | 2015 |
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Analysis | 2015 |
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Spain | 2015 |
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Incidence; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Genetic; Thrombocytopenia | 2015 |
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Follow-Up Studies; Genotype; Germany; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Insurance, Health; Irinotecan; Leucovorin; Neoplasm Staging; Prognosis; Quality of Life; Quality-Adjusted Life Years; Survival Rate | 2016 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2015 |
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Function Tests; Male; Middle Aged; Retrospective Studies | 2015 |
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Leucovorin; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Survival Analysis; Young Adult | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Drug Carriers; Fluorouracil; Hepatic Artery; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Middle Aged; Organoplatinum Compounds; Prospective Studies; Remission Induction | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Camptothecin; Eligibility Determination; Female; Fluorouracil; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Insufficiency; Retrospective Studies | 2017 |
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
[Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2015 |
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gene Frequency; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Polymorphism, Single Nucleotide; Proteolysis; Treatment Outcome; Ubiquitin-Conjugating Enzymes; Ubiquitination | 2015 |
[Rapidly Growing Interval Colon Cancer].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colonoscopy; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed | 2015 |
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2015 |
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; Camptothecin; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polymorphism, Genetic; Retrospective Studies; Severity of Illness Index; Young Adult | 2015 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome | 2016 |
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Ramucirumab; Randomized Controlled Trials as Topic; United States | 2015 |
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Subcutaneous tuberculosis formation during FOLFIRI and bevacizumab treatment: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Subcutaneous Tissue; Tuberculosis | 2016 |
An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cell Adhesion Molecule; Flow Cytometry; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Leucovorin; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Vitamin B Complex; Xenograft Model Antitumor Assays | 2015 |
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cross-Sectional Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pakistan; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2015 |
[Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds; Stomach Neoplasms | 2015 |
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colitis, Microscopic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2015 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Humans; Immunoassay; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate | 2015 |
Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Survival Rate | 2016 |
Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diffusion Magnetic Resonance Imaging; Early Detection of Cancer; Female; Fluorouracil; Humans; Image Processing, Computer-Assisted; Leucovorin; Liver Neoplasms; Male; Middle Aged; Motion; Neoplasm Metastasis; Perfusion; ROC Curve; Spleen; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
[Long-Term Successful Management of Recurrent Rectal Cancer in the Predialysis State with FOLFIRI Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dialysis; Fatal Outcome; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds; Rectal Neoplasms; Recurrence; Renal Insufficiency, Chronic; Time Factors | 2015 |
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Codon; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Panitumumab; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Treatment Outcome | 2016 |
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Body Fluids; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Prospective Studies; Risk Factors | 2016 |
BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?
Topics: Adult; Aged; Aged, 80 and over; Australia; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Genetic Testing; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins B-raf; Treatment Outcome; Young Adult | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Panitumumab; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Metastasectomy; Microsatellite Instability; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Singapore | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Bevacizumab safety in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Heart Failure; Hemorrhage; Humans; Hypertension; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Product Surveillance, Postmarketing; Proteinuria; Risk Factors | 2016 |
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2015 |
[A Patient with Recurrent Ulcerative Colitis-Associated Rectal Cancer Attaining a Complete Response with FOLFIRI plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colitis, Ulcerative; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Rectal Neoplasms; Recurrence; Remission Induction | 2015 |
[Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Intestinal Mucosa; Leucovorin; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Staging; Rectal Neoplasms; Recurrence; Time Factors | 2015 |
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dexamethasone; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Young Adult | 2016 |
Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Cell Proliferation; Fluorouracil; Humans; Infusion Pumps, Implantable; Iontophoresis; Leucovorin; Mice; Mice, Nude; Organoplatinum Compounds; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2016 |
Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cohort Studies; Colectomy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Prognosis; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Survival Rate | 2015 |
Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Decision-Making; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Leucovorin; Quality-Adjusted Life Years | 2016 |
[Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tertiary Care Centers; Treatment Outcome | 2016 |
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Female; Fluorouracil; Humans; Leucovorin; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neutrophils; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2016 |
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Safety | 2016 |
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies | 2016 |
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Long Term Adverse Effects; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2016 |
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Survival Rate | 2016 |
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neoplasms, Second Primary; Urologic Neoplasms | 2016 |
Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome; Turkey | 2016 |
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calreticulin; Camptothecin; Cell Death; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Leucovorin; Mice; Panitumumab; Phagocytosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Sulfonamides; Unfolded Protein Response; Vemurafenib; X-Box Binding Protein 1 | 2016 |
Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2016 |
[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; France; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis | 2016 |
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2016 |
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Genotype; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Polymorphism, Single Nucleotide; Retreatment; Toll-Like Receptor 1; Treatment Outcome | 2016 |
[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Colorectal Neoplasms; Dexamethasone; Female; Fluorouracil; Granisetron; Humans; Leucovorin; Male; Morpholines; Organoplatinum Compounds; Vomiting | 2016 |
Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Humans; Intestinal Neoplasms; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis | 2017 |
In brief: liposomal irinotecan (Onivyde) for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Compounding; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Cachexia; Camptothecin; Cell Line; Colorectal Neoplasms; Flavonoids; Fluorouracil; Humans; Leucovorin; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mice; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle Fatigue; Muscle, Skeletal; Muscular Atrophy; Myoblasts; Myostatin; Organoplatinum Compounds; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Up-Regulation | 2016 |
Colonic perforation following endoscopic mucosal resection in a patient on bevacizumab treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Diseases; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Endoscopic Mucosal Resection; Female; Fluorouracil; Humans; Intestinal Perforation; Irinotecan; Leucovorin | 2016 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Camptothecin; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Operative Time; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Sarcopenia | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Cetuximab; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Palliative Care; Pregnancy; Survival Rate; Tegafur; Tumor Suppressor Protein p53 | 2016 |
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Comorbidity; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Fractal Dimension of Tc-99m DTPA GSA Estimates Pathologic Liver Injury due to Chemotherapy in Liver Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemical and Drug Induced Liver Injury; Fatty Liver; Female; Fluorouracil; Fractals; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Risk Factors; ROC Curve; Technetium Tc 99m Aggregated Albumin; Technetium Tc 99m Pentetate | 2016 |
Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Preoperative Care; Retrospective Studies; Treatment Outcome | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Robotic-Assisted Placement of an Hepatic Artery Infusion Pump and Catheter for Regional Chemotherapy of the Liver.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Robotic Surgical Procedures; Vascular Surgical Procedures | 2016 |
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Ramucirumab | 2016 |
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2016 |
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; DNA Topoisomerases, Type I; Female; Fluorouracil; Genotype; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2016 |
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gamma Rays; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Quality of Life; Stents; Survival Analysis | 2016 |
Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Prognosis; Rare Diseases; Retrospective Studies; Survival Analysis | 2016 |
Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bilirubin; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2017 |
Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Retreatment; Stomach Neoplasms; Survival Rate; Vomiting; White People | 2016 |
Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C-Reactive Protein; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Lymphocyte Count; Male; Middle Aged; Neutrophils; Platelet Count; Prognosis; Retrospective Studies; Serum Albumin; Treatment Outcome; Turkey; Young Adult | 2017 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, Community; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
Topics: Amphiregulin; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; ras Proteins; Retrospective Studies | 2016 |
Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Real-Time Polymerase Chain Reaction | 2016 |
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vitamin B Complex | 2017 |
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Phenylurea Compounds; Pyridines; Retreatment; Treatment Outcome | 2017 |
A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.
Topics: Abdominal Pain; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Camptothecin; Chemotherapy, Adjuvant; Diagnosis, Differential; DNA Contamination; Duodenal Neoplasms; Duodenum; Female; Fluorouracil; Heterozygote; High-Throughput Nucleotide Sequencing; Hospice Care; Humans; Janus Kinase 2; Leucovorin; Mouth Mucosa; Mutation; Nails; Organoplatinum Compounds; Pancreaticoduodenectomy; Phlebotomy; Polycythemia Vera; Sequence Analysis, DNA; Tomography, X-Ray Computed | 2016 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Prospective Studies; Young Adult | 2017 |
[Aflibercept: focus on tolerability.]
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2016 |
Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Gastrointestinal Neoplasms; Genomics; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Pancreatectomy; Precision Medicine; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2017 |
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Erlotinib Hydrochloride; Europe; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires | 2016 |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fluorouracil; Gene Amplification; High-Throughput Nucleotide Sequencing; Humans; Laparoscopy; Leucovorin; Liver Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Off-Label Use; Palliative Care; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Tomography, X-Ray Computed; Trastuzumab; Tumor Suppressor Protein p53; Ultrasonography | 2017 |
Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2017 |
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoplasm Staging; Patient Care Management; Pharmacogenomic Testing; Pharmacogenomic Variants; Retrospective Studies; Topoisomerase I Inhibitors | 2017 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; CD3 Complex; CD56 Antigen; CD8 Antigens; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2017 |
FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds | 2017 |
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2017 |
[Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Rectal Neoplasms; Treatment Outcome | 2016 |
[A Case of Rectal Cancer with Unresectable Liver Metastasis Responding to Rechallenge with FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies | 2017 |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome; Vomiting | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2017 |
Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; France; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Prospective Studies; Survival Rate | 2017 |
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis; Survival Rate; Transcriptome; Treatment Outcome | 2017 |
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Delivery of Health Care; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Length of Stay; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Time Factors | 2017 |
Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Islet Cell; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Laparotomy; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Period; Treatment Outcome | 2017 |
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity | 2017 |
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy-Induced Febrile Neutropenia; Dose-Response Relationship, Drug; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2017 |
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Colostomy; Fluorouracil; Humans; Irinotecan; Kidney Neoplasms; Kidney Pelvis; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Treatment Outcome; Ureterostomy; Urologic Neoplasms; Urothelium | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States | 2017 |
[A Case Report on a Successful Resection after FOLFIRI plus Cetuximab Therapy for Unresectable Colorectal Cancer with Multiple Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colectomy; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Rectal Neoplasms; Treatment Outcome | 2017 |
[A Case of Effective Chemoradiotherapy Using mFOLFOX6 for Locally Advanced Rectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Rectal Neoplasms; Tegafur; Treatment Outcome | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; RNA, Messenger; Toll-Like Receptor 7 | 2017 |
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Retreatment; Retrospective Studies; Survival Rate | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Lung Diseases, Interstitial; Male; Neutropenia; Organoplatinum Compounds; Tomography, X-Ray Computed | 2018 |
Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fasciitis, Necrotizing; Fatal Outcome; Fluorouracil; Fournier Gangrene; Humans; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2017 |
Aggressive large-cell neuroendocrine carcinoma of the sigmoid colon in a patient with ulcerative colitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Colitis, Ulcerative; Fatal Outcome; Female; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Precancerous Conditions; Risk Factors; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Cost of Illness; Deoxycytidine; Drug Costs; Female; Filgrastim; Fluorouracil; Gemcitabine; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors | 2017 |
Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Imaging, Three-Dimensional; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Tumor Burden; Ultrasonography | 2017 |
Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Mice, Inbred NOD; Mice, SCID; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays; Zebrafish | 2017 |
Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Malnutrition; Middle Aged; Nutritional Status; Organoplatinum Compounds; Prognosis; Serum Albumin; Treatment Outcome | 2017 |
FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Treatment Outcome | 2017 |
A Pancreatic Predicament.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiosurgery; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Medical Oncology; Nanostructures; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Treatment Outcome | 2018 |
Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Registries; Retrospective Studies; Saskatchewan; Survival Rate; Travel | 2017 |
5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorine; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Patient Safety; Platinum; Pyrimidines; Stomach Neoplasms; Taxoids; Treatment Outcome | 2018 |
Early small bowel perforation due to aflibercept.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intestinal Perforation; Intestine, Small; Leucovorin; Liver Neoplasms; Middle Aged; Pancreaticoduodenectomy; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2017 |
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Organoplatinum Compounds; Panitumumab; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, ErbB-2; Receptor, ErbB-3; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Wnt Signaling Pathway | 2017 |
Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
Topics: Adenocarcinoma; Adult; Biomarkers; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colectomy; Colonic Neoplasms; Fluorouracil; Hepatectomy; Humans; Inflammation Mediators; Irinotecan; Leucovorin; Liver Neoplasms; Male; Microspheres; Organoplatinum Compounds; Oxaliplatin; Remission Induction | 2017 |
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Retreatment; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Cachexia; Camptothecin; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Femur; Fluorouracil; Induction Chemotherapy; Leucovorin; Male; Mice; Mice, Inbred Strains; Muscle, Skeletal; Muscular Dystrophies | 2017 |
Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Panitumumab; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Retrospective Studies; Treatment Outcome | 2018 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2017 |
Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2017 |
Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Intra-Abdominal Fat; Leucovorin; Male; Middle Aged; Obesity; Organoplatinum Compounds; Retrospective Studies; Young Adult | 2018 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
[A Case of Fatal Interstitial Pneumonia during FOLFIRI plus Cetuximab Therapy for Liver Metastasis of Colon Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Sigmoid Neoplasms | 2018 |
[Experience of Ramucirumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer in Our Hospital].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Ramucirumab; Rectal Neoplasms; Sigmoid Neoplasms | 2017 |
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Models, Economic; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins p21(ras); Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Young Adult | 2018 |
Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer.
Topics: Adult; Antineoplastic Agents, Immunological; Bevacizumab; Camptothecin; Capecitabine; Colonic Neoplasms; Female; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Posterior Leukoencephalopathy Syndrome; Treatment Outcome | 2018 |
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer.
Topics: Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin | 2018 |
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GTP Phosphohydrolases; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Rate | 2018 |
Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cohort Studies; Colectomy; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Margins of Excision; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Radiotherapy; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome | 2018 |
Correlation between CT morphologic appearance and histologic findings in colorectal liver metastasis after preoperative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contrast Media; Female; Fluorouracil; Humans; Iohexol; Iopamidol; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Preoperative Care; Tomography, X-Ray Computed | 2018 |
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Topics: Activin Receptors, Type II; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colon; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Italy; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Progression-Free Survival; Prospective Studies; RNA, Messenger | 2018 |
[A Case of Chemotherapy with FOLFOXIRI plus Cetuximab for Liver Metastasis of Sigmoid Colon Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Sigmoid Neoplasms | 2018 |
Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein.
Topics: Adenocarcinoma, Mucinous; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Veins; Mesentery; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Positron Emission Tomography Computed Tomography; Thrombectomy; Treatment Outcome; Venous Thrombosis | 2019 |
Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Palliative Care; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Quality of Life; Retrospective Studies; Salivation; Syndrome; Young Adult | 2018 |
[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedule; Equivalence Trials as Topic; Fluorouracil; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Rectal Neoplasms; Treatment Outcome | 2018 |
How should BRAF V600E-mutated colorectal cancer be treated?
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Genetic Markers; Genetic Testing; Health Care Costs; Humans; Leucovorin; Precision Medicine; Quality-Adjusted Life Years; Treatment Outcome | 2018 |
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Datasets as Topic; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Progression-Free Survival; Registries | 2018 |
Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Camptothecin; Carcinoid Tumor; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Goblet Cells; Humans; Hyperthermia, Induced; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Peritoneal Neoplasms; Progression-Free Survival; Retrospective Studies | 2019 |
[A Case Describing Treatment with FOLFIRI plus Bevacizumab after a Self-Expandable Metallic Stent Placement for Local Recurrence].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Intestinal Obstruction; Leucovorin; Male; Middle Aged; Rectal Neoplasms; Recurrence; Self Expandable Metallic Stents; Sigmoid Neoplasms | 2018 |
[Five-Year Survival of Two Patients with Para-Aortic Lymph Node Metastasis Treated with Four FOLFOX6and Four FOLFIRI Courses in Combination with Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Time Factors; Treatment Outcome | 2018 |
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Febrile Neutropenia; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Organoplatinum Compounds; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2019 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; ras Proteins | 2018 |
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
[Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Panitumumab; Retrospective Studies; Stomatitis | 2018 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; GPI-Linked Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, Purinergic P1; Survival Rate | 2019 |
Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Metastasis; Prospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |
Laparoscopic repair of bevacizumab-induced vesicovaginal fistula in metastatic colon cancer - a video vignette.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neoplasms; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Hysterectomy; Laparoscopy; Leucovorin; Middle Aged; Peritoneal Neoplasms; Salpingo-oophorectomy; Vesicovaginal Fistula | 2019 |
[A Case of a Patient with Rectum Cancer with Multiple Metastases, Who Was Able to Undergo Conversion Therapy Using Alternating mFOLFOX6 and FOLFIRI Regimens in Combination with Alternating Cetuximab and Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Rectal Neoplasms; Treatment Outcome | 2018 |
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Camptothecin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Cornea; Dry Eye Syndromes; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies; Protein Kinase Inhibitors | 2018 |
Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Arthralgia; Camptothecin; Dreams; Drug Interactions; Fluorouracil; Hallucinations; Humans; Leucovorin; Male; Nausea; Opium; Polypharmacy; Powders; Sigmoid Neoplasms | 2019 |
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Up-Regulation | 2019 |
Case of purpuric drug eruption probably induced by panitumumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Colonic Neoplasms; Drug Eruptions; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Middle Aged; Panitumumab; Prednisolone; Purpura; Skin; Staphylococcal Skin Infections; Staphylococcus aureus; Vasculitis, Leukocytoclastic, Cutaneous | 2019 |
[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2018 |
[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2018 |
[Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin- based treatment due to potentially resectable liver metastases].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2018 |
[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Mutation; Proto-Oncogene Proteins B-raf; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2018 |
Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronates; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Organoplatinum Compounds | 2019 |
Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Neutropenia | 2019 |
Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Differentiation; Colon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Macrophages; Middle Aged; Neuroendocrine Cells; Oxaliplatin; Prognosis; Progression-Free Survival; Prospective Studies; Rectum | 2019 |
Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothecin; Cell Line, Tumor; Energy Metabolism; Fluorouracil; Glucose; Leucovorin; Liver; Male; Metabolomics; Mice; Muscle Strength; Muscle, Skeletal; Neoplasms; Reactive Oxygen Species; Receptors, LDL | 2019 |
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Europe; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Panitumumab; Prospective Studies; ras Proteins | 2019 |
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Early Diagnosis; Early Medical Intervention; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Diseases, Interstitial; Male; Panitumumab; Radiography, Thoracic; Tomography, X-Ray Computed | 2019 |
The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Progression-Free Survival | 2019 |
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Remission Induction | 2019 |
FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Utilization; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Medicare; Neoplasm Staging; Organoplatinum Compounds; Progression-Free Survival; SEER Program; United States | 2019 |
Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; Middle Aged; Muscle, Skeletal; Muscular Atrophy; Organoplatinum Compounds; Panitumumab; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2019 |
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Ramucirumab; Retrospective Studies | 2019 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Computational Biology; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Radiographic Image Interpretation, Computer-Assisted; Response Evaluation Criteria in Solid Tumors; Survival Rate; Tomography, X-Ray Computed | 2020 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Forecasting; Glucuronates; Humans; Irinotecan; Leucovorin; Leukopenia; Machine Learning; Male; Middle Aged; Models, Biological; Neutropenia; Oxaliplatin; Topoisomerase I Inhibitors | 2019 |
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Analysis; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nomograms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
[FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Polymorphism, Genetic | 2019 |
[A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Rectal Neoplasms | 2019 |
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Factors; Sarcopenia; Survival Analysis | 2019 |
FOLFIRI-Mediated Toxicity in Human Aortic Smooth Muscle Cells and Possible Amelioration with Curcumin and Quercetin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Cells, Cultured; Curcumin; DNA Damage; Fluorouracil; Humans; Leucovorin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Necrosis; Oxidative Stress; Quercetin; Signal Transduction | 2020 |
Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Lymph Nodes; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Nomograms; Organoplatinum Compounds; Oxaloacetates; Prognosis; Retrospective Studies; Survival Rate; Tumor Burden | 2019 |
Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy: a case report.
Topics: Abdominal Pain; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease Progression; Fluorouracil; Gastrointestinal Hemorrhage; Hemostasis; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Palliative Care; Radiotherapy; Radiotherapy Dosage; Rectal Neoplasms; Treatment Outcome | 2020 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Fluorouracil; Hepatectomy; Humans; Hyperthermia, Induced; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies | 2019 |
Laparoscopic versus open two-stage hepatectomy for bilobar colorectal liver metastases: A bi-institutional, propensity score-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Laparoscopy; Length of Stay; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Postoperative Complications; Propensity Score; Retrospective Studies | 2019 |
Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell-Free Nucleic Acids; Circulating Tumor DNA; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Progression-Free Survival; Treatment Outcome | 2019 |
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Topics: Aged; Alternative Splicing; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Prognosis; Prospective Studies; Protein Isoforms; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2019 |
Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2019 |
Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Germ Cells; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Prognosis; Ribosomal Proteins; Survival Rate; Tumor Cells, Cultured | 2019 |
Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Conversion to Open Surgery; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Treatment Outcome; Tumor Burden | 2019 |
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Insulin-Like Growth Factor Binding Protein 1; Interleukin-8; Japan; Kallikreins; Leucovorin; Placenta Growth Factor; Prognosis; Progression-Free Survival; Prospective Studies; Pulmonary Surfactant-Associated Protein D; Receptor for Advanced Glycation End Products; Receptors, Tumor Necrosis Factor, Type II; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms; Regression Analysis; Tenascin; Tissue Inhibitor of Metalloproteinase-1; Vascular Endothelial Growth Factor Receptor-1 | 2019 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure | 2020 |
[A Case Altered Consciousness Due to 5-Fluorouracil-Induced Hyperammonemia in a Patient with Recurrent Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consciousness; Fluorouracil; Humans; Hyperammonemia; Leucovorin; Male; Neoplasm Recurrence, Local | 2019 |
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Progression-Free Survival; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies | 2020 |
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Hypertension; Leucovorin; Neoplasm Metastasis; Prognosis; Ramucirumab; Randomized Controlled Trials as Topic; Survival Rate; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies | 2020 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome | 2019 |
Cost-effectiveness analysis of selective first-line use of biologics for unresectable
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Protein Kinase Inhibitors; ras Proteins | 2019 |
[A Case of FOLFOXIRI plus BV Therapy Responding to Liver Metastasis of Rectal Cancer with the Portal Venous Tumor Thrombi(Vp4)as Oncologic Emergency].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Portal Vein; Rectal Neoplasms; Venous Thrombosis | 2019 |
Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colorectal Neoplasms; Fluorouracil; Green Fluorescent Proteins; Humans; Leucovorin; Mice; Mice, Nude; Mice, Transgenic; Random Allocation; Trabectedin; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Consensus; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Humans; Leucovorin; Male; Middle Aged; Models, Biological; Molecular Targeted Therapy; Patient Selection; Progression-Free Survival; Randomized Controlled Trials as Topic; Tumor Microenvironment | 2019 |
A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Canada; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Proto-Oncogene Proteins p21(ras); Young Adult | 2019 |
Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
Topics: Adenomatous Polyposis Coli Protein; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell-Free Nucleic Acids; Circulating Tumor DNA; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liquid Biopsy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Remission Induction; Tumor Suppressor Protein p53 | 2020 |
Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Panitumumab; Quality-Adjusted Life Years | 2020 |
EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Image; Camptothecin; Cetuximab; Colorectal Neoplasms; Cross-Sectional Studies; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Paronychia; Protein Kinase Inhibitors; Pruritus; Quality of Life; Skin Diseases; Surveys and Questionnaires | 2020 |
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pyrrolidines; Thymine; Treatment Outcome; Trifluridine; United Kingdom; Uracil | 2020 |
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multivariate Analysis; Prognosis; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Analysis | 2020 |
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; China; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Panitumumab; Progression-Free Survival; Retrospective Studies | 2020 |
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease Progression; DNA Mismatch Repair; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatectomy; Humans; Immune Checkpoint Inhibitors; Leucovorin; Liver Neoplasms; Microsatellite Instability; Neoadjuvant Therapy; Nivolumab; Organoplatinum Compounds; Treatment Outcome | 2020 |
[A Case of Nephrotic Syndrome Induced by FOLFIRI plus Ramucirumab for Metastatic Descending Colon Cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colon, Descending; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Nephrotic Syndrome; Ramucirumab | 2019 |
[Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Organoplatinum Compounds; Rectal Neoplasms | 2019 |
[Experience of Using Aflibercept Beta and FOLFIRI Chemotherapy for Metastatic Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Vascular Endothelial Growth Factor A | 2019 |
FOLFOXIRI reintroduction in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; China; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Polymorphism, Genetic; Precision Medicine; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2020 |
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Genotyping Techniques; Humans; Intercellular Signaling Peptides and Proteins; Leucovorin; Male; Middle Aged; Mutation; Patient Selection; Polymorphism, Single Nucleotide; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic | 2020 |
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2020 |
[Locally Advanced Rectal Cancer Curatively Resected after Modified FOLFOXIRI plus Bevacizumab Chemotherapy-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Recurrence, Local; Organoplatinum Compounds; Rectal Neoplasms | 2020 |
[A Case of Complete Pathological Response in a Patient with Advanced Ascending Colon Cancer That Invaded the Liver and Duodenum after FOLFOXIRI plus Bevacizumab Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colon, Ascending; Colonic Neoplasms; Duodenum; Female; Fluorouracil; Humans; Leucovorin; Liver; Organoplatinum Compounds | 2020 |
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; HLA-G Antigens; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Molecular; Protein Binding; Protein Conformation; Protein Isoforms; Solubility; Spectrometry, Fluorescence | 2020 |
Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fatal Outcome; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Proto-Oncogene Proteins B-raf; Skin Neoplasms | 2020 |
TRIBE2 results and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2020 |
TRIBE2 results and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds | 2020 |
TRIBE2 results and toxicity - Authors' reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Rectal Neoplasms; Retreatment | 2020 |
[Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Europe; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Pancreatic Neoplasms; Quality of Life | 2020 |
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Peripheral Nervous System Diseases | 2020 |
Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Sectional Studies; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrimidines | 2020 |
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Microenvironment | 2020 |
Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Humans; Hyperthermic Intraperitoneal Chemotherapy; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Peritoneal Neoplasms; Proportional Hazards Models | 2020 |
Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer.
Topics: Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Gastrointestinal Microbiome; Humans; Leucovorin | 2020 |
Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Positron Emission Tomography Computed Tomography; Proto-Oncogene Proteins B-raf; Treatment Outcome | 2020 |
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Decision-Making; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Patient Selection; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Portal Vein; Pyrazoles; Pyridones; Rectal Neoplasms | 2021 |
Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colitis-Associated Neoplasms; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Progression-Free Survival; Prospective Studies; Retrospective Studies | 2020 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Databases, Factual; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Logistic Models; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Sex Factors; Stomatitis; Thrombocytopenia; Vomiting | 2021 |
Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oxaliplatin | 2020 |
FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Retrospective Studies | 2020 |
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Drug Combinations; Fluorouracil; Humans; Leucovorin; Liquid Biopsy; Male; Middle Aged; Mutation; Phenylurea Compounds; Pyridines; Pyrrolidines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thymine; Trifluridine | 2020 |
Salvage Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Japan; Leucovorin; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2021 |
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Incidence; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; United States | 2020 |
Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; China; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Quality-Adjusted Life Years | 2020 |
Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Postmenopause; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2020 |
Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Organoplatinum Compounds; Panitumumab; Treatment Outcome | 2021 |
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2020 |
[A Case of Neoadjuvant Chemotherapy with Modified FOLFOXIRI plus Bevacizumab for Transverse Colon Cancer with Invasion of the Gastric Antrum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colon, Transverse; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Pyloric Antrum | 2020 |
Dual deficiency of DPD and UGT1A1 in a case of colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Middle Aged; Mutation; Tomography, X-Ray Computed | 2020 |
Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; DNA Repair; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Treatment Outcome | 2021 |
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Panitumumab; Propensity Score; Proto-Oncogene Proteins B-raf; Quality of Life | 2021 |
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prognosis; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A | 2021 |
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Panitumumab; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2021 |
Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Treatment Outcome | 2021 |
Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Phenylurea Compounds; Pyridines | 2020 |
In Reply: Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Phenylurea Compounds; Pyridines | 2020 |
FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Panitumumab; Proto-Oncogene Proteins B-raf | 2021 |
Hepatectomy for liver metastasis from rectal cancer in a patient with mitochondrial disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diabetes Mellitus, Type 2; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Mitochondrial Diseases; Organoplatinum Compounds; Pedigree; Rectal Neoplasms | 2021 |
Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mutation; Neoplasm Staging; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2021 |
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylesterase; Cytochrome P-450 CYP3A; Fluorouracil; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Biological; Oxaliplatin; Pancreatic Neoplasms; Polymorphism, Genetic | 2021 |
Conversion therapy in patients with colorectal liver metastases.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Logistic Models; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Retrospective Studies | 2021 |
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consensus; Fluorouracil; Humans; Leucovorin; Prognosis | 2021 |
Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Calcium; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Sodium | 2021 |
Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Saskatchewan | 2022 |
Chemotherapy of metastatic colon cancer in France: A population-based study.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; France; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Palliative Care; Registries; Retrospective Studies | 2021 |
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2021 |
Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors | 2021 |
Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2021 |
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Prognosis | 2021 |
[Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Consensus; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2021 |
Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Indonesia; Leucovorin; Markov Chains; Neoplasm Metastasis; Organoplatinum Compounds; Quality-Adjusted Life Years | 2021 |
[Establishment of a Needle-Removal Method Considering Anticancer Drug Exposure after Continuous Administration of Fluorouracil Using an Infusion Pump].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps; Japan; Leucovorin; Organoplatinum Compounds | 2021 |
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Treatment Outcome | 2021 |
Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brazil; Camptothecin; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multidrug Resistance-Associated Proteins; Organoplatinum Compounds; Peptide Synthases; Pharmacogenomic Variants; Polymorphism, Single Nucleotide | 2021 |
Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Computed Tomography Angiography; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Microenvironment | 2021 |
A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Microbubbles; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome; Uridine | 2021 |
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Progression-Free Survival; Pyrimidines; Retrospective Studies; Time Factors | 2021 |
[A case of pembrolizumab responding to recurrent small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome].
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Recurrence, Local; Peutz-Jeghers Syndrome | 2021 |
Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2022 |
p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atlases as Topic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Crk-Associated Substrate Protein; Epiregulin; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Leucovorin; Male; Middle Aged; Molecular Sequence Annotation; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf; RNA, Small Interfering; Signal Transduction; Survival Analysis | 2021 |
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Treatment Outcome; Young Adult | 2021 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Prospective Studies; Rectal Neoplasms | 2022 |
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Young Adult | 2022 |
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Pyridines; Rectal Neoplasms | 2022 |
[A Resected Case of Advanced Lower Rectal Cancer with Neoadjuvant Chemotherapy by FOLFOXIRI plus Cetuximab].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Fluorouracil; Humans; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Rectal Neoplasms | 2021 |
[A Case of Metastatic Pancreatic Ductal Adenocarcinoma Successfully Treated with Modified FOLFIRINOX and Concurrent Radiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreatic Neoplasms | 2021 |
[A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Neoplasm Recurrence, Local; Organoplatinum Compounds; Rectal Neoplasms | 2021 |
[Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Prognosis; Retrospective Studies | 2022 |
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Comorbidity; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms; Treatment Outcome | 2022 |
Comparison of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Retrospective Studies | 2022 |
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fever; Fluorouracil; Humans; Interleukin-6; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Sigmoid Neoplasms | 2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Treatment Outcome | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2022 |
Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mutation; Organoplatinum Compounds; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyridines | 2021 |
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Oxaliplatin; Rectal Neoplasms; Republic of Korea | 2023 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; Camptothecin; Diarrhea; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Thrombocytopenia; Vomiting | 2022 |
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms; Retrospective Studies | 2022 |
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Rectal Neoplasms | 2022 |
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Interferons; Leucovorin; Membrane Proteins; Nucleotidyltransferases; Rectal Neoplasms | 2022 |
[Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Japan; Leucovorin; Neoplasm Metastasis; Ramucirumab | 2022 |
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis | 2022 |
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Proto-Oncogene Proteins B-raf; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2022 |
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2022 |
Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Diseases, Metabolic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neutropenia; Organoplatinum Compounds; Retrospective Studies | 2022 |
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Rectal Neoplasms; Retrospective Studies | 2022 |
Managing life-threatening 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Camptothecin; Cardiotoxicity; Cardiotoxins; Colorectal Neoplasms; Coronary Vasospasm; Diltiazem; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Nitrates | 2022 |
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; East Asian People; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Product Surveillance, Postmarketing; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Rectal Neoplasms | 2023 |
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin | 2022 |
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2022 |
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating MicroRNA; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; MicroRNAs; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2023 |
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Hypertension; Leucovorin; Middle Aged; Neoplasm Metastasis; Recombinant Fusion Proteins; Rectal Neoplasms; Retrospective Studies | 2023 |
[Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration].
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nephrotic Syndrome; Proteinuria; Ramucirumab; Sigmoid Neoplasms | 2022 |
[FOLFIRI plus RAM Therapy in Later Line of Unresectable Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Retrospective Studies | 2023 |
[A Case of Recurrent Rectal Cancer with Acute Lower Extremity Arterial Occlusion during Treatment with Bevacizumab].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Rectal Neoplasms | 2023 |
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mice; Xenograft Model Antitumor Assays | 2023 |
[Educational Project of Self-Removal of the Intravenous Central Venous Access Port Guided by Patients with Advanced Colorectal Cancer Instructed by a Nurse in the University Hospital].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; Colorectal Neoplasms; Fluorouracil; Hospitals; Humans; Leucovorin; Retrospective Studies | 2023 |
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Incidence; Leucovorin; Proteinuria; Ramucirumab; Rectal Neoplasms | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient Care; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Pancreatic Neoplasms | 2023 |
Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Radiation-Sensitizing Agents; Treatment Outcome | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Rectal Neoplasms; Retrospective Studies; Vascular Endothelial Growth Factor A | 2023 |
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Liposomes; Male; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Indonesia; Leucovorin; Oxaliplatin; Rectal Neoplasms | 2023 |
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Prospective Studies; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rectal Neoplasms | 2023 |
FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2023 |